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receptors. One of the analogs, N,N-dibenzyl [Phe(p-NCS)4]leucine enkephalin, had
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radioligand binding in a dose-dependent manner.
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receptors, and these attributes made this peptide an attractive candidate for affinity label
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Chapter 1
 
Introduction
 
The alleviation of suffering has been a major medical goal for centuries. One of the 
most efficacious means by which analgesia is achieved is through the application of 
opioids. Unfortunately, the serious side effects of tolerance, physical dependence, and 
respiratory depression severely limits their use. It is a well documented fact that opioid 
effects are mediated through three major types of opioid receptors: the mu (p.), delta (8) and 
kappa (x) receptors. The opioids that exhibit high abuse potential have been shown to 
interact preferentially with theµ receptor (Raynor et al., 1994), and it is hoped that an 
analgesic that is selective for either 8 or x opioid receptors would limit the occurrence of 
undesired side effects. Therefore, pharmacological investigation involving the 8 and x 
receptors is an active area of research. 
One receptor that has been implicated as a potential target for analgesia, as well as a 
number of other therapeutic applications, is the 8 opioid receptor (Rapaka and Porreca, 
1991). The discovery of 8 opioid receptors was was due to the judicious use of the first 
endogenous opioid peptides to be described, the enkephalins (Lord et al., 1977). Also, 8 
opioid receptors have the distinction of being the first opioid receptors to be cloned (Evans 
et al., 1992, Kieffer et al., 1992). Not only have the 8 opioid receptors been described as 
being able to mediate analgesia with lessened tolerance and dependence, but they have also 
been implicated in a number of other ailments, including the reinforcing effects of alcohol 
consumption (Gianoulakis, 1996). The promise of therapeutic intervention for a number of 
medical problems has spurred active investigation involving the 8 opioid receptor. 2 
Despite the recent cloning of all three opioid receptor types from a variety of species 
and tissues (Kieffer, 1995), questions regarding 8 opioid receptors still remain Through 
cloning, the primary (and much of the secondary) structure of the opioid receptors are 
known, but the tertiary arrangement of these domains is still unknown. As a result, the 
amino acid residues responsible for receptor selectivity and activation are as yet 
undetermined Recent pharmacological studies suggest the existence of 8 receptor subtypes 
(Zaki et al., 1996), but to date, hybridization screening has been unable to identify these 
subtypes. It may be necessary to isolate and map these receptors in order to characterize 
these putative 8 receptor subtypes. Structural information about 8 opioid receptors is not 
the only area of current interestthe physiological consequences of 8 opioid receptor 
activation also remains under extensive investigation. 
One pharmacological tool that has been used successfully in various types of receptor 
studies is the affinity label. An affinity label is a ligand whose interaction with a receptor is 
essentially non-equilibrium in nature. Because of this interaction (which may or may not 
involve a covalent bond), affinity labels have many advantages over conventional ligands in 
a number of pharmacological experiments. If radiolabeled, an irreversible ligand could 
greatly aid in isolation and tryptic digest mapping, and its long-acting blockade of receptor 
function would help in determining 8 opioid receptor-mediated physiological effects. The 
affinity label has also been used to determine residues near the binding site of receptors, as 
was done by Liu-Chen and co-workers (Chen et al., 1996) with theµ opioid receptor and 
its interaction with the irreversible ligand (3-funal tr examine (Ward et al., 1982). 
Although there are affinity labels selective for 6 opioid receptors are currently available, 
these ligands are either based on non-peptide antagonists (i.e. naltrindole 5'-isothiocyanate, 
NTH) (Portoghese et al., 1990), or peptide agonists (i.e. [D-Ala2,Leu5,Cys6]enkephalin, 
DALCE) (Bowen et al., 1987). In order to fully understand the binding interactions of 8 
opioid receptors, a wide variety of affinity labels should be developed and used. 3 
In an earlier study, Aldrich-Lovett and Portoghese (Lovett and Portoghese, 1987) 
synthesized potential affinity labels for 8 opioid receptors by incorporating melphalan (Mel) 
into N,N-dialkylated enkephalin derivatives. Mel is the nitrogen-mustard derivative of 
Phe, and the large steric bulk and relatively low reactivity of the N,N-bi s (2 ­
chloroethypaniline side chain was considered to be the reason for the lack of wash-resistant 
binding by the synthesized derivatives. 
In order to further investigate these N,N-dialkylated enkephalins as potential affinity 
labels for 5 opioid receptors, more reactive and less sterically demanding functional groups 
were planned for inclusion into the 5-selective peptide antagonists N,N-dibenzyl leucine 
enkephalin and ICI-174,864 (N,N-diallyl[Aib2,Aib3,Leu5]enkephalin). One of the specific 
aims of this project was to design and utilize a general synthetic methodology for the 
construction of peptide-based affinity labels. This was accomplished through the use of a 
tert-butyloxycarbonyl (Boc)/9-fluorenyl-methoxycarbonyl (Fmoc) orthogonal protection 
strategy. The Boc and tert-butyl based protecting groups provided semi-permanent 
protection for the peptides, while the Fmoc group allowed transient protection for a g­
amine functionality on Phe, which was selectively deprotected and derivatized into either 
isothiocyanate or bromoacetamide groups. The key step in the synthesis was the selective 
deprotection of the Boc group in the presence of a tert-butyl ester. This deprotection was 
accomplished through the use of one equivalent of trimethylsilyl trifluoromethanesulfonate 
(Vorbruggen and Kroliklewicz, 1975). Once synthesized, the peptides were then tested 
under standard and wash-resistant binding conditions against Chinese hamster ovary 
(CHO) cells stably transfected with the mouse 8 opioid receptor. 
An important aspect in the development of affinity labels is the choice of the parent 
molecule to be derivatized. Affinity and selectivity for the receptor to be studied are 
important aspects to be considered. For these reasons, the highly potent and selective 
peptide antagonist TIPP (Tyr-Tic-Phe-Phe) (Schiller et al., 1992) was also chosen for 
derivatization into potential affinity labels. This tetrapeptide was only recently described, 4 
and it represented a major advance in the field of 8 opioid selective ligands. The synthesis 
of the TIPP -based derivatives utilized the Boc/Fmoc synthetic methodology developed in 
the synthesis of the enkephalin series. These potential affinity labels were synthesized with 
an isothiocyanate group at the para position of either Phe3 or Phe4, and underwent 
pharmacological evaluation using 8 receptors expressed on CHO cells. 
In this study, peptide ligands based on antagonists for 8 opioid receptors were 
synthesized and tested. The application of the same synthetic methodology for differing 
peptide targets highlights the utility of this scheme for the construction of a wide variety of 
peptide-based affinity labels. From the binding studies, three potential affinity labels were 
identified: N,N-dibenzyl [Phe(p-NCS)4]leucine enkephalin, and the [Phe(p-NCS)3] and 
[Phe(p- NCS)4] derivatives of TIPP. To our knowledge, these peptides represent the only 
examples of peptide-based affinity labels using an isothiocyanate group as their labeling 
moiety. In the future, these ligands might be used for the further investigation of 8 opioid 
receptor-mediated phenomena. 5 
Chapter 2
 
Literature Review: Opioid Receptors
 
2.1 Introduction 
For centuries, people have exploited the analgesic and narcotic properties of the opium 
poppy, Popover somniferum. The ancient Sumerians cultivated the plant for its painkilling 
properties, and named the opium poppy "hul gil" or "plant of joy." A major breakthrough 
in the understanding of opioid pharmacology came in 1806, when Serturner isolated the 
major alkaloid constituent of opium responsible for much of its pharmacological properties. 
He named the compound morphine, after Morpheus, Greek god of sleep and dreams. 
While morphine is useful in the treatment of pain and other illnesses, it is often 
accompanied by unwanted side effects, most notably tolerance, physical dependence, and 
respiratory depression. In an effort to separate the analgesic properties of morphine from 
its undesired side effects, many synthetic and semi-synthetic analogs have been created and 
tested. With the numerous opiates synthesized, differences in both structure-activity 
relationships and opioid-mediated physiological effects prompted Portoghese (Portoghese, 
1965) and Martin (Martin, 1967) to separately postulate the existence of multiple opioid 
receptors in the mid-1960's. This hypothesis was substantiated by subsequent experiments 
done by Martin and co-workers who observed the pharmacological profiles of several types 
of ligands in dogs chronically treated with opiates (Martin et al., 1976). Based on this 
study, Martin and co-workers hypothesized the existence of three separate opioid receptors, 
which the researchers named after the ligand used in its characterization: mu (p., for 
morphine), kappa (c, for ketocyclazocine) and sigma (a, for compound SKF- 10,047 or N­
allylnormetazocine) receptors. Since that study, it has been shown that the actions of SKF­
10,047 are not reversed by the opioid antagonist naltrexone (Vaupel, 1983), and therefore 
the a receptor is no longer considered a "true" opioid receptor. 6 
The isolation and characterization of the first endogenous opioid peptides allowed for 
the identification of another type of opioid receptor. In studies done by Lord et al. (Lord et 
al., 1977), these endogenous pentapeptides (the enkephalins) showed higher potency than 
morphine in the mouse vas deferens (MVD) smooth muscle assay, but lower potency than 
morphine in the guinea pig ileum (GPI) assay. The reversal in the rank order of agonist 
potency suggested that the enkephalins were acting at a distinct receptor in the MVD assay, 
and this receptor was therefore entitled the delta (8) receptor. 
Opioid receptors play a major role in the endogenous pain-controlling systems of 
vertebrates. In addition to its involvement in antinociceptive pathways, the opioid receptors 
have been implicated in a number of different biological events (Table 2.1) such as stress-
induced analgesia, locomotor activity, and learning and memory (Olson et al., 1989, Olson 
et al., 1995). These receptors also modulate autonomic functions such as respiration, 
blood pressure, thennoregulation, and intestinal motility. Most recently, pharmacological 
research has implicated the involvement of opioid receptors with the reward pathways for 
alcohol usage (Gianoulakis, 1996), and in the modulation of certain immunological 
functions (Roy and Loh, 1996). 
2.2  Endogenous mammalian opioid peptides 
Opioid receptors can be demonstrated in every vertebrate and even a few invertebrate 
species. Since the existence of opioid receptors are widespread and have survived 
millennia of evolution, scientists had postulated that these receptors must function in an 
endogenous fashion favorable for species survival. The search for endogenous opiate-like 
ligands had a major breakthrough in 1975, when two laboratories independently reported 
that brain extracts contained substances that exhibited opioid activity. In 1975, Hughes and 
co-workers (Hughes et al., 1975) isolated two pentapeptides with opioid receptor activity 
from pig brain, which they named the enkephalins (from "encephalos," or "in the head"). 
Shortly after the identification of the enkephalins, a 31-amino acid fragment of 13­7 
8 
Table 2.1 Physiological consequences of opioid receptor activation 
receptor	  action 
analgesia 
respiratory depression 
physical dependence 
reduction of immunological function 
inhibition of GI transit 
K	  analgesia 
feeding 
diuresis 
analgesia 
positive reinforcement for ethanol 
consumption 
Adapted from: Olson, G.A.; Olson, R.D.; Kastin, A.J. Endogenous Opiates: 1994. 
Peptides. 1995, 16, 1517-1555. 8 
lipotropin, named r3-endorphin, was found to bind to opioid receptors and exhibit potent, 
long-lasting analgesia (Loh et al., 1976). Dynorphin A, representative of another major 
class of endogenous opioid peptides, was isolated and characterized by Goldstein and co­
workers in 1981 (Goldstein et al., 1981). Dynorphin A was shown to be a potent ligand 
for the lc class of receptors. Other endogenous mammalian peptides include a- and 13-neo­
endorphin (Kangawa et al., 1981, Minamino et al., 1981), which are both obtained from 
prodynorphin, and casomorphin (Brand et al., 1979), obtained from the enzymatic 
digestion of the milk protein casein. All of these endogenous opioid peptides share the 
common N-terminal sequence of H-Tyr-Gly-Gly-Phe-Leu/Met (Table 2.2). 
The enkephalins have been postulated as putative endogenous ligands for 8 opioid 
receptors, while the dynorphins are considered to be endogenous ligands for ic receptors. 
Until very recently, the endogenous ligands for 11 receptors were uncertain. Then in 1997, 
Zadina and co-workers (Zadina et al., 1997) described the discovery and isolation of two 
related tetrapeptides, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr­
Pro-Phe-Phe-NH2). The high affinity (Ki = 360 pM) and selectivity (4000- and 15,000 ­
fold preference for g. over 8 and K, respectively) make the endomorphins potential 
endogenous ligands for theg receptor. 
2.2.1  Biosynthesis 
The differentiation of the three opioid peptide families represented by the enkephalins, 
endorphins and the dynorphins was justified by the cloning of their representative opioid 
precursors (Fig. 2.1). The primary sources of these peptides were found to be three 
distinct major protein precursors: pro-opiomelanocortin (POMC) (Nakanishi et al., 1979), 
proenkephalin A (Noda et al., 1982), and prodynorphin (Fisch li et al., 1982) (also known 
as proenkephalin B). The discovery of pro-opiomelanocortin was of great importance in 
that it was the first example of a protein precursor to give rise to several important and 9 
Table 2.2 Endogenous mammalian opioid peptides 
Precursor protein 
Pro-opiomelanocortin 
Proenkephalin A 
Proenkephalin B 
(Prodynorphin) 
Opioid Peptides 
0-endorphin 
8-endorphin 
(0-endorphin 1-27) 
y-endorphin 
((3-endorphin 1-17) 
a-endorphin 
((3-endorphin 1-16) 
Met-enkephalin 
Sequence 
YGGFMTSEKSQTPLVTLFKNAII 
KNAYKKGE 
YGGFMTSEKSQTPLVTLFICNAII 
KNAY 
YGGFMT'SEKSQTPLVTL 
YGGFMTSEKSQTPLVT 
YGGFM 
Met-enkephalin-Arg-Phe  YGGFMRF 
Met-enkephalin-
Arg-Gly-Leu 
Leu-enkephalin 
Peptide E 
a-neo-endorphin 
0-neo-endorphin 
Dynorphin A (1-17) 
Dynorphin A (1-8) 
Dynorphin B 
Dynorphin B (1-29) 
(Leumorphin) 
YGGFMRFGL 
YGGFL 
TGGFMRRVGRPEWWMDYQK 
FL 
YGGFLRKYPK 
YGGFLRICYP 
YGGFLRRIRPKLKWDNE 
YGGFLRRI 
YGGFLRRQFKVVT 
YGGFLRRQFKVVTRSQEDPNAY 
YELPDV 10 
20,  40  ° 
100  120  140  140  100  200  220  240  260 
" 
5 
B.  -a 
ACTH -LPH
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-
r e r,  e r..  e e  r r  e e  r
-i 1 -1  <J  < <  < '5 «  < 
Jt jt 4. AAA.  r.r,  .L..  r,  il.  7.. N  1;  t.  iI. r  i i  . 
L L  C.4  ..1  ..7 
1 YI  I I I  II
 
Pispinenkephalin A
  till  illt  ill  II 
L.! 
Signal  Mm-et Vet-enk Met-enk  Met-enk- Meifenk Ler-enk  Met-enk­
peptide  Arie-Gly'-Leue  Are-Pbe 
Peptide F  Peptide E 
co Ea  to 
< < 1 < elo <-J  a te 'AA  A 
I I  I I 
Preproenkephalin  I 
&vial  Leu -enk  Leu-enk  Leu-enk 
Peptide 
Neo-endorphin  Dynorphin Leumorphin 
Fig. 2.1  Diagram of the protein precursors of the opioid peptides.  Melanocyte­
stimulating hormone (MSH) and enkephalin (enk) are depicted as solid or shaded boxes. 
Cysteines and dibasic cleavage points are shown in the upper portion and biologically 
active peptides are shown in the lower portion of each diagram. 
Source: Imura, H. et al. Endogenous Opioids and Related Peptides: From Molecular 
Biology to Clinical Medicine. J. Endocr. 1985, 107 , 147-157. 11 
distinct biologically active peptides. In addition to the endorphins, pro-opiomelanocortin 
also provides adrenocorticotropin and a family of melanocyte-stimulating hormones 
(MSH): a, (3, and T-MSH. 
Proenkephalin was first discovered in bovine adrenal cortex, and it has subsequently 
been cloned from bovine and human tissues (Evans et al., 1988). It contains one copy of 
Leu enkephalin, four copies of Met-enkephalin, and two copies of C-terminal extended 
Met-enkephalin, one a heptapeptide, and the other an octapeptide. 
The last of the opioid peptide precursors to be characterized was prodynorphin. It has 
been isolated from a variety of mammalian tissues, including brain and spinal cord, 
pituitary, adrenal and reproductive organs. All of the opioid peptides derived from this 
protein, dynorphin A and B and a- and (3-neoendorphin, are C-terminal extensions of leu­
enkephalin. 
There are many similarities between the three opioid peptide precursors (Evans et al., 
1988). They all are similar size, and have several opioid peptides in the C-terminal half of 
the protein. These opioid peptides are framed by basic amino acids which are thought to be 
targets for proteolytic cleavage by processing enzymes. A cysteine-rich N-terminal 
sequence is preceded by signal peptides of comparable size in all three cases. Between 
proenkephalin and prodynorphin, there is a high degree of homology which exceeds 50%. 
The precursor genes also show analogous introns and exons with respect to size and 
placement. All of these similarities suggest that the three genes all arise from a common 
ancestral gene by gene duplication. 
2.2.2  Metabolism 
As in the case of other biologically active peptides, the opioid peptides are quickly 
degraded by a number of peptidases (Marks et al., 1986). The Tyr-Gly bond is cleaved by 
an aminopeptidase (EC 3.4.11), and the Gly-Phe bond is susceptible to enzymatic 12 
proteolysis by either the metalloendopeptidase EC 3.4.24.11 (enkephalinase) or 
angiotensin converting enzyme. An example of how important enkephalinase is to the 
elimination of the opioid peptides is shown by in vivo application of thiorphan, a potent 
inhibitor of enkephalinase. After infusion of thiorphan, analgesic properties were seen as a 
result of potentiated opioid activity through inhibited degradation (Garbay-Jaureguiberry et 
al., 1984). 
2.3  Opioid receptor molecular biology 
A major goal of opioid pharmacology is to develop analgesics devoid of addictive 
potential. It is hoped that through the exclusive activation of one receptor type, adverse 
side effects could perhaps be avoided. Various structure-activity relationships have been 
compiled for the ligands of each of the major receptor types, but ultimately, it is the 
receptor itself that must be characterized in order to fully understand binding and activation 
requirements. A major breakthrough in this area was achieved in 1992, when Evans 
(Evans et al., 1992) and Kieffer (Kieffer et al., 1992) simultaneously cloned the mouse 8 
opioid receptor (mDOR). This was achieved by incorporating cDNA libraries into COS-7 
cells and then testing for radioligand binding of opioids. The clone expressing an opioid-
binding protein was then isolated and characterized.  During the search for novel 
somatostatin receptor clones, the mouse x receptor (mKOR) was isolated and cloned by 
Yasuda and co-workers (Yasuda et al., 1993), which was followed by the cloning of the 
ratµ receptor (rMOR) by Chen and co-workers (Chen et al., 1993a) using a low stringency 
hybridization probe from mDOR. Since these early advancements, the major opioid 
receptors have been cloned from a variety of species and tissues (Satoh and Minami, 1995) 
(Table 2.3). High homology was seen between receptor types, and for each receptor type 
from different species. The conservation of amino acid residues in the receptors of 
differing species hints at the evolutionary importance of these receptors in mammalian 
development. 13 
Table 2.3 Molecular cloning of opioid receptors 
Receptor Class 
8 
11 
x 
Species 
mouse 
rat 
human 
mouse 
rat 
human 
mouse 
rat 
guinea pig 
human 
Origin 
NG108-15 
cerebrum 
striatum 
SH SY5Y 
brain 
cereral cortex 
brain 
brain 
brain 
placenta 
Reference 
(Evans et al., 1992) 
(Kieffer et al., 1992) 
(Fukuda et al., 1993) 
(Knapp et al., 1994) 
(Simonin et al., 1994) 
(Kaufmann et al., 1994) 
(Chen et al., 1993a) 
(Wang et al., 1993) 
(Bunzow et al., 1995) 
(Wang et al., 1994) 
(Yasuda et al., 1993) 
(Chen et al., 1993b) 
(Xie et al., 1994) 
(Mansson et al., 1994) 14 
The availability of all three major opioid receptors reveals similarities and differences 
between the opioid receptor types (Kieffer, 1995, Reisine and Bell, 1993, Satoh and 
Minami, 1995). The amino acid sequences of these receptors suggest the existence of 
seven transmembrane regions, a trait seen in the family of receptors known as G-protein 
coupled receptors. Regions that differ the most are the N- and C-termini. All three 
receptors have the DRY sequence and Asp residues in the second and third transmembrane 
regions (TM2 and TM3) that are also characteristic of G-protein coupled receptors. In the 
N-terminus, two potential glycosylation sites have been identified, and a possible site for 
palmitoylation is located near the C-terminus. A proposed disulfide linkage may be 
achieved between two conserved Cys residues located in the first and second extracellular 
loops (EL1 and EL2) (see Fig. 2.2). 
The availability of the cloned receptors offers an opportunity for researchers to study 
individual opioid receptor types with regard to pharmacological profile, structure-function 
analysis, cellular effector coupling, and receptor regulation. The cloned opioid receptors 
exhibited the expected binding affinities for various ligands based on earlier 
pharmacological studies, and it was confirmed that analgesics with high abuse potential 
have high selectivity for the 11 receptor (Raynor et al., 1994) (Table 2.4).  Thus, the 
addictive opioids morphine, fentanyl, and methadone have high affinities for the II 
receptor, but little or no affinity for the 8 or lc receptors. 
2.3.1  Structure-function analysis of the opioid receptors 
A pattern was found in the different opioid receptors in which the transmembrane 
helices, intracellular loops and a small portion of the C-terminus are highly homologous, 
but EL2 and EL3 and the N- and C-termini are divergent (Kieffer, 1995). These 
observations, combined with the knowledge of how G-protein coupled receptors 15 
Table 2.4 Binding affinities (nM) of ligands for the cloned  8-, and wopioid receptors 
lc receptor  8 receptor  11 receptor 
[3H]U- 69,593  [3}Thaltrindole  [31I]DAMGO 
Non-selective compounds 
Dynorphin A  0.5  >1000  32 
Leu-enkephalin  >1000  4.0  3.4 
Met-enkephalin  >1000  1.7  0.65 
3- endorphin  52  1.0  1.0 
(-)-Naloxone  2.3  17  0.93 
Levorphanol  6.5  5.0  0.086 
Ethylketocyclazocine  0.40  101  3.1 
Etorphine  0.13  1.4  0.23 
Pentazocine  7.2  31  5.7 
Diprenorphine  0.017  0.23  0.072 
Naltrexone  3.9  149  1.0 
Nalbuphine  3.9  >1000  11 
Nalorphine  1.1  148  0.97 
g-selective compounds 
CTOP1  >1000  >1000  0.18 
Dermorphin  >1000  >1000  0.33 
Methadone  >1000  >1000  0.72 
DAMGO2  >1000  >1000  2.0 
PL0173  >1000  >1000  30 
Morphiceptin  >1000  >1000  56 
Codeine  >1000  >1000  79 
Fentanyl  255  >1000  0.39 
Sufentanyl  75  50  0.15 
Lofentanil  5.9  5.5  0.68 
Naloxonazine  11  8.6  0.054 
Morphine  538  >1000  14 
K-selective compounds 
Norbinaltorphimine  0.027  65  2.2 
Spiradoline  0.036  >1000  21 
U-50,488  0.12  >1000  >1000 
U-69,593  0.59  >1000  >1000 
ICI 204,488  0.71  >1000  >1000 
1 D-Phe-cyc/o[Cys-Tyr-D-Trp-Orn-Thr-Pen]-111r-NH2 
2Tyr-D-Ala-Gly-NMePhe-NHCH2OH 
3Tyr- Pm- NMePhe- D- Pro-NH2 16 
Table 2.4 -continued 
x receptor  8 receptor  p. receptor 
[3H]U- 69,593  [3H]naltrindole  [311]DAMGO 
8-selective compounds 
DPDPE4  >1000  14  >1000 
D-Ala2-Delt II  >1000  3.3  >1000 
DSLET5  >1000  4.8  39 
BW 3734  17  0.013  26 
DADLE6  >1000  0.74  16 
SIOM  >1000  1.7  33 
Naltrindole  66  0.02  64 
Nalriben  13  0.013  12 
BNTX7  55  0.66  18 
Source: Raynor, K. et al. Pharmacological Characterization of the Cloned lc-, 8- and p.­
Opioid Receptors Mol. Pharmacol. 1994, 45, 330-334. 
4Tyr-cyclo[D-Pen-Gly-Phe-D-Pen]-0H 
5Tyr-D-Ser-Gly-Phe-Leu-Thr 
6Tyr-D-Ala-Gly-Phe-D-Leu 
77-Benzylidenenahrexone 17 
A" 
K
 
Fig. 2.2 Schematic diagram of the rat p., 8, and x receptors. The opioid receptors share
common characteristics with other G-protein coupled receptors, such as the seven 
transmembrane regions, a putative palmitoylation site near the C-terminus, and conserved 
Cys residues that may be involved in disulfide formation. Dark circles indicate identical 
residues among all three receptors; shaded circles indicate identical residues in two out of 
three receptors; open circles indicate unique residues for each receptor. 
Source: Chan, Y.; Mestek, A.; Liu, J.; Yu, L. Molecular Cloning of a Rat x Opioid 
Receptor Reveals Sequence Simi Rarities to the p. and 8 Opioid Receptors. Biochem. J. 
1993,295, 625-628. 18 
communicate across the cell membrane, suggest a structure-function relationship for opioid 
receptors. Presumably, a binding pocket can be formed by the seven transmembrane 
helices with the extracellular loops discriminating between different opioid 
ligands, thereby affording the apparent selectivity between t, 8, and x receptors. The 
strong sequence homology seen in the third intracellular loop (1L3) and a small sequence in 
the C-terminus implies that the opioid receptors all interact with similar G-proteins. The 
high level of divergence in the C-terminus presents the possibility that different regulation 
patterns for the 11., 8, and x receptors by intracellular mechanisms may be in effect 
(Chakrabarti et al., 1997) (Fig. 2.2). 
2.3.2  Chimeric and site-directed mutagenesis studies 
With the use of recombinant DNA, many studies have begun shedding light on the 
binding areas of the receptors, and on requirements for activation as well. Especially 
useful has been the application of chimeric receptors and site-directed mutagenesis. It was 
found that removal of the N-terminal regions of the opioid receptors did not adversely 
affect ligand binding or signal transduction (Kong et al., 1994, Wang et al., 1993). These 
findings suggest that putative N-glycosylation may play a role in protein targeting to the cell 
surface without being of crucial importance for receptor function (Kieffer, 1995). Initial 
studies to assess structural requirements at the receptor binding site primarily relied upon 
domain-swapping experiments. The resulting hybrid receptors are referred to as chimeras, 
after the legendary beast of Greek mythology. Chimeric studies have allowed the 
identification of determinants for opioid receptor selectivity. 
2.3.2.1  Determinants of 8-selectivity 
Comparisons of the amino acid sequences of the three major types of opioid receptors 
reveal that the extracellular loops and N-termini of the receptors have the highest degrees of 19 
variability. Kong and co-workers (Kong et al., 1994) have shown that replacement of the 
first 78 residues of the 8 receptor by those of the x did not modify the 8-selectivity of 
DPDPE, naltrindole, [D-Ser2,Thr6]enkephalin (DSLET) or deltorphin II. Meng and 
colleagues (Meng et al., 1996) have also demonstrated that introduction of more x 
sequences (from the N-terminus up to TM3) into 8 receptors barely affects 8 ligand 
binding, suggesting that the first three transmembrane regions are little used in 8 ligand 
recognition. These early chimeric studies therefore pointed towards the C-terminal half of 
the receptor as being involved in ligand recognition. 
With the putative region largely responsible for 8 ligand binding identified, many 
research groups then turned to point mutation studies to identify residues critical for ligand 
binding. From work done on fl-adrenergic receptors (Strader et al., 1987), the Asp residue 
in TM3 provides important electrostatic stabilization for the cation of f3- adrenergic ligands. 
In order to test this hypothesis for 6- opioid binding, Livingston et.al. (Livingston et al., 
1995) mutated Asp128 in TM3 to Asn in the mDOR, and tested the effects of this mutation 
on ligand binding. The mutation abolished high affinity agonist binding to the receptor but 
did not affect selective antagonist binding. In a related study (Kong et al., 1993), Asp95 
located in TM2 of mDOR was mutated to Asn. It was determined that this residue is 
essential for the binding of specific agonists, but does not seem to play an especially 
important role in binding either non-specific agonists or antagonists. These two studies 
show that both Asp95 and Asp128 of the mDOR are essential for high affinity binding of 
selective agonists, but that only Asp128 is needed for non-selective agonist binding to the 
receptor. The lack of effect of either mutation on the binding of antagonists suggests that 
agonists and antagonists may bind to 6 receptors via distinct molecular mechanisms, 
possibly to different ligand binding domains. An interesting note that was not touched 
upon is that the selective agonists used in these studies were peptide-based, whereas the 
non-selective agonists and selective antagonists were non-peptide in nature. Therefore, 20 
another possibility extrapolated from this data could be that peptides bind differently to the 
8 receptor than do non-peptides. 
For the stabilization of the carboxy terminus of 8 peptide ligands, Wang et al. (Wang et 
al., 1996) proposed that vicinal Arg residues located in EL3 (Arg291 and Arg292) may be 
responsible for anion stabilization. Another group (Varga et aL, 1996) suggested that these 
Arg residues may act to neutralize nearby Asp residues within the receptor itself, and that it 
is this decrease of local negative charge that determines the selectivity of 8 opioid peptides. 
Charged residues are not the only important factors in ligand/receptor complex 
formation. Hydrophobic residues are involved in van der Waals interactions which can 
play a significant role in receptor binding. In a study done by Valiquette et. al. (Valiquette 
et al., 1996) involving both chimeric and point mutation studies, it was found that residues 
Trp284, Va1296, and Va1297 of the human 8 opioid receptor (hDOR) constituted a 
hydrophobic region which was important for normal binding of 8-selective ligands. These 
residues reside on EL3 of hDOR, and replacement of these residues by alanine resulted in a 
decrease in binding of the 8-selective ligands SNC-80, cyclo[D- Pen2,D- Pen5]enkephalin 
(DPDPE), deltorphin II, and naltrindole, while not affecting the binding of the non­
selective ligand bremazocine. Replacement of Trp284 resulted in the largest decrease in 8 
binding, suggesting that this residue plays a major role in ligand recognition. In a similar 
study, Hjorth and co-workers (Hjorth et al., 1995) proposed that G1u297 of rKOR plays a 
similar role in the binding of K ligands, and Valiquette notes that G1u297 of the K receptor 
and Trp284 of the 8 receptor are located at corresponding positions of the two receptors. 
The authors then suggest that the residue at this position (8=Trp, K=Glu, and g=Lys) may 
represent a crucial recognition site for opioid ligands. 
The crucial nature of this hydrophobic region near the end of EL3 was further 
emphasized by a novel "restoration of function" assay (Pepin et al., 1997). In this study, 
the region corresponding to EL3 of hMOR was inserted into hDOR. A library of mutants 
was generated in which some of the 10 amino acids in EL3 were reverted back to the 21 
corresponding 8 amino acid. The "restored" mutants all exhibited a hydrophobic region 
between residues 295-300, and an Arg residue at position 292. 
2.3.2.2	  Agonist vs. antagonist activity 
In a study done by Claude and co-workers (Claude et al., 1996), chimeric studies of the 
opioid receptors revealed that opioid antagonists (i.e. naloxone, naltrexone, naltriben, and 
TIPPW) were able to act as agonists with respect to inhibiting forskolin-stimulated adenylyl 
cyclase activity in chimeric opioid receptors expressed in CHO cells. By sequence analysis 
and back mutation, it was found that the observed agonist activity was due to the mutation 
of a conserved Ser to Leu in TM4. The importance of this serine residue was further 
demonstrated by analogous mutations created in the p. (MORS196L) and the 8 
(DORS177L) receptors, which resulted in imparting agonist activity to the aforementioned 
antagonists. The authors hypothesize that the mutation of the Ser to a non-hydrogen 
bonding residue results in a disruption of receptor tertiary structure, resulting in a more 
"permissive" receptor activation state. 
2.3.2.3  Receptor down-regulation 
The techniques of molecular biology have also been used in the study of opioid receptor 
down-regulation.  It has been long known that prolonged exposure to opioids leads to 
decreased response to the ligand; this reduced sensitivity is thought to be due to the loss of 
receptors, or down-regulation.  Previous studies done with other G-protein coupled 
receptors (i.e. adrenergic receptors) (Dohlman et al., 1991) have shown that the C-terminus 
is instrumental in down-regulation via the phosphorylation of certain side chains. A C­
tenninal truncated mDOR was cloned in CHO cells, and exhibited no change in receptor 
density even after prolonged (2-48 h) exposure to the 8 agonist [D-Ala2,D-Leu5]enkephalin 
(DADLE) (Cvejic et al., 1996). The C-terminal truncated mutant did not exhibit any 22 
difference in functional coupling, which confirms the observation that the C-terminus is not 
important for G-protein coupling. Point mutation studies of the phosphorylatable groups in 
the C-terminus (i.e. Ser344, Thr352, and Thr353) showed that mutation of Thr353 to Ala 
results in a receptor type that does not down-regulate even after 48 h of agonist treatment. 
2.4  Delta opioid receptor subtypes 
Over the past twenty years, the opioid receptor family has been well documented, and 
the existence of the three major opioid receptor types is well established and accepted. In 
addition, pharmacological evidence for receptor subtypes for all three opioid receptors has 
been increasing these past few years (Mania et al., 1991, Paul et al., 1989, Sofuoglu et al., 
1991, Zukin et al., 1988). Especially compelling evidence for the existence for receptor 
subtypes has been compiled for the 8 opioid receptor (Zaki et al., 1996). 
The first studies involving 8 opioid receptor subtypes dealt with DPDPE and the 8­
selective peptide derived from amphibian skin [D-Ala2,G1u4]deltorphin, sometimes referred 
to as deltorphin II. It was found that treatment with [D-Ala2,Cys6]enkephalin (DALCE), a 
8-selective affinity label, selectively antagonizes the antinociceptive effects of DPDPE, but 
not that of [D- Ala2,Glu4]deltorphin or of p. agonists (Jiang et al., 1991). Conversely, it 
was also found that the 8-selective affinity label naltrindole isothiocyanate (NTII) could 
selectively antagonize the effects of [D-Ala2, Glu4]deltorphin, but not DPDPE. 
The hypothesis of subtypes of 8 opioid receptors was further explored by employing 
classic tolerance and cross-tolerance studies. It was postulated that if DPDPE and [D-Ala2, 
Glufldeltorphin were producing their supraspinal antinociception at different receptors, 
then antinociceptive cross-tolerance might not occur.  It was found that after inducing 
analgesia with repeated applications of the aforementioned 8-selective compounds and the 
g-agonist DAMGO, cross tolerance between these three compounds could not be observed 
(Mania et al., 1991, Sofuoglu et al., 1991). These studies have led to the classification of 
the 8 opioid receptors as the 81 and 82 subtypes, a classification based on selective 23 
antagonist studies. The 81 receptor subtype is defined as being activated by DPDPE, and 
antagonized by DALCE. The 82 receptor subtype is activated by ED-Ala2, Gluideltorphin, 
and antagonized by NTH. 
Despite the existence of compelling pharmacological evidence, demonstration of 8 
opioid receptor subtypes in binding studies has been inconclusive so far.  Negri and 
colleagues (Negri et al., 1991) have suggested the existence of 8 subtypes in rat brain, as 
evidenced by biphasic inhibition of [311][D-A1a2, Gluldeltorphin binding by DPDPE. 
However, competition binding experiments done with [D-Ala2,Glu4]deltorphin inhibition 
of [3H]DPDPE binding exhibited a monophasic binding pattern, suggesting receptor 
homogeneity. More recently, Fang and co-workers (Fang et al., 1994) have studied the 
binding characteristics of [31-I]NTI binding in mouse brain and mouse vas deferens. 
Through competitive interaction with selective agonists, multiple binding sites were 
observed in mouse brain, but only a single binding site was evident in the vas deferens. 
These studies have added support for the heterogeneity of 8 receptors in mouse brain and 
suggests the possibility that 8 receptors in the mouse vas deferens may differ from those 
found in the brain. 
With the cloning of the 8 receptor the possible existence of subtypes can be examined by 
using antisense oligodeoxynucleotides (ODN) (Wahlestedt, 1994). Antisense ODNs are 
short, synthetic, single stranded DNA whose mode of action is through their hybridization 
to complementary sequences in the target gene or its messenger RNA; this interferes with 
the normal translation of the gene, resulting in a reduction, or "knock down," of the protein 
product. Pasternak and co-workers (Bilsky et al., 1994) examined antisense ODNs for the 
8 opioid receptor in mice. When given intracerebroventrically (i.c.v.), pretreatment with an 
antisense (but not mismatch) ODN for the 8 opioid receptor blocked the antinociceptive 
actions of i.c.v. [D-Ala2,G1u4]deltorphin, but not that of i.c.v. DPDPE. However, when 
the antisense (or mismatch) ODN was given intrathecally (i.t.), it was found that the 
antinociceptive actions of DPDPE and [D-Ala2,G1u4]deltorphin were both inhibited, but 24 
that the antinociceptive actions of the p.-agonist DAMGO was unaffected.  These 
experiments added pharmacological evidence for receptor heterogeneity in mouse 
supraspinal sites, and that the analgesic activity of 8 opioid agonists at the spinal level is 
mediated by a single 8 receptor subtype, the 82 opioid receptor. 
Despite the growing amount of evidence implicating subtypes of the opioid receptors, 
attempts to isolate and clone the genes for the different subtypes have not yet been 
successful. Therefore, on the molecular level, the existence of opioid receptor subtypes 
has yet to be proven. The fact that extensive homologous screening for these subtypes has 
not proven successful has prompted researchers to speculate as to why the subtypes are so 
elusive. The theories for receptor diversity include alternative splicing, posttranslational 
modifications, a difference in associated proteins, and perhaps a difference in receptor 
location and ligand accessibility (compartmentalization) (Zaki et al., 1996). 
There is also evidence that there are interactions between p- and 8-receptors (Traynor 
and Elliott, 1993). Porreca and co-workers (Jiang et al., 1990b) have shown that at sub-
analgesic doses, 8-opioid receptor agonists can modulate the efficacy of p.-opioid receptor 
agonists. At subanalgesic doses, DPDPE was able to potentiate the effects of i.c.v. 
morphine. Conversely, the agonists [D-Ala2,Met5]enkephalinamide (DAMA) and [Met5]­
enkephalin were found to inhibit the antinociceptive effects of morphine. Although these 
modulatory effects are also seen in opioid-induced inhibition of intestinal motility, 8­
agonists do not seem to effect the development of morphine tolerance. The positive and 
negative modulatory effects of 8-agonists can be prevented by pretreatment with the 8 
antagonist ICI-174,864. 
As in the case of classifying the 81 and 82 subtypes, irreversible antagonists were 
important in the study of the complexed 8 receptor (80E) and the non-complexed 8 receptor 
(8nex) (Jiang et al., 1990a). When DALCE was given i.c.v., inhibition of 8-mediated 
analgesia was observed, but it did not affect the modulatory effects of DPDPE or 
[Met5]enkephalin on morphine-induced antinociception. In contrast, the conformationally 25 
constrained enkephalin analog [D-Ala2,(2R,35)cyclopropylPhe4] enkephalin (CP-OH) is 
able to modulate the actions of morphine, but does not show direct analgesia. 
2.5  Conclusions 
The field of opioid pharmacology has made incredible gains towards the understanding 
of the actions and binding requirements of opioid receptor activation. Starting with the 
demonstration of stereoselective binding of opioids (Pert and Snyder, 1973, Simon et al., 
1973, Terenius, 1973), through the isolation of endogenous opioids and the development 
of selective ligands, and culminating with the cloning of and recombinant experimentation 
with the opioid receptors, the pieces of the opioid puzzle are starting to fit together. Despite 
the overall achievements in the field, some lingering questions remain: is it possible to 
achieve analgesia without undesired side effects? Given the primary structures of the 
opioid receptors, which residues are essential for ligand binding and/or selectivity? If 
opioid receptor subtypes exist, are they different in amino acid composition, or by other 
differences, such as posttranslational modifications? 
One way to help answer those questions is through the development of selective 
irreversible ligands (affinity labels). The affinity labels already in use have contributed 
greatly towards the understanding of opioid pharmacology. The recent recombinant work 
with opioid receptors has suggested potential differences in the binding sites of agonists 
and antagonists, and possibly peptides and non-peptides. A wider variety of affinity labels 
would help identify which residues are near the binding site by alkylation, and their 
irreversible nature would help in the isolation and characterization of receptors expressed in 
various tissues. Selective affinity labels based on antagonists may also be used for the 
elucidation of physiological effects. 26 
Chapter 3
 
Literature Review: Delta-Selective Opioid Ligands
 
3.1 Introduction 
While pain is an important adverse stimulus necessary for survival, for millennia 
humans have sought to alleviate it. For the treatment of pain, the extract of the opium 
poppy Papaver sommferum has been a mixed blessing: it is an excellent analgesic, but the 
serious side effects of addiction and respiratory depression precludes its therapeutic 
usefulness. In an effort to separate the analgesic properties of the opiate drugs from their 
undesired side effects, many synthetic and semi-synthetic were created and tested. These 
early attempts in the field of opioid medicinal chemistry did not yield a "perfect" analgesic, 
but many clinically useful drugs did result from these studies, such as meperidine, 
methadone, propoxyphene, nalorphine, and phenazocine. 
Synthetic methods, screening studies, and isolation from various biological sources 
have resulted in a wide variety of structurally diverse opioid ligands. Selective agonists 
and antagonists have been instrumental in the characterization of the three major types of 
opioid receptors: the mu (p.), kappa (c) and delta (5) opioid receptors. The heterogeneity 
of these receptors has recently been confirmed through molecular biology (Kieffer, 1995, 
Reisine and Bell, 1993, Satoh and Minami, 1995). In addition, selective ligands have been 
used to accumulate evidence strongly suggesting the existence of receptor subtypes for all 
three opioid receptors (Mattia et al., 1991, Paul et al., 1989, Sofuoglu et al., 1991, Zukin 
et al., 1988). 
The opioids with high addiction potential have been shown to interact preferentially with 
the p. receptor (Raynor et al., 1994). As a result, interest in the 5 receptor is increasing 
rapidly, as research suggests that this receptor is able to produce antinociception with lesser 
abuse potential (Rapaka and Porreca, 1991), and it is also implicated in the reward 
pathways of cocaine and alcohol abuse (Gianoulakis, 1996). 27 
3.2 Delta-selective opioid peptide agonists 
In the study of heterogeneous receptors, it is important to utilize agonists and 
antagonists with selectivity for the receptor under question. The earliest examples of 
ligands with a slight preference for 8 opioid receptors were the endogenous opioid peptides 
Leu- and Met-enkephalin (Hughes et al., 1975). These peptides were found to be more 
effective in inhibiting the electrically stimulated twitch of the mouse vas deferens than 
morphine, and were instrumental in defining the 8 opioid receptor (Lord et al., 1977). 
Since the isolation of the enkephalins from pig brain extracts, the search for other naturally 
occurring opioid peptides have revealed the existence of numerous peptides from a variety 
of sources. An unusual source of 8-selective opioid peptides are the subcutaneous glands 
of the Phyllomedusa bicolor frog of South America (Erspamer, 1992).  These 
heptapeptides are orders of magnitude more selective for the 8 receptor than the 
endogenous opioids found in mammalian systems. This exceptional selectivity is reflected 
in the name for this class of opioid peptides: the deltorphins (the first reported deltorphin 
peptide is also referred to as dermenkephalin). The deltorphins share a common N-tenninal 
sequence (Tyr-D-Xaa-Phe) with a class of p.-selective opioid peptides also secreted by the 
same species of frog, known as the dermorphins. This shared N-terminal sequence 
contrasts with the common sequence seen in mammalian opioid peptides, Tyr-Gly-Gly-
Phe. The differences between the mammalian and amphibian opioid peptides can be seen 
in Table 3.1. 
In the drive to synthesize peptide analogs, it should be no surprise that early attempts to 
develop 8-selective ligands were based on modifications to the enkephalin parent 
molecules, the earliest ligands known with preference for 8 receptors. Enkephalin is 
quickly metabolized by various peptidases to inactive fragments (Hambrook et al., 1976), 
and therefore, one of the earliest goals of enkephalin modification was to increase metabolic 28 
stability. Depending on the nature of the modification, the enkephalin analog could show 
selectivity for either 11 or 5 receptors (enkephalins generally have very low affinity for x 
receptors). Substitution of a D-amino acid in position 2 was one of the early modifications 
to enkephalins in order to increase metabolic stability. It was found that this substitution 
increased potency at bothµ and 8 receptors and is therefore found in a majority of 
enkephalin analogs. [D-Ala2,D-Leu5]enkephalin (DADLE) was an early derivative which 
took advantage of placing a D-amino acid in position 2 in order to increase S selectivity 
(Beddell et al., 1977). These modifications to the enkephalin parent molecule were 
performed well before the discovery of the deltorphins, which also have a D-amino acid at 
the 2 position. Generally, if a hydrophilic D-amino acid (i.e. D-Ser, D-Thr) is substituted 
in position 2, 5 selectivity is observed. Mu ligands generally prefer a more hydrophobic 
residue at position 2.  At the C-terminus more selective 8 ligands usually contain a free 
carboxylic acid, and lengthening the peptide chain with an amino acid such as Thr can 
result in increased 8-selectivity. Incorporation of a D-Ser at position 2 coupled with peptide 
chain lengthening with Thr, led to [D-Ser2,Thr6]enkephalin (DSLET), which shows a 
slight preference for S receptors (Gacel et al., 1988). Changing the D-Ser to a D-Thr leads 
to the increased 8 selectivity seen for the ligand [D-Thr2,11r6]enkephalin (DTLET) (Zajac 
et al., 1983). It was also found that increasing the steric bulk at positions 2 and 6 also 
helped confer increased 8 selectivity to the peptides. This was done by incorporating a tBu 
ether into those positions. These substitutions led to [D-Ser(OtBu)2,Thr6]enkephalin 
(DSTBULET) 
and [D-Ser(OtBu)2,Thr(OtBu)6]enkephalin (BUBU) (Gacel et al., 1988). The increased 
steric bulk decreased affinity for the ix receptor, and in doing so, increased selectivity for 
the 8 receptor. These modifications to enkephalin and their effect on S receptor binding and 
selectivity can be seen in Table 3.2. 29 
Table 3.1 Binding affinities of naturally occurring 8-selective opioid peptides 
Ki (nM)  Ki 
peptide  sequence  A  6  ratio 
Leucine enkephalin  YGGFL  9.43  2.54  3.71 
Methionine enkephalin  YGGFM 
Deltorphin (or Dermenkephalin)  Y-DM-FHLMD-NH2  1630  2.41  676 
[D-Ala2]deltorphin I  Y- DA- FDVVG -NH2  3150  0.15  21000 
[D-A1a2]deltorphin II  Y- DA- FEVVG -NH2  2450  0.71  3450 
Table 3.2 Binding affinities of linear enkephalin analogs 
Ki(nM)  Ki 
peptide  sequence  ratio V 8 
DSLET  Y-DS-GFLT  31.0  4.80 MI= 
6.46 
Y-DT-GFLT  23.3  1.35  17.3 
DSTBULET  Y-DS(tBu)-GFLT  374  6.14  60.9 
BUBU  Y-DS UBM-GFLT(tBu)  475  4.68  101 
Source: Aldrich, J.V. in Burger's Medicinal Chemistry and Drug Discovery, 5th ed; 
Wolff, M.E., Ed.; John Wiley and Sons: New York, 1996; Vol. 3, Chapter 41. 30 
Conformational constraints are commonly used in peptide chemistry to limit peptide 
flexibility and stabilize a "bioactive" conformer in an effort to increase affinity and/or 
selectivity for a given receptor. These constraints can either be global (through head-to-tail 
or side-chain to side-chain cyclizations) or local (through incorporation of amino acid 
derivatives with side chain modifications). In the case of 8 opioid peptides, conformational 
constraints were used successfully to increase 8 selectivity (Table 3.3). The first examples 
of disulfide cyclization utilizing Cys residues at positions 2 and 5 were done by Sarantakis 
(Sarantalds, 1979) and Schiller (Schiller et al., 1981). These cyclic enkephalin analogs 
only exhibited a slight preference for 8 over 11 receptors, but 8 selectivity increased 
dramatically by substituting penicillamine (Pen) residues for Cys. The cyclic pentapeptide 
cyclo[D- Pen2,D- Pen5]enkephalin (DPDPE) is one of the most selective 8 agonists to date 
(Mosberg et al., 1983).  It is thought that the geminal dimethyl groups of Pen further 
reduces conformational flexibility of the peptide, resulting in increased selectivity. 
Investigation of substituents on the Phe4 residue revealed that a p-chlorine at this position 
resulted in increased 8 selectivity (Schiller et al., 1989).  In order to further limit 
conformational freedom, the ring size of DPDPE was contracted by deleting the Gly3 
residue. The result was increased 8 selectivity in the cyclic tetrapeptide Tyr-c[D- Cys -Phe-
D- Pen] -OH (JOM-13) (Mosberg et al., 1988). Unlike the DPDPE series in which 8­
selectivity is maintained despite various substitutions in residues 2 and 5, any variation in 
JOM-13 results in greatly reduced 5 affinity. 31 
Table 3.3 Binding affinities of cyclic enkephalin analogs 
Ki (nM)  Ki 
peptide  II  8  ratio 
Tyr -c[D- Pen -Gly- Phe -D- Pen] -OH 
(DPDPE)  609  5.25  116 
Tyr -c[D- Pen -Gly- Phe -L- Pen] -OH 
(DPLPE)  3710  10.0  371 
Tyr-c[D-Pen-Gly-pC1-Phe-D-Pen]-0H  901  1.57  574 
Tyr- c[D -Cys- Phe -D- Pen] -OH 
(J0M-13)  1210  1.90  637 
Source: Aldrich, J.V. in Burger's Medicinal Chemistry and Drug Discovery, 5th ed; 
Wolff, M.E., Ed.; John Wiley and Sons: New York, 1996; Vol. 3, Chapter 41. 
R = H (±)-BW373U86 
R = CH3 (+)-SNC-80 (aR, 2S, 5R) 
OR 
* . 0 
HO  H  HO  O  0 
Oxymorphindole (OMI)  7-Spiroindanyloxymorphone (SIOM) 
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3.3 Delta-selective non-peptide opioid agonists 
Until very recently, all of the 8-selective agonists were peptidic in nature, but in the past 
few years the first nonpeptidic 8-selective opioid agonists were described (Fig. 3.1). 
BW373U86 was discovered through pharmacological screening, and shows a modest 
selectivity for 8 receptors (Chang et al., 1993). In antinociceptive tests done in mice, it 
seems to act as a partial agonist at both 8 and g receptors.  Initial tests involving 
BW373U86 were done with the racemate, which complicated the pharmacological profile 
of the compound. Therefore Rice and co-workers separated and characterized the different 
isomers and subjected them to opioid binding assays. It was found that isomers with the R 
configuration at the benzylic carbon exhibited greater affinity for S receptors than did 
isomers with the S configuration. The methyl ether derivative of (+)-BW373U86 exhibited 
increased selectivity for the 8 over p. receptor in binding assays and in smooth muscle 
assays (-2000-fold selectivity) (Calderon et al., 1994). The methyl ether derivative is 
known as SNC-80, and to date it is the most selective non-peptide agonist for the 8 opioid 
receptor. 
A different approach was taken by Portoghese and co-workers, in which they postulated 
a properly spaced aromatic moiety (an "address" sequence) held away from the morphinan 
structure (the "message" sequence) would increase 8-affinity to a non-selective opioid 
agonist. The non-selective agonist oxymorphone underwent indole functionalization to 
give the 8-selective partial agonist, oxymorphindole (OMI) (Portoghese et al., 1990). The 
partial success of OMI prompted the researchers to investigate the orientation of the 
aromatic ring in their agonist derivatives. This led to the attachment of a spiroindane ring 
system onto oxymorphone to give the 8i-selective agonist, 7-spiroindanyloxymorphone 
(SIOM) (Portoghese et al., 1993). 33 
3.4 Delta-selective opioid peptide antagonists 
Antagonists for a specific receptor are valuable research tools for the elucidation of 
receptor-specific physiological effects. Such antagonists for 8 opioid receptors were 
instrumental in ascertaining the ability of 8 receptors mediate analgesia. Early work done 
on antagonists were based on modifying the 4,5- epoxymorphinan structure by varying the 
N-substituent. It was found that while certain N-substituents (like the phenethyl moiety) 
increase agonist activity, many other substituents, like propyl, allyl, cyclopropylmethyl, 
and cyclobutylmethyl, impart antagonist activity to the ligand. Following this example, the 
early work in synthesizing peptide-based antagonists for the 8 opioid receptor concentrated 
on N-terminal substituents to impart antagonistic activity. This led to the synthesis of ICI­
174,864, a pentapeptide enkephalin analog with diallyl functionalization at the N-terminus 
(Cotton et al., 1984). The glycines of enkephalin in positions 2 and 3 are replaced with 
Aib (2-aininoisobutyric acid) in ICI-174,864. These sterically hindered residues limit the 
conformational flexibility of the peptide backbone. It was also found that N,N-dibenzyl 
derivatives of enkephalin exhibited 8-selective antagonism (Lovett and Portoghese, 1987a). 
Through either synthesis or isolation, it was found that a number of opioid peptides 
have a Phe residue at the 3 or 4 position, and a Tyr residue at position 1. Examples of 
opioid peptides with Phe at position 3 include the amphibian-derived peptides deltorphin 
and dennorphin, and examples of peptides with a Phe at position 4 include the mammalian 
endogenous opioid peptides the enkephalins. Through the synthesis and pharmacological 
testing of a number of opioid peptide derivatives containing para-nitro Phe derivatives at the 
3 or 4 position, it has been postulated that Phe3-containing opioid peptides utilize a 
different aromatic binding site than do Phe4-containing peptides (Schiller et al., 1983). In 
an effort to utilize both putative aromatic binding sites, Schiller and co-workers investigated 34 
Table 3.4 Activities of peptide-based antagonists for delta opioid receptors 
peptide  sequence  Kc (nM1
ICI-174,864  diallyl-Tyr-Aib-Aib-Phe-Leu-OH  17 
(3n)2 Leu enk  dibenzyl-Tyr-Gly-Gly-Phe-Leu-OH 210
TIPP  Tyr-Tic-Phe-Phe-OH  3.0-5.9 
TIPP-NH2  Tyr-Tic-Phe-Phe-NH2  14-18 
Tyr-D-Tic-Phe-Phe-NH2  (p.- agonist, IC50=37 in GPI) 
Source: Aldrich, J.V. in Burger's Medicinal Chemistry and Drug Discovery, 5th ed; 
Wolff, M.E., Ed.; John Wiley and Sons: New York, 1996; Vol. 3, Chapter 41. 
X = NH naltrindole (NTI)  7-benzylidenenaltrexone
X = 0  naltriben (NTB)  (BNTX) 
Fig. 3.2 Non-peptide antagonists for delta opioid receptors 35 
a number of tetrapeptides containing Phe at both the 3 and 4 positions. Depending on the 
identity and stereochemistry of the amino acid at position 2, a number of  or 8-selective 
ligands were synthesized. When the researchers incorporated the conformationally 
constrained Phe analog L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in position 
2, a highly potent and selective 8 antagonist Tyr-Tic-Phe-Phe (TIPP) resulted (Schiller et 
al., 1992). 
3.5 Delta-selective non-peptide opioid antagonists 
Non-peptide opioid antagonists historically have been based on the morphinan­
structure, and generally exhibited low (if any) selectivity for a specific receptor type. 
Examples of such antagonists include naloxone and naltrexone. Portoghese and co­
workers postulated that a properly placed aromatic ring on a non-selective antagonist would 
serve to mimic the Phe4 of the enkephalins, thereby imparting 8-selectivity to the ligand. 
This approach to ligand design resulted in a number of selective compounds, two of which 
showed exceptional 8-selective antagonism: naltrindole (NTI) (Portoghese et al., 1990), 
naltriben (NTB) (Portoghese et al., 1991) and 7-benzylidenenaltrexone (BNTX) 
(Portoghese et al., 1992) (Fig. 3.2). In both of these compounds, the additional aromatic 
ring which imparts the 8-selectivity is held away from the naltrexone skeleton by a spacer 
moiety, either the pyrrole of NTI, the furan of NTB, or the ethylene bridge in BNTX. The 
authors suggest that the co-planar orientation of the aromatic rings of the indole-containing 
analogs may stabilize an antagonist state of the 8 receptor. In contrast, the orthogonal 
arrangement of the aromatic ring in the agonist SIOM prevents such a stabilization from 
occurring, resulting in full agonist properties. 36 
Fig. 3.3 Delta opioid receptor pharmacophore 37 
3.6 Conformational analysis of 8 receptor ligands 
With the large number of diverse ligands (both peptidic and non-peptidic) selective for 
the 8 receptor, many groups have turned to molecular modeling in order to identify the 3­
dimensional orientation of pharmacophoric groups required for 8 receptor recognition. It is 
a generally held belief that the minimal requirements for 8 receptor binding is a pmtonated 
amine, a phenolic functionality (as in Tyre of the 8-selective opioid peptides), and an 
aromatic moiety (as in Phe3 or Phe4 residues of 8-selective peptides) (Fig. 3.3). In the 
design and synthesis of 8 opioid receptor selective ligands, an understanding of the binding 
requirements of the 5 opioid receptor must be further understood. More specifically, it is 
important to define the 3-dimensional spatial orientation of the important pharmacophores 
of 8-selective opioid peptides. The ligands used most often in conformational analyses are 
the 8-opioid peptides DPDPE and JOM-13, and the non-peptidic NTI and its analogs. 
In the 8-selective cyclic peptide DPDPE, the constraint imposed by the internal disulfide 
bond serves to limit conformations available to the peptide, thereby simplifying 
computational procedures.  Early molecular modeling work done with this peptide 
confirmed that the peptide backbone within the ring had a somewhat rigid structure, 
whereas exocyclic portions of the molecule (including the important Tyr and Phe side 
chains) still exhibited a wide range of conformations, which made defining a "bioactive" 
conformer for DPDPE difficult (Mosberg et al., 1990). Like DPDPE, the results of 
molecular modeling experiments with JOM-13 indicated that the Tyr and Phe side chains 
still exhibited a great deal of conformational freedom (Lomize et al., 1994).  The 
researchers then turned to NMR and other experiments to analyze low energy solution 
conformations of these cyclic peptides. 
NMR analyses of DPDPE done in H2O and DMSO had shown that there is a rapid 
interchange between a number of local conformations (Hruby et al., 1988), and therefore 
did not provide a clear representation of a single low energy conformer as the receptor 
bound candidate. More answers as to the conformation needed for receptor binding may be 38 
expected from recent X-ray crystallographic studies done with DPDPE (Deschamps et al., 
1996). In the X-ray structure, there were three independent molecules of DPDPE in the 
asymmetric unit. The conformation of the 14-membered ring and the orientation of the 
Phe4 side chain (xl = 60 0) were essentially the same in all three molecules. Once again, 
the only significant conformational difference was in the orientation of the exocyclic Tyr 
side chain. The Tyr amide bond was trans in all conformations, but a large difference was 
seen in the vi torsion angle (-157o, -175 °, +90). X-ray studies done on JOM-13 resulted 
in very similar findings. The crystallographic studies done with JOM-13 revealed the 
presence of two distinct conformations for the 2 independent peptide molecules in the 
asymmetric unit. Like DPDPE, JOM-13 exhibited the greatest difference in the vi angle 
(159°, 102 °); there was also a difference in the disulfide bond conformation as well (890 
vs. -990). 
An extensive study done by Mosberg and co-workers (Mosberg et al., 1996, Mosberg 
et al., 1994a, Mosberg et al., 1994b) modified JOM-13 with amino acid analogs by 
introducing conformationally restricted side chains in order to investigate the spatial 
orientations of the phenolic and aromatic side chains of Tyri and Phe3, respectively. 
Through the use of such analogs, the researchers had found that the Tyr' side chain 
preferred the trans conformation, while the Phe3 residue preferred the gauche (-) 
conformation. Mosberg and co-workers (Lomize et al., 1996) then validated their work by 
superimposing different 8-selective ligands (both agonists and antagonists) onto their JOM­
13 molecule exhibiting optimal pharmacophore placement. In their molecular modeling 
studies, they found that there was high spatial overlap of the major pharmacophoric groups 
with opioid peptides DPDPE and antagonist TIPP; and also extensive overlap with the non­
peptide ligands oxymorphindole (OMI) and spiroindanyloxymorphone (SIOM). The 
researchers also noted that when the peptidic and non-peptidic antagonists (TIPP and 
naltrindole, respectively) were superimposed on JOM-13, the aromatic rings had 39 
similar orientation, but exhibited different 7c2 angles. The authors hypothesize that this 
difference in the 2c2 angles is a possible explanation for the different actions observed for 
NTI and JOM-13 at the 8 receptor (i.e. antagonist vs. agonist activity, respectively). 
A peptide of interest in many conformational analyses is the tetrapeptide antagonist TIPP 
(Schiller et al., 1992). It is an unusual opioid peptide in that it is completely comprised of 
aromatic amino acids. Many groups have postulated as to which aromatic moiety is 
responsible for the 8-selectivity of this compound. Two possibilities exist: either the Tyr-
Tic dipeptide or the more commonly recognized Tyr-Xaa-Phe moiety is acting as the 8 
receptor pharmacophore (Fig. 3.4). The residue of Phe4 is not considered essential for 8 
receptor recognition, because deletion of this C-terminal residue only results in a slight 
(-10-fold) loss of affinity at the 8 receptor (Schiller et al., 1992). 
It has been reported that the dipeptide H-Tyr-Tic-NH2 and the tripeptide H-Tyr-Tic-Ala-
OH have weak but measurable 8 antagonist activity (Temussi et al., 1994). In order to test 
whether or not the second residue of TIPP simply acts as a spacer for the aromatic Phe3 
residue, another study replaced the Tic residue with pipecolic acid (Pip). The resulting 
tetrapeptide H-Tyr-Pip-Phe-Phe-OH was a full agonist in the MVD and GPI assay. These 
observations suggest that the Tice aromatic ring in TIPP- related 8-opioid antagonists is 
essential for 8-receptor antagonism. Therefore it has been proposed that it is the aromatic 
ring of Tice (and not Phe3) that represents the second aromatic ring needed for opioid 
receptor binding and antagonist activity. 
In hypothesizing which aromatic residue of TIPP is responsible for 8 opioid 
antagonism, an important compound for comparison is the previously mentioned 8-opioid 
antagonist NTI. Of interest to computational chemists is the fact that NTI is a rigid 
molecule, and with the assumption that both molecules bind to the same receptor subsites, 
NTI could serve as a template in molecular modeling studies comparing both 8 antagonists. 
Many such molecular modeling studies have been undertaken (Amodeo et al., 1996, Chew 
et al., 1993, Wilkes and Schiller, 1994, Wilkes and Schiller, 1995), but due to the flexible 40 
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nature of the peptide backbone and side chains, coupled with the added complexity of 
cis/trans isomerism about the peptide bond between Tyr' and Tic2, the results have been 
somewhat inconclusive. Several researchers have proposed that it is the Tic2 residue that 
provides the aromatic ring which corresponds to the indole of NTI. 
Other research groups also have investigated the "receptor-bound" conformer of 8 
opioid ligands. In an extensive molecular modeling study done by Loew and co-workers 
(Chao et al., 1996), they found that both agonists and antagonists can satisfy the spatial 
requirements needed for 8 receptor recognition. 
3.7 Affinity labels for opioid receptors 
Affinity labels are ligands which bind irreversibly to a receptor, and therefore are 
important pharmacological tools for the study of a receptor. The irreversible nature of an 
affinity label makes the ligand more advantageous than a reversible ligand for certain 
receptor studies. Affinity labels are very effective in mapping the location and distribution 
of specific receptor types. Selective agonists used in conjunction with affinity labels can be 
used in determining the relative involvement of a certain receptor in a particular opioid-
induced pharmacological effect. Finally, non-equilibrium ligands are inherently long-
lasting, and as such, may find use as a therapeutic agent, e.g. as a long-lasting narcotic 
antagonist (Takemori and Portoghese, 1985). 
In order to interact with receptors in a non-equilibrium fashion, many affinity labels 
have electrophilic or photolabile moieties that are able to form a covalent linkage with 
reactive side chains found on the receptor. The success of an electrophilic affinity label is 
primarily due to four parameters: (1) the affinity label must exhibit high affinity for the 
receptor, (2) the affinity label should preferentially exhibit selectivity for the ligand; (3) the 
location of the electrophilic moiety on the affinity label must be able to align itself with a 
reactive group on receptor; and (4) the electrophilic group must be reactive enough to be 42 
subject to attack by a receptor-bound nucleophile. If any of the above parameters are not 
met, the result could be an ineffective affinity label. 
The affinity labeling process is thought to proceed via two distinct recognition steps 
(Fig. 3.5). The first recognition step involves reversible binding to the receptor (which is 
reflected by the affinity of the ligand for the receptor), and the second step involves the 
alignment of the electrophile with a compatible nucleophile on the receptor, resulting in 
covalent bond formation. These two separate recognition steps may lead to enhanced 
receptor selectivity, which is known as recognition amplification. 
The nitrogen mustard derivative of oxymorphone, f3- chloroxymorphamine ((3-COA), is 
an irreversible agonist in the GPI (Caruso et al., 1980b, Caruso et al., 1979). This 
observation suggests that receptor occupation rather than rate of ligand-receptor 
dissociation is important for agonist activity in the GPI. I3-COA also appears to bind 
irreversibly to opioid receptors in brain membranes, as exhaustive washing and eight hours 
of dialysis of 13 -COA treated membranes did not eliminate the inhibition of [31I]naltrexone 
binding.  In mice, 13-COA produces analgesia with a duration four times that of its 
reversible analog, oxymorphone.  This 13-00A-induced analgesia is inhibited by 
pretreatment of mice with naloxone. In addition, I3-COA given i.c.v. has long-lasting 
antagonist effect ( 6 days) against morphine-induced analgesia. 
In the study of receptors, and especially in the elucidation of pharmacological effects, 
antagonists have been particularly useful. Such contributions can be seen by the use of 
naloxone and naltrexone as pharmacological tools in the area of opioid research. The 
reversible nature of such antagonists and their cross-reactivity with various opioid receptor 
types are inherent limitations to their use as receptor probes. Thus, there have been a 
number of efforts to develop highly selective antagonists of the non-equilibrium type. 
The first successful antagonist affinity label synthesized was a nitrogen mustard 
derivative of naltrexone, I3-chlornaltrexamine (f -CNA) (Portoghese et al., 1978). I3-CNA 
proved to a potent affinity label selective for opioid receptors both in vitro and in vivo. (3­43 
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Fig. 3.5 A schematic representation illustrating the concept of recognition amplification. 
Although reversible binding (10 recognition) is occurring with receptor types A-C, only 
receptor type A is able to undergo the labeling process (20 recognition). In this case, 
recognition amplification is possible due to differences in the reactivity and proximity of the 
receptor-based nucleophiles G1 and G2. 
Source: Takemori, A.E.; Portoghese, P.S. Affinity Labels for Opioid Receptors Ann. 
Rev. Pharmacol. Toxicol. 1985, 25, 193-223. 44 
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CNA irreversibly inhibits the binding of either [3H]naloxone or [311]naltrexone to brain 
membranes. This inhibition of binding withstands extensive binding and eight hours of 
dialysis. In the GPI and MVD, 13 -CNA produces irreversible antagonism that can be 
prevented but not reversed by treatment with naloxone. Treatment with (3-CNA blocks all 
opioid receptor types. In mice, (3-CNA produces ultra-long antagonism (> 3 days) of 
morphine-induced analgesia after a single i.c.v. injection (Caruso et al., 1980b). [3H] 
has been used to isolate opioid receptor components from brain membranes (Caruso 
et al., 1980a). Since (3-CNA is not selective between opioid receptor types, it has been 
used in protection studies in the presence of selective reversible ligands for membrane 
enrichment of a receptor type. For example, in the MVD (3-CNA has been used with 
DSLET as the protector to irreversibly block p, and lc receptors. Such preparations can 
result in a near-homogenous population of 5 receptors which can then be used to assess 8 
activity of agonists (Ward et al., 1982). Although ligand protection is an effective way of 
enriching receptor types in smooth muscle preparations, the protection of selected receptor 
types is only as good as the selectivity of the protector. In this regard, receptor-selective 
affinity labels are far more advantageous. 
The reason for the lack of selectivity seen for 13-CNA may be due to the extremely 
reactive aziridinium ion generated from (3-CNA. The aziridinium ion facilitates the 
alkylation of opioid receptors but makes the second recognition step less selective because 
this electrophile can react with a wide variety of nucleophiles. In an effort to develop 
affinity labels with increased selectivity, the nitrogen mustard of 13-CNA was replaced with 
less reactive electrophilic moieties. One of the most selective ligands synthesized was the 
fumarate methyl ester derivative (3-funaltrexamine ((3-FNA) (Portoghese et al., 1980). It 
was found that 0-FNA actually interacted with all three receptor types reversibly, but the 
irreversible process of 13-FNA binding showed selectivity for p. over 5 and lc binding sites. 
One of the initial uses of I3-FNA was to deplete the GPI of functional p. receptors, resulting 
in a smooth muscle assay with a near homogenous population of lc receptors (Ward et al., 46 
1982). 13-FNA has also been used to study the involvement of g receptors in various 
opioid-induced effects, such as respiratory depression (Ward and Takemori, 1983a), 
decreased gastrointestinal motility (Ward and Takemori, 1983b), cardiovascular effects 
(Holaday and Ward, 1982), prolactin secretion (Holaday et al., 1983), spinal analgesia 
(Hylden and Wilcox, 1983a, Hylden and Wilcox, 1983b), and antidiuresis (Zimmerman et 
al., 1984). It was also instrumental in examining the phenomena of tolerance and physical 
dependence associated with the p. receptor. In rats, the physical dependence produced by a 
continuous intraperitoneal infusion of morphine was completely blocked by O-FNA (Aceto 
et al., 1984). When (3-FNA was given intrathecally, the tolerance and dependence 
produced by subcutaneous morphine pellets was markedly inhibited (Delander et al., 
1984). These results suggest that g receptors in the central nervous system plays an 
important part in the development of dependence. In a recent study, Liu-Chen and co­
workers identified a Lys residue involved in binding to 13-FNA in g opioid receptors (Chen 
et al., 1996). 
In an effort of obtain selective affinity labels, the isothiocyanate derivatives of fentanyl 
(FIT)  , cis-(+)-3-methylfentanyl (SUPERFIT), etonitazene (BIT), and the fumaramido 
derivative of endoethenotetrahydrooripavine (FAO) were synthesized (Burke et al., 1984, 
Rice et al., 1983). In opioid binding assays using both rat brain membranes and NG 108­
15 hybrid cells, FIT, SUPERFIT and FAO appear to be highly selective alkylators of 8 
receptors and BIT appeared to alkylate g receptor selectively. FIT and SUPERFIT are both 
based on fentanyl, a g agonist, but the incorporation of an isothiocyanate group confers 
irreversible 8-binding properties to the ligands. This is another example of recognition 
amplification. Employing NG 108-15 cells, [3H]FIT has been used to identify a protein 
with Mr 58,000 (Klee et al., 1982). The binding of [3H]FIT to this protein withstood 
extensive washing, and levorphanol (but not dextrorphan) inhibited irreversible binding. 
In a recent study, Zhu et al. used SUPERFIT in combination with chimeric studies in 
order to determine the binding domain of the 8 opioid receptor (Zhu et al., 1996). Through 47 
the incubation of SUPERFIT with a variety of p/8 chimeric receptors, it was found that the 
receptor needed the region from the beginning of the first intracellular loop to the middle of 
the third transmembrane region for wash-resistant binding of the affinity label. 
The first reported opioid peptide-based electrophilic affinity label was the chloromethyl 
ketone derivative of DADLE, called DALECK (Pe lton et al., 1980). The binding of this 
agent to opioid receptors in the receptor binding assay using [3H]DADLE, [3H]etorphine, 
and [3H]naloxone appeared to be irreversible. However, the agonist effects of DALECK 
in the GPI, MVD, and analgesic assays were all fully reversible by naloxone .  Therefore, 
it is uncertain whether DALECK possesses selectivity or if covalent association of opioid 
receptors is possible with this agent in biological systems. 
In another approach to develop a potential peptide affinity label, [D ­
Ala2,Leu5]enkephalin (DALA) was extended with the methyl ester of the nitrogen mustard 
derivative of phenylalanine melphalan (Mel) at the C-terminus. This compound, DALA-
Mel-OMe, displays high affinity in displacing [3H]DALA and [3H]naloxone from brain 
membranes (Szucs et al., 1983). Although DALA-Mel-OMe appears to irreversibly block 
the binding of [3H]naloxone, the fact that pretreatment with naloxone or DALA affords 
only partial protection suggests that nonspecific labeling also occurred. Melphalan was 
also incorporated into the 4-position of N,N- dialkylated enkephalin derivatives, and these 
derivatives exhibited wash-resistant antagonism at high concentrations (10 MM) (Lovett and 
Portoghese, 1987b). 
The affinity label [D-Ala2,Leu5,Cys6]enkephalin (DALCE) is believed to form a 
disulfide linkage with a Cys residue at or near the binding site of opioid receptors thereby 
causing receptor inactivation (Bowen et al., 1987). Studies by Larsen and co-workers 
(Larsen et al., 1981) have also suggested that in the opioid receptors there are at least two 
different thiol groups sensitive to N-ethylmaleimide (NEM)  .  One of the thiols was found 
to be the Cys residue contained in the a-subunit of the GTP-binding protein Gi. The other 
was suggested to be present within the receptor protein itself. In order to further exploit 48 
this receptor-based nucleophile, Matsueda and co-workers (Matsueda et al., 1993, 
Matsueda et al., 1992) have designed peptide-based affinity labels for 8 and lc opioid 
receptors using S-(3-nitropyridinesulfenyl)cysteine [Cys(Npys)] incorporated into 
enkephalin and dynorphin analogs, respectively. The Npys group is stable as a protecting 
group for Cys, and could therefore be directly incorporated into the peptide during 
synthesis without any special precautions. Both [D-Ala2,Cys(Npys)5]leucine enkephalin 
and [Cys(Npys)8]dynorphin analogs exhibited high affinity and wash-resistant binding 
inhibition at 8 and K receptors, respectively. 
3.8 Conclusions 
In the area of opioid medicinal chemistry, a wide variety of 8-selective ligands have 
been either synthesized or isolated. The modifications of endogenous opioid peptides have 
resulted in ligands with excellent selectivity and affinity for the 8-opioid receptor. From the 
numerous analogs synthesized, extensive structure-activity relationships for 8-selective 
peptides have been compiled. In the case of non-peptidic ligands, the application of 
rational drug design allowed for the development of 8-selective agonists and antagonists 
based on oxymorphone and naltrexone, respectively. These selective ligands have made 
detailed examination of the 8-receptor possible and enabled researchers to define 5-receptor 
subtypes by virtue of analgesia induced by selective agonists and differentially blocked by 
selective antagonists. 
In order to selectively bind to a specific opioid receptor type (or subtype), the subtle 
differences in structural requirements of the receptors must be understood and utilized. 
From the systematic synthesis and conformational analysis of constrained analogs, 
researchers are close to understanding the "bioactive" orientation of important 
pharmacophoric groups necessary for 8-receptor binding and activation. 49 
In addition to molecular modeling and various NMR techniques, affinity labels have 
also been successfully used to study receptor structure and function. Due to their 
irreversible nature, these ligands should enable researchers to ascertain which amino acid 
residues are at or near the binding site based on their covalent attachment. Due to potential 
differences in binding modes, a wider variety of peptidic/non-peptidic-, and 
agonist/antagonist-based affinity labels may yield increased structural information about the 
binding sites of the opioid receptors. Affinity labels could also be used in the isolation and 
purification of the putative receptor subtypes, which have not yet been characterized by 
molecular biological techniques. 
As the use of selective agonists and antagonists further define the physiological role of 
the 8 receptor, potential therapeutic applications of 8-selective ligands may be uncovered. 
Through the use of peptidomimetics and/or peptide drug delivery systems, 8-selective 
therapeutic agents for the treatment of pain and other disorders may soon be realized. 50 
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4.1 Abstract 
In order to develop affinity labels for the delta (8) opioid receptor based on peptide 
antagonists, the Phe4 residues of N,N-dibenzyl leucine enkephalin and ICI-174,864 (N,N­
diallyl[Aib2,Aib3]leucine enkephalin) were substituted with either Phe(p-NCS) or Phe(p­
NHCOCH2Br). The target peptides were synthesized using Phe(p-NH2) and a Boc/Fmoc 
orthogonal protection strategy which allowed for late functional group conversion of a p­
amine group to the desired affinity labeling moieties within the peptides. The key step in 
the synthesis was the selective deprotection of a Boc group in the presence of a t-butyl ester 
using trimethylsilyl trifluoromethanesulfonate (TMS -OTf). Developed by our laboratory, 
this synthetic scheme represents a general method for the conversion of peptide substrates 
into potential affinity labels. 
The target peptides were evaluated through radioligand binding inhibition experiments in 
Chinese hamster ovary (CHO) cells expressing 6 or 11 opioid receptors. Of the target 
peptides tested, only the N,N-dibenzyl [Phe(p- NCS)4]leucine enkephalin analog exhibited 
inhibition of radioligand binding inhibition in a wash-resistant fashion at a concentration of 
1.012M. Therefore, this peptide analog emerges as a potential affinity label useful for 
further study of 6 opioid receptors. 52 
4.2 Abbreviations
 
Abbreviations used for amino acids are according to the rules specified by the IUPAC­
IUB Joint Commission of Biochemical Nomenclature (Eur. J. Biochem. 1984, /38, 9­
37). All amino acids are in the L-configuration unless otherwise specified. Additional 
abbreviations used are: Aib, 2-aminoisobutyric acid; BAW, butanol/acetic acid/water, Boc, 
tert-butyloxycarbonyl;  Bpoc,  1-methyl-1-(4-biphenypethoxycarbonyl;  Cbz, 
benzyloxycarbonyl; CHO, Chinese hamster ovary; DADLE, Tyr-D-Ala-Gly-Phe-D-Leu; 
DALCE, Tyr-D-Ala-Gly-Phe-Leu-Cys; DAMGO, Tyr-D-Ala-Gly-MePhe-Leu-Gly-ol; 
DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMF, N .N ­
dimethylformamide; DMSO, dimethylsulfoxide; DPDPE, Tyr-cyclo[D- Pen -Gly- Phe -D­
Pen]-OH; FAB-MS, fast  atom bombardment mass spectrometry; FAO, 
fumaramidooripavine; FIT, fentanyl isothiocyanate; Fmoc, 9-fluorenylmethoxycarbonyl; 
Fmoc -Cl, 9-fluorenylmethyl chloroformate; GPI, guinea pig ileum; HPLC, high 
performance liquid chromatography; HRFAB-MS, high resolution fast atom bombardment 
mass spectrometry; Mel, melphalan; MVD, mouse vas deferens; NMM, N ­
methylmorpholine; NMR, nuclear magnetic resonance spectroscopy; NTII, naltrindole 
isothiocyanate; Pen, penicillamine; Ppoc, 2-triphenylphosphonioisopropoxycarbonyl; 
SUPERFIT, cis-(+)-3-methyl fentanyl isothiocyanate; TAEA, tris(2- aminoethyl)amine; 
TEA, triethylamine; Tfa, trifluoroacetyl; TFA, trifluoroacetic acid; THF, tetrahydrofuran; 
TMS- OTf, trimethylsilyl trifluoromethanesulfonate; Tris, tris(hydroxymethyl)­
aminomethane. 53 
4.3 Introduction 
Opioid-based analgesics are effective in the alleviation of pain, but many of them exhibit 
serious side effects, such as respiratory depression, tolerance, and physical dependence. 
The characterization of three heterogeneous opioid receptor types [mu (p.), kappa (x), and 
delta (8)] has raised the possibility that an opioid agonist selective for a specific receptor 
type may exhibit analgesic properties with lessened side effects. These receptors have been 
well documented both pharmacologically and at the molecular level by cloning (for 
reviews, see (Kieffer, 1995, Reisine and Bell, 1993, Satoh and Minami, 1995). 
Opioid analgesics with a high degree of abuse potential have been shown to interact 
preferentially with p. receptors (Raynor et al., 1994), and so considerable attention has been 
given to the study of 8 receptors and their potential for analgesia with lessened narcotic side 
effects. Much has been learned about the 8 opioid receptor through the use of 8-selective 
ligands, but the emergence of 8 receptor subtypes and the problems associated with 
identifying receptor-specific physiological effects emphasize the continuing need for novel 
ligands in the study of 8 opioid receptors. Affmity labels are ligands whose interaction 
with a receptor is considered to be essentially non-equilibrium, and they have proven to be 
useful pharmacological tools in the study of similar problems with various types of 
receptors. An affinity label most commonly incorporates an electrophilic functional group 
within its structure that can interact with a receptor-based nucleophile. Due to their 
irreversible nature, these ligands are useful for the isolation and mapping of receptors, and 
the resultant long-term blockade of receptor binding aids in the elucidation of physiological 
effects of receptor activation (Takemori and Portoghese, 1985). Affmity labels are also 
being used to ascertain the residues present in the binding pocket of the receptor. 
Several compounds have been prepared as potential affinity labels for the 8 opioid 
receptor. These ligands include fentanyl isothiocyanate (FIT) (Rice et al., 1983) and its 
chiral (+)-3-methyl derivative (SUPERFIT) (Burke et a., 1986), fumaramidooripavine 
(FAO) (Burke et al., 1984), and most recently, naltrindole isothiocyanate (NTII) 54 
(Portoghese et al., 1990). All of these 8-selective affinity labels are based on non-peptidic 
opioid ligands. 
Peptide-based affinity labels are important because they could offer complimentary 
pharmacological information to the non-peptidic affinity labels. Two affinity labels based 
on peptides are [D-A1a2,Cys6]leucine enkephalin (DALCE) (Bowen et al., 1987) and its 
recently developed S-3-nitro-pyridinesulfenyl (Npys) protected derivative, [D­
A1a2,Cys(Npys)6]leucine enkephalin (Matsueda et al., 1992). Both of these affinity labels 
exhibited 8-selective wash-resistant inhibition of binding, and are based on [D-A1a2]leucine 
enkephalin, which is an agonist at the 8 opioid receptor. 
In an effort to develop affinity labels based on 8-selective peptide antagonists, Aldrich-
Lovett and Portoghese investigated N-terminal dialkylated enkephalins for antagonistic 
activity at the 8 opioid receptor (Lovett and Portoghese, 1987a). In this study, it was 
found that N,N-dibenzyl leucine enkephalin exhibited the highest potency and selectivity 
for the 8 opioid receptor. In a subsequent study (Lovett and Portoghese, 1987b), Phe4 of 
this pentapeptide and another 8-selective peptide antagonist, N,N- diallyl[Aib2,Aib3]leucine 
enkephalin (ICI-174,864) (Cotton et al., 1984), were then substituted with the nitrogen 
mustard analog of phenylalanine, melphalan (Mel) at the 4-position. Unfortunately, neither 
of the Mel-containing peptides synthesized exhibited significant wash-resistant binding 
inhibition in the mouse vas deferens smooth muscle assay. 
The labeling process is thought to occur in two discrete steps: first, reversible binding of 
the affinity label to the receptor, followed by covalent linkage with the receptor. The 
researchers postulated that the lack of irreversible binding of the Mel-containing peptides 
might be attributed to potential problems in both steps. The large, sterically demanding 
nitrogen mustard moiety of the Mel residue may have had a deleterious effect on the 
reversible binding of the synthesized peptides. In addition, the relatively low reactivity of 
the Mel residue may have hindered the process of covalent bond formation with the 
receptor. 55 
To further investigate these N,N-dialkylated enkephalins as potential affinity labels, we 
have incorporated more reactive and less sterically demanding functional groups at the para 
position of Phe4. A second goal of the syntheses of these peptide derivatives was the 
development of a general methodology flexible enough for the incorporation of various 
labeling moieties into a target peptide. The functional groups incorporated were the 
isothiocyanate and the bromoacetamide groups, which have shown their effectiveness in 
various non-peptidic affinity labels for opioid receptors, but have not been used in opioid 
peptides. The target peptides for this study included the p-amine, p-isothiocyanate, and the 
p-bromoacetamide derivatives of N,N-dibenzyl leucine enkephalin and ICI-174,864 (see 
Fig. 4.1). The amine-containing derivatives were prepared as reversible controls for 
establishing washing procedures used in the assays for wash-resistant binding inhibition. 
The reversible and wash-resistant assays for inhibition of radioligand binding used Chinese 
hamster ovary (CHO) cells stably transfected with the mouse 8 opioid receptor. 
4.4 Chemistry 
4.4.1 Synthetic strategy 
In the synthetic scheme for these potential affinity labels, consideration of how these 
electrophilic groups were to be introduced had to be addressed. In the earlier study, the 
nitrogen mustard of Mel lent itself very well to standard conditions of peptide synthesis. It 
could be directly incorporated into the growing peptide chain with no special protection or 
reaction conditions. Unfortunately, the isothiocyanate and the bromoacetamide moieties 
were not expected to fare as well under the rigors of multiple peptide couplings and 
functional group deprotections. Therefore, a synthetic scheme was devised that would 
allow functional group conversion late in the peptide synthesis. p-Nitrophenylalanine was 56 
N,N-clibenzyl leucine enkephalin: R = Bn; R' = H; X = H 
1:R=Bn;R'=H;X=NH2 
2:R=Bn;R'=H;X=NCS 
3: R = Bn; R' = H; X = NHCOCH2Br 
ICI-174,864: R = Allyl; R' = CH3; X = H 
4: R = Allyl; 12.1 = CH3; X = NH2 
5: R = Allyl; R' = CH3; X = NCS 
6: R = Allyl; R' = CH3; X = NHCOCH2Br 
Fig. 4.1 Target enkephalin-based affinity labels and related peptides 57 
chosen for the design of the peptide-based affinity labels because the nitro group can be 
reduced to an amine which can then transformed into a number of affinity labeling moieties, 
including the aforementioned isothiocyanate and bromoacetamide. However, late reduction 
of the nitro group to the amine was not an option in the synthesis of the target peptides, due 
to the N-terminal substitution by groups subject to hydrogenolysis. 
An important aspect of peptide chemistry is the selective deprotection of amine and/or 
carboxyl groups in the presence of other protecting groups. Traditionally, acid-labile 
groups have been used for peptide functional group protection, primarily due to the stability 
peptides exhibit under acidic conditions. During the removal of acid-labile groups, 
selectivity arises through differences in the acid strengths needed to induce removal. The t­
butyloxycarbonyl (Boc) group and t-butyl protecting groups are easily and effectively 
removed using trifluoroacetic acid (TFA), and therefore these t-butyl-based protecting 
groups were chosen as the semi-permanent protection for the peptides due to the mild 
conditions required for final deprotection. This then required the choice of a transient 
protecting group for the p-amino functionality which could be selectively deprotected to 
allow electrophilic functional group conversion. The protecting group in question would 
have to be able to be deprotected without causing appreciable loss of the tert-butyl based 
protecting groups. There are many "hyper acid"-labile groups for this, such as the Bpoc, 
Ppoc, and Ddz protecting groups, that are typically removed using acidic conditions which 
have little effect on Boc groups. Therefore, our laboratory initially explored the use of 
some of these protecting groups for these syntheses. These protecting groups are generally 
introduced as the azides or active esters, but unfortunately, these derivatives were not 
reactive enough to protect the p-amine functionality of Phe(p-NH2). The difficulty in 
protection is caused by the lower nucleophilicity of the aniline-type amine due to 
conjugation with the aromatic ring. 
We then explored possible orthogonal protection strategies to be used with Boc-type 
groups. One such group used in conjunction with acid-labile groups was the trifluoroacetyl 58 
(Tfa) group. However, during the course of the synthesis it was found that this group 
could not be easily removed by saponification, and therefore this protection strategy was 
abandoned. 
Another protection strategy that in the past several years has gained significant 
popularity in the solid phase synthesis of peptides is the use of the 9­
fluorenylmethoxycarbonyl (Fmoc) protecting group (Carpino and Han, 1972), which is 
typically removed through 11-elimination using an organic base, most commonly piperidine. 
As with the Tfa group, the basic conditions for Fmoc removal provides orthogonal 
protection to the Boc group. The Fmoc group was readily introduced onto the p-amine 
functionality using 9-fluorenylmethyl chloroformate, whereas the use of the less reactive 
succinimide resulted in much lower yields. The p-amine of the phenylalanine could be 
deprotected near the end of the synthesis, so that the electrophilic functional groups would 
not be subjected to a lengthy synthetic process. 
The target peptides share a common C-terminal dipeptide fragment, and therefore the 
synthetic scheme used a convergent [3 + 2] fragment condensation utilizing the C-terminal 
dipeptide fragment coupled to the different N-terminal fragments to yield the desired 
pentapeptides. 
4.4.2 Synthesis 
The synthesis of the C-terminal dipeptide (see Fig. 4.2) began with the isobutyl 
chloroformate-mediated coupling of Boc-Phe(p-NO2)-OH to H-Leu-OtBu  as the 
hydrochloride salt, to give dipeptide 7 in 81% yield. Reduction of the p-nitro group by 
catalytic transfer hydrogenation provided the amine derivative 8 in near quantitative yield. 
Protection of the resulting amine by the application of 9-fluorenylmethyl chloroformate 
under standard conditions gave the fully protected dipeptide derivative 9 in 80% yield. The 
p-amine functionality was protected at the dipeptide stage rather than the amino acid 59 
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i) iBuOCOC1, NMM; ii) HC111-Leu-OtBu, NMM (81%); iii) NH4HCO2, 10% Pd/C (94%); iv) 
Fmoc-C1, 10% NaHCO3, dionne (80%); v) TMS -OTf, toluene (97%) 
Fig. 4.2 Synthesis of the C-terminal common dipeptide fragment 10. 60 
because the protected amino acid derivative Boc-Phe(p-NHFmoc)-OH is rather insoluble 
and proved difficult to purify and use in subsequent reactions. 
In the key step of the synthesis, the Boc group had to be removed in the presence of a t­
butyl ester. This selective deprotection was achieved using one equivalent of trimethylsilyl 
trifluoromethanesulfonate (TMS -OTf) in toluene (Vorbruggen and Kroliklewicz, 1975). 
The selective removal of the Boc group was possible because of the increased 
nucleophilicity of the carbamate carbonyl vs. the ester carbonyl. After the addition of the 
reagent, the product 10 (as the triflate salt) precipitated out of solution as a gel. 
In Fig. 4.3, the assembly of the N-terminal fragment of the ICI-174,864 derivatives is 
outlined (Lovett and Portoghese, 1987a). The ICI-174,864 derivatives have the N-terminal 
tripeptide (N,N- diallyl)Tyr- Aib -Aib, (Aib = 2-aminoisobutyric acid). This a-disubstituted 
amino acid is difficult to couple, and attempts to couple Aib to Aib using iBuOCOC1 can 
result in high levels of the isobutyl carbamate rather than peptide bond formation. 
Therefore, for the difficult coupling of Cbz-Aib-OH to H-Aib-OMe, the pivaloyl chloride 
method of peptide bond formation was used. This coupling reaction proceeded in 63% 
yield to give the Cbz-protected dipeptide 12. In the subsequent step when the Cbz group 
was removed by hydrogenolysis, care had to be taken to keep the resultant amine 
protonated in order to avoid spontaneous diketopiperazine formation. Hydrogenolysis of 
the Cbz group in the presence of one equivalent of HC1 was then followed by iBuOCOC1­
mediated coupling to Cbz- Tyr(O- tBu) -OH to give the fully protected tripeptide 14. 
Hydrogenolysis of the Cbz group, followed by treatment with an excess of ally' bromide 
and N,N-diisopropylethylamine (DIPEA) provided the diallylated tripeptide 16 in 83% 
yield. Saponification of the methyl ester then provided the desired N-terminal tripeptide 
fragment 17. 
The corresponding synthesis of the dibenzylated N-terminal tripeptide fragment (see 
Fig. 4.4) involved similar procedures with a few exceptions: the Gly-Gly-OEt dipeptide 
fragment was obtained commercially as the hydrochloride salt, and derivatization of the 61 
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Fig. 4.3 Synthesis of the N-terminal tripeptide fragment 17 for ICI-174,864 derivatives 62 
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Fig. 4.4 Synthesis of the N-terminal tripeptide fragment 21 for the dibenzyl leucine 
enkephalin derivatives 63 
N-terminal tripeptide used benzyl bromide/DIPEA to effect the dialkylation to tripeptide 20. 
Saponification of 20 led to the desired N- terminal dipeptide fragment 21 in an overall yield 
of 65% over 4 steps (Lovett and Portoghese, 1987a). 
In Figs. 4.5 and 4.6, the N-terminal tripeptides were then coupled to the C-terminal 
dipeptide 10 using either iBuOCOC1 (for 21) or pivaloyl chloride (for 17) to provide 
pentapeptides 22 and 27, respectively. The next step involved the removal of the Fmoc 
group to expose the p-amine for affinity label functionalization. The Fmoc protection 
strategy is not very widely used in solution phase synthesis because the resulting 
dibenzofulvene by-product is able to react with the organic base through a Michael 
addition. This adduct is difficult to remove, thereby complicating product purification. 
Such problems are circumvented in the solid-phase synthesis of peptides by virtue of the 
peptide's anchorage to the insoluble support. In order to simplify the purification process 
of Fmoc-based peptide synthesis in solution, Carpino and co-workers developed a 
deprotection strategy using tris(2-aminoethyl)amine (TAEA) (Carpino et al., 1990). This 
reagent was used to deprotect the Fmoc group, and the resulting dibenzofulvene/TAEA 
adduct was then removed from the organic layer by repeated washes with pH 5.5 
phosphate buffer. 
Following the assembly of desired pentapeptides 23 and 28, the penultimate step in the 
synthetic strategy was the incorporation of the bromoacetamide and isothiocyanate 
functional groups. During the synthesis of the dibenzyl leucine enkephalin derivatives, 
functional group conversion of the amine to the bromoacetamide used bromoacetyl 
chloride, but extended reaction times led to the formation of the chloroacetamide 25 
through halide exchange. The chloroacetamide side-product was identified by high-
resolution mass spectrometry.  This problem was circumvented through the use of 
bromoacetyl bromide. The isothiocyanates 24 and 29 were formed by reaction of the 
amine compounds 23 and 28 with thiophosgene, respectively. Final deprotection of the 64 
iii 
23: X = NH2 
R = OtBu 
Amine (control) synthesis: 
iv  1: X = NH2  23 
(72%)  R = OH 
Isothiocyanate synthesis: 
24: X = NCS  iv  2: X = NCS 23 
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R = OtBu	  R = OH (41%) 
Chloroacetarnide synthesis: 
vi  iv
23  25: X = NHCOCH2C1  3a: X = NHCOCH2C1 
R = OtBu  (95%)  R = OtBu 
Bromoacetamide synthesis: 
vii  26: X = NHCOCH2Br	  iv 
R = OtBu 
23	  3: X = NHCOCH2Br 
(73%)  R = OH 
i) iBuOCOC1, NMM; ii) 10, NMM (74%); iii) TAEA, DCM (75%); iv) TFA/10% anisole; v) 
thiophosgene, DIPEA (94%); vi) bromoacetyl chloride, DIPEA, overnight at r.t. (54%); vii) bromoacetyl 
bromide, DIPEA, 2h at 0 °C (91%) 
Fig. 4.5 Synthesis of dibenzyl leucine enkephalin derivatives 1-3 65 
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Fig. 4.6 Synthesis of ICI-174,864 derivatives 4-6 66 
peptide derivatives was accomplished using TFA and anisole as a t-butyl cation scavenger, 
to yield target peptides 1-6 for pharmacological evaluation. 
4.5 Pharmacological evaluation 
4.5.1 Binding assays under standard conditions 
These final peptides were subjected to radioligand binding assays under standard 
conditions using cloned S andg receptors expressed in Chinese hamster ovary (CHO) cells 
(Table 4.1).  For the dibenzyl derivatives, substitution at the para position of Phe4 
generally caused a decrease in 8-receptor binding affinity, with the notable exception of the 
isothiocyanate derivative, which exhibited the highest affinity of all of the peptides tested. 
Substitution at the para position was better tolerated by the diallyl derivatives,  as the 
isothiocyanate and bromoacetamide-containing peptides demonstrated higher affinity for 
The S receptor than the unsubstituted parent compound, ICI-174,864. Despite being the 
smallest substituent, the amine-containing derivatives of both N,N-dibenzyl leucine 
enkepialin and ICI-174,864 displayed the lowest affinity in their respective groups, 
indicating that steric bulk alone did not determine decreases in affinity at the d receptor The 
dipara position was better tolerated by the diallyl derivatives, as the isothiocyanate and 
bromoacetamide-containing peptides demonstrated higher affinity for the S receptor than the 
unsubstituted parent compound, ICI-174,864. Despite being the smallest substituent, the 
amine-containing derivatives of both N,N-dibenzyl leucine enkephalin and ICI-174,864 
displayed the lowest affinity in their respective groups, indicating that steric bulk alone did 
not determine decreases in affinity at the S receptor The different substituent effects may 
suggest subtle differences in the interactions between the peptide derivatives and the 
receptor. 
In these assays, it was interesting to note that against [3H]DPDPE binding, N,N­
dibenzyl leucine enkephalin exhibited a 10-fold greater affinity yet similar selectivity than 67 
Table 4.1 Binding affinities of peptides 1- 6 under standard conditions 
compound  IC50 ± S.E.  IC50 
tested  S (nM)  11. (11M)  ratio 
(vs.I3111DPDPE1  (vs. 13111DAMGO) 
DPDPE  0.87 ± 1.2  ND
 
DAMGO  ND  3.8 ± 1.2 (nM)
 
N,N-dibenzyl Leu enk  78.2 ± 1.1  1.6 ± 1.1  20 
1 Bn2[Phe(p-NH2)4]Leu enk  486.1 ± 1.2  23.0 ± 1.3  47 
2  " (p-NCS) 
II  34.9 ± 3.3  1.9 ± 1.3  54 
3  " (p-NHCH2Br) "  149.4 ± 23  9.1 ± 1.3  61 
3a  " (p-NHCH2C1) "  144.8 ± 3.6  19.0 ± 1.2  131 
N,N-diallyl[Aib2,Aib3]Leu enk  703.0 ± 1.1  18.9 ± 1.1  27 
(ICI-174,864) 
4 All2[Aib2,Aib3,Phe(p-NH2)4] 
Leu enk.  1394 ± 1.1  87.7 ± 1.9  63 
5  " (p-NCS)  "  361.3 ± 2.8  33.4 ± 1.3  92 
6  " (p-NHCH2Br) "  391.9 ± 2.8  >100  >255 68 
All of the derivatives tested displayed a higher degree of selectivity for the 8 receptor 
than the unsubstituted lead compounds. Between the two groups, the diallyl derivatives 
were more selective for the 8 receptor than the dibenzyl derivatives due to greatly decreased 
binding to the g receptor, but the dibenzyl compounds displayed higher affinitites 
compared to the diallyl derivatives. Within a series, the larger acetamides were more 8­
selective than either the isothiocyanates or the amines. 
4.5.2 Wash-resistant binding assays 
The derivatized peptides were then tested for wash-resistant binding of [31-I]DPDPE 
binding to 6- receptors in CHO cells. The experiment involved incubation of the test 
compound with the CHO cell membranes for 90 min at room temperature, and then the 
membranes were washed via centrifugation, decanting of the buffer solution, and re-
suspension in fresh buffer solution. Due to its lower affintity, the amine-containing 
dibenzyl peptide 1 was tested at a concentration of 3 gM, and it was found that a series of 
five washes was sufficient to remove most of the amine-containing compounds without an 
appreciable loss of protein from the CHO cell membranes. The washed CHO cell 
membranes then underwent radioligand binding assays. The binding assays after the 
washing procedure indicated that binding levels of [3H]DPDPE were close to control 
(untreated) binding levels (Fig.4.7). The only exception was the isothiocyanate-containing 
dibenzyl compound 2, which still inhibited radioligand binding by about 81% even after 
the washing procedures. This level of wash-resisant binding inhibition is close to that of 
NTII at a similar concentration. This data suggests that the isothiocyanate-containing 
dibenzyl compound 2 may be used as an affmity label in the study of 8 opioid receptors. 69 
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Fig. 4.7 Graphical representation of the percent radioligand binding (normalized against 
control values) displayed by the peptide derivatives 1-6 following incubation and washing. 
Compound 1 was tested at 3 AM. All other compounds were tested at 1.0 p.M. 70 
4.6 Results and discussion 
Utilizing a convergent [3+2] synthetic strategy, affinity labels based on the 8-selective 
peptide antagonists N,N-dibenzyl leucine enkephalin and la-174,864 were prepared. An 
orthogonal Boc/Fmoc protection strategy was utilized in the synthesis, and this method 
should prove to be a versatile method for the preparation of a wide variety of peptide-based 
affinity labels. Substitution at the para position of Phe of the N,N-dibenzyl enkephalin 
analogs generally decreased binding affinity at the 8 opioid receptor, but isothiocyanate and 
bromoacetamide functionalization increased 8 opioid receptor binding for the ICI-174,864 
derivatives.  This would suggest that the differences of N-terminal and backbone 
substitution between the N,N-dibenzyl and ICI-174,864 derivatives resulted in different 
interactions with 8 opioid receptors. 
Of the compounds tested, only the isothiocyanate-containing derivative of N,N-dibenzyl 
leucine enkephalin 2 exhibited wash resistant binding inhibition in CHO cell assays. At a 
concentration of 1 11,M, it exhibited binding inhibition of [3H]DPDPE after repeated 
washings through centrifugation. The corresponding ICI-174,864 derivative 5 did not 
exhibit wash-resistant binding, despite its apparent similarity to 2. The N-terminal and 
backbone substitutions in 5 perhaps contributed to different spatial orientation during 
binding, thereby resulting in lower binding affinity and prohibiting proper alignment of the 
isothiocyanate with a receptor-based nucleophile. 
From these observations, enkephalin analog 2 appears to be a potential affinity label 
selective for the 8 opioid receptor.  This peptide provides the first example of an 
isothiocyanate group used to prepare opioid peptide-based potential affinity labels. In order 
to confirm the irreversible nature of this compound, our laboratory is developing methods 
to incorporate [3H] labeling within the Phe residue. Further pharmacological studies with 
2 in conjunction with other 8-selective affinity labels may provide further insight on the 
binding requirements and physiological roles of 8 opioid receptors. 71 
4.7 Experimental section 
4.7.1 Materials 
All amino acids except for Boc-Phe(p-NO2) and Aib were purchased from Sigma 
Chemical Co. (St. Louis, MO). Synthetic reagents and the amino acids Boc-Phe(p-NO2) 
and Aib were purchased from Aldrich Chemical Co. (Milwaukee, WI). General laboratory 
solvents were obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ), and HPLC-grade 
solvents were obtained from Burdick and Jackson (Muskegon, MI). 
Syntheses were monitored using thin-layer chromatography using Kieselgel 60 F254 
plates of 0.20 mm thickness purchased from EM Separations (Gibbstown, NJ). 
Intermediates were purified by flash chromatography using 230-400 mesh, 60A silica gel 
also purchased from E. Merck. 
NMR analyses were done on an Bruker AC300 instrument at the Department of 
Chemistry, Oregon State University, Corvallis, OR. The molecular weights of the amino 
acid derivatives and peptides were determined by fast atom bombardment (FAB) mass 
spectrometry in the postitive mode on a Kratos MS5ORFTC in the Department of 
Agricultural Chemistry at Oregon State University, Corvallis, OR. 
The purity of intermediates and the final peptides were determined by analysis on a 
Beckman model 431A high performance liquid chromatography (HPLC) system. The 
HPLC column used in the analyses was either a Vydac (C4, 300 A, 5 t, 4.6 x 250 mm, 
column A) or a Zorbax Protein Plus (C3, 300A, 1011, 4.6 x 250 mm, column B) analytical 
column. The compounds were eluted using a linear gradient of 0 to 75% B over 50 min at 
a flow rate of 1.5 mL/min and detected at 214 nm; solvent A was aqueous 0.1% TFA and 
solvent B was acetonitrile containing 0.1% TFA. 72 
4.7.2 Methods
 
4.7.2.1 Synthetic methods 
Isobutyl chloroformate-mediated peptide coupling (Method I): Under an N2 
atmosphere, a 0.25 M solution of the carboxyl component (1.0 eq) in dry tetrahydrofuran 
(THF) was cooled to -15 0C (dry ice/Me0H) and neutralized with one equivalent of N­
methylmorpholine (NMM). A stoichometric amount of isobutyl chloroformate was then 
added, followed 90 sec later by a 0.5 M solution of the amine component and NMM (each 
1.0 eq) in DMF. The reaction mixture was kept at -15 0C for 30 min, and then allowed to 
warm to room temperature. When the reaction was complete, the THF was evaporated, 
and the residue suspended in EtOAc. The organic layer was washed with H2O, 5% 
KHSO4, H2O, 5% NaHCO3, H2O, and then finally with saturated NaCl. The organic 
layer was then dried over MgSO4 and the EtOAc evaporated to give the crude peptide. 
Final deprotection with TFA (Method II): The peptide was treated with a 10% 
anisolefITA for one hour at room temperature. The TFA was then evaporated and the 
product precipitated with cold ether. The precipitate was washed five times with cold ether, 
and then dried in vacuo. 
Na-tert-Butyloxycarbonyl-L-p-nitrophenylalanyl-G-leucine tert-butyl ester 
(7) 
N-tert-Butyloxycarbonyl-L-p-nitrophenylalanine (1.18 g, 3.80 mmol) was coupled to L-
leucine tert-butyl ester hydrochloride (0.85 g, 3.80 mmol) according to Method I to give 
1.48 g (81%) of 7 as a white solid: Rf (EtOAc) = 0.68; Rf [butanol/acetic acid/water, 
(BAW) 3:1:1] = 0.87; HPLC (col. A) tR = 37.5 min; mp 161-163 °C; [a]p = -15.9 ° (c = 
0.94, Me0H); 1H NMR (CDC13) 8 = 0.88 (d, 3H, J = 1.7 Hz), 0.91 (d, 3H, J = 1.4 Hz), 
1.39 (s, 9H), 1.41 (s, 9H), 1.55 (m, 3H), 3.09 (dd, 2H, J = 6.7 Hz, 14.3 Hz), 4.10 (m, 73 
2H), 5.08 (d, 1H), 6.21 (d, 1H), 7.35 (d, 2H, J = 8.7 Hz), 8.12 (d, 2H, J = 8.7 Hz);
 
FAB-MS [M+H]+ 480.1 (calc. 480).
 
Na- tert -B utyloxycarbonyl- L- p- aminophenylalanyl -L- leucine tert-butyl ester
 
(8) 
Ammonium formate (1.5 g, 24.5 mmol) was added to a solution of N-tert­
butyloxycarbonyl-L-p-nitrophenylalanyl-L-leucine ten -butyl ester 7 (1.30 g, 2.70 mmol) 
in Me0H (10 mL). Once the ammonium formate had dissolved, a suspension of 10% 
Pd/C (0.26 g) in Me0H/H20 (1:1, 1 mL) was then added dropwise. After 0.5 h, the 
reaction mixture was filtered through celite, and the Me0H evaporated. The residue was 
then dissolved in EtOAc (15 mL), and the organic layer washed with H2O (10 mL) and 
saturated NaC1 (10 mL), and then dried over MgSO4. The EtOAc was evaporated to yield 
dipeptide 8 as a white solid (1.15 g, 94 %): Rf (EtOAc) = 0.57; Rf (EtOAc/hexane, 9:1) = 
0.52; HPLC (col. A) tR = 27.2 min; mp 158-160° C; fairs = -19.0 ° (c=1.04, Me0H); 1H 
NMR (CDC13) 8 = 0.88 (d, 3H, J = 2.1Hz), 0.90 (d, 3H, J = 1.8 Hz), 1.39 (s, 9H), 1.42 
(s, 9H), 1.54 (m, 3H), 2.94 (d, 2H, J = 6.5 Hz), 4.24 (broad s, 1H), 4.41 (m, 1H), 4.95 
(broad s, 1H), 6.28 (d, 1H, J = 8.4 Hz), 6.65 (d, 2H, J = 8.4 Hz), 6.98 (d, 2H, J = 8.3 
Hz); FAB-MS [M+H]+ 450.2 (calc. 450). 
Na-tert-Butyloxycarbonyl-L-p-amino(9-fluorenylmethoxycarbonyl) 
phenylalanyl-L-leucine tert-butyl ester (9) 
Ten percent Na2CO3 was added to a solution of N-tert-butyloxycarbonyl-L-p-axninophenyl­
alanyl-L-leucine tert-butyl ester 8 (1.10 g, 2.40 mmol) in dioxane (10 mL) to adjust the pH 
to 8. A solution of 9-fluorenylmethoxychloroformate (0.56 g, 2.2 mmol) was added, and 
the pH was maintained using additional 10% Na2CO3; a light, white precipitate was seen to 
form immediately. The reaction was allowed to proceed overnight. The resultant 
suspension was then diluted with H2O (10 mL) and the precipitate filtered and washed with 
0.1 N HC1. The crude solid (1.53 g, 105%) was dried and recrystallized from Me0H/H20 
to yield 1.29 g (80%) of 9 as a white solid: Rf (EtOAc) = 0.69; HPLC (col.A) tR = 43.7 74 
min; mp 207-210 °C; [C]r = -6.20 (c = 0.45, Me0H); 1H NMR (CDC13) S = 0.88 (d, 3H, 
J = 3.3 Hz), 0.89 (d, 3H, J = 8.9 Hz), 1.40 (s, 9H), 1.41 (s, 9H), 1.51 (m, 3H), 3.01 (d, 
2H, J = 6.5 Hz), 4.25 (t, 2H, J = 6.5 Hz), 4.31(m, 1H), 4.41 (m, 1H), 4.51 (d, 2H, J = 
6.6 Hz), 6.22 (d, 1H, J = 7.9 Hz), 6.56 (s, 1H), 7.12 (d, 2H, J = 8.2 Hz), 7.31 (t, 4H, J
 
= 7.5 Hz), 7.40 (t, 2H, J = 7.3 Hz), 7.59 (d, 2H, J = 7.2 Hz), 7.76 (d, 2H, J = 7.4 Hz);
 
FAB-MS [M+H]+ 672.3 (caic. 672).
 
tert-Butyl L-p-amino(9-fluorenylmethoxycarbonyl)phenylalanyl-L-leucinate
 
(10) 
A solution of TMS -OTf in toluene (0.358 M, 4.77 mL, 1.66 mmol) was added dropwise to 
a solution of N-tert-butyloxycarbonyl-L-p-amino(9-fluorenylmethoxycarbonyl) phenyl­
alanyl-L-leucine tert-butyl ester 9 (1.10 g, 1.70 mmol) in DCM (15 mL) After a few 
minutes, the product (as the triflate salt) precipitated out as a gelatinous mass. After 4.0 h, 
the gel was filtered and washed with additional DCM, and then dried to give 0.94 g (97%) 
of intermediate 10 as a white solid: R1 (Et0Ac) = 0.68; HPLC (col. A.) tR = 24.3 min; 
[a]i) = -14.5° (c = 1.00, Me0H); 1H NMR (CDC13) 8 = 0.90 (d, 6H, J = 3.3 Hz), 1.45 
(s, 9H), 1.57 (m, 3H), 1.78 (broad s, 1H), 4.25 (t, 1H, J = Hz), 4.45 (m, 1H), 4.56 (d, 
2H, J = Hz), 6.65 (s, 1H), 7.12 (d, 2H, J = 8.2 Hz), 7.31 (t, 4H, J = 7.5 Hz), 7.40 (t, 
2H, J = 7.3 Hz), 7.59 (d, 2H, J = 7.2 Hz), 7.76 (d, 2H, J = 7.4 Hz); FAB-MS [M+H]+ 
572.3 (calc. 572); Anal. calcd. for C34H42N305CF3S03H: C, 58.24; H, 5.86; N, 5.82.
 
found: C, 60.29; H, 6.25; N, 6.01.
 
Methyl a-aminoisobutyrate hydrochloride (11)
 
Thionyl chloride (0.70 mL, 9.7 mmol) was added dropwise to a cold (ice/H20) suspension
 
of a-aminoisobutyric acid (1.00 g, 9.7 mmol) in dry Me0H. Upon addition, the
 
suspension slowly dissolved. The reaction mixture was then warmed to 50 °C for 1 h,
 
followed by stirring at room temperature overnight. The Me0H was then removed in
 
vacuo to yield 1.40 g (94%) of 11 as a white solid. A sample was then recrystallized from
 75 
Me0H/Et20 for analysis: mp 178-179 0C (lit. 183-184 °C (Lovett and Portoghese, 
1987a)); 1H NMR (d6 -DMSO) 8 = 1.45 (s, 6H), 3.72 (s, 3H), 8.78 (s, 3H). 
N-Benzyloxycarbonyl-a-aminoisobutyryl-a-aminoisobutyrate methyl ester 
(12) 
Trimethylacetyl chloride (0.52 mL, 4.2 mmol) was added to a cold (NaCl/ice) solution of 
Na-benzyloxycarbonyl-a-aminoisobutyrate (1.00 g, 4.21 mmol) and triethylamine (0.58 
mL, 4.21 mmol) in toluene. Following the addition, a precipitate immediately formed. 
The reaction mixture was stirred for 2 h at the lowered temperature, and then for 2 h at 
room temperature. The resultant suspension was filtered, and the solid washed with 
additional toluene.  The filtrates were combined and concentrated, and methyl a­
aminoisobutyrate (free amine, 0.65 g, 5.6 mmol) was then added. The solution was heated 
to 60 °C for 3 h, and then stirred at room temperature overnight. The reaction mixture was 
diluted with EtOAc (25 mL) and washed with 5% NaHCO3, H2O, 1N HC1, H2O, and 
saturated NaC1, and then dried over MgSO4. The solvent was removed in vacuo to give 12 
as a white solid (0.80 g, 63 %). A sample was recrystallized from Et20/light petroleum 
ether for analysis: Rf (CH2C12/5%Me0H) = 0.44; (EtOAc) = 0.56; mp 105-107 °C (lit. 
107-109 °C (Lovett and Portoghese, 1987a)); 1H NMR (CDC13) 5 = 1.19 (s, 6H), 1.50 (s, 
3H), 1.51 (s, 3H), 1.54 (s, 3H), 3.71 (s, 3H), 5.09 (s, 2H), 5.20 (s, 1H), 6.96 (s, 1H), 
7.33 (m, 5H).
 
Methyl a-aminoisobutyryl-a-aminoisobutyrate hydrochloride (13)
 
A mixture of methyl N-benzyloxycarbonyl-a-aminoisobutyryl-a-aminoisobutyrate 12
 
(0.93 g, 2.78 mmol), 10% Pd/C (0.23 g) and conc. HC1 (0.23 mL, 2.78 mmol) in Me0H 
(10 mL) was hydrogenated for 45 min at 1 atm. The catalyst was then filtered through 
celite, and the Me0H was removed in vacuo. The resultant gummy residue was triturated 
with Et20 to give 13 as a white solid (0.59 g, 89%): Rf (CH2C12/10%Me0H) = 0.40-0.27; 
(BAW, 3:1:1) = 0.60; mp 174-177 °C (lit. 175.5-178.5 0C (Lovett and Portoghese, 76 
1987a)); 1H NMR (d6 -DMSO) 8 = 1.07 (s, 3H), 1.40 (s, 6H), 1.48 (s, 3H), 3.51 (s,
 
3H), 8.25 (broad s, 3H), 8.49 (s, 2H).
 
N-Benzyloxycarbony1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a­
aminoisobutyrate methyl ester (14)
 
N Benzyloxycarbonyl -O -tert- butyl -L- tyrosine (1.20 g, 3.20 mmol) was coupled to methyl
 
a-aminoisobutyryl-a-aminoisobutyrate hydrochloride 13 (0.60 g, 2 5 mmol) using 
Method Ito give 1.34 g (98%) of 14 as an oil (1.34 g, 98%): Rf (EtOAc) = 0.50; [a]D = 
+30.8° (lit. = +31.2 °, c = 1.0, Me0H); 1H NMR (CDC13) 8 = 1.31 (s, 9H), 1.42 (s, 3H), 
1.44 (s, 3H), (s, 6H), 2.95 (t, 2H), 3.69 (s, 3H), 4.18 (q, 1H), 5.18 (s, 2H), 5.25 (broad 
d, 1H), 5.98 (s, 1H), 6.90 (d, 2H), 6.98 (s, 1H), 7.05 (d, 2H), 7.35 (m, 5H). 
Methyl 0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyrate (15) 
Methyl N-benzyloxycarbony1-0-tert-butyl-tyrosyl-a-aminoisobutyryl-a-aminoisobutyrate 
14 (1.18 g, 2.13 mmol) was dissolved in Me0H (10 mL) and ammonium formate (0.41 g, 
6.41 mmol) was then added. Once the ammonium formate had dissolved, a suspension of 
10% Pd/C (0.23 g) in Me0H/H20 (1:1, 1 mL) was added dropwise. After 1.0 h, the 
reaction mixture was filtered through celite, and the Me0H evaporated. The residue was 
then dissolved in EtOAc (15 mL) and the organic layer washed with H2O (10 mL) and 
saturated NaC1 (10 mL), and then dried over MgSO4. The EtOAc was evaporated to yield 
0.83 g (92%) of 15. A sample was recrystallized from EtOAc/hexane for analysis: HPLC 
(col. A) tR = 19.5 min; m.p. 119-121 °C; [a]D = +27.7 ° (c=1.0, Me0H); 1H NMR (d6­
DMS0) 8 = 1.31 (s, 9H), 1.35 (s, 6H), 1.47 (s, 6H), 2.88 (d of d, 1H), 2.91 (d of d, 
1H), 3.48 (t, 1H), 3.68 (s, 3H), 6.90 (d, 2H), 7.11 (d, 2H). 
N,N-Diall y1-0 -tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyrate 
methyl ester (16) 
Methyl 0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyrate 15 (0.83 g, 1.9 
mmol), DIPEA (1.1 mL, 5.94 mmol) and allyl bromide (1.7 mL, 20 mmol) were dissolved 
in benzene/MeCN (4:1, 10 mL) and stirred at room temperature overnight. The reaction 77 
mixture was then concentrated in vacuo, and diluted with EtOAc (50 mL). The organic 
layer was then washed with H2O (30 mL), saturated NaC1, and then dried over MgSO4. 
The solvent was removed under vacuo, and the oily residue was applied to a flash silica gel 
column with EtOAc/hexane (4:1) as the eluent. The collected fractions gave 0.83 g (83%) 
of 16 as a slightly yellowish oil: Rf (CH2C12/5% Me0H) = 0.42; HPLC (col. A) tR = 21.2 
min; NOD = -1.9° (c = 1.02, Me0H); FAB-MS [M+H]+ 502.0 (calc. 502). 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyric 
acid (17) 
Methyl N,N-dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyrate 16 
(0.83 g, 1.6 mmol) was dissolved in THE (5.0 mL) and set in an ice water bath. To the 
cold solution, 1 M NaOH (1.8 mL, 1.8 mmol) was added dropwise. The reaction mixture 
stirred at 0 °C for 1 h, and then at room temperature for 3.5 h.  The solution was 
concentrated, and applied to a medium pressure C8 column. The amount obtained from the 
column was 0.62 g (72 %) of 17 as a clear glass: Rf (CH2C12/10% Me0H) = 0.0-0.33; 
[a]D = -6.2° (c = 0.40, Me0H). 
N-Benzyloxycarbony1-0-tert-butyl-L-tyrosylglycylglycine ethyl ester (18) 
As described in Method I, N-benzyloxycarbony1-0-tert-butyl-L-tyrosine (0.65 g, 1.8 
mmol) was coupled to ethyl glycylglycinate hydrochloride (0.35 g, 1.80 mmol) to give 
0.83 g (91%) of 18 as a white solid. A sample was recrystallized from Et20/hexane for 
analysis: Rf (CH2C12/5% Me0H) = 0.27; Rf (EtOAc) = 0.32; mp 102-104 °C (lit. 104-105 
0C (Lovett and Portoghese, 1987a)); [a]r = -18.1 ° (lit. -18.5 0, c = 1.0, DMF (Lovett and 
Portoghese, 1987a)). 
Ethyl O- tert - butyl -L- tyrosylglycylglycinate (19) 
Ammonium formate (0.31 g, 4.9 mmol) was added to a solution of N-benzyloxycarbony1­
0-tert-butyl-L-tyrosylglycylglycine ethyl ester 18 (0.84 g, 1.60 mmol) in Me0H (10 ml) 
and allowed to stir until all traces of the salt dissolved. To the solution, 10% Pd/C (0.10 g) 
was then added as a suspension in H20/Me0H (1:1, 1 mL). After 30 min, the reaction 78 
mixture was filtered through celite, and the Me0H removed in vacuo. The residue was 
dissolved in EtOAc (10 mL), and the solution washed with saturated NaC1 and dried over 
MgSO4 to give 0.59 g (97%) of 19 as a white solid: Rf (CH2C12/10% Me0H) = 0.48; mp 
112-113 °C (lit. 113-115 0C (Lovett and Portoghese, 1987a)); [a]D = -25.5 ° (lit. -26.0 0, 
c = 0.63, DMF (Lovett and Portoghese, 1987a)). 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycine ethyl ester (20) 
Benzyl bromide (1.5 mL, 12.4 mmol) was added to a solution of ethyl 0-tert-butyl-L­
tyrosylglycylglycinate 19 (587 mg, 1.50 mmol) in MeCN (8.0 mL). After a few minutes, 
DIPEA (0.8 ml, 4.6 mmol) was added. After 24 h, the MeCN was removed in vacuo, and 
the residue was dissolved in EtOAc (20 mL). The solution was then washed with saturated 
NaCl (10 mL) and dried over MgSO4. The EtOAc was evaporated, and the residue was 
applied to a flash silica gel column with EtOAc/hexane (4:1) as the eluent to give 0.70 g 
(81%) of 20 as a clear oil: Rf (EtOAc) = 0.55; [a]D = -4.3° (lit. -4.4 0, c = 1.05, Me0H 
(Lovett and Portoghese, 1987a)). 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycine (21) 
A NaOH solution (0.25 N, 4.8 mL, 1.2 mmol) was added dropwise to a cold (ice/H20) 
solution of N,N-dibenzy1-0-tert-butyl-L-tyrosylglycylglycine ethyl ester 20 (678 mg, 1.20 
mmol) in THE (5.0 mL). The reaction mixture was allowed to stir at 0 °C for 1 h, and then 
it was allowed to warm to room temperature and stirred for an additional 4.0 h. The 
reaction mixture was neutralized with 1N HC1 and the solvent removed in vacuo. The 
residue was dissolved in EtOAc (20 mL) and washed with saturated NaC1 and dried over 
MgSO4 to give 0.59 g (91%) of 21 as a foam: Rf (DCM/Me0H, 9:1) = 0.0 - 0.25. 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-amino(9-fluorenyl­
methoxycarbonyl)phenylalanyl-L-leucine tert-butyl ester (22) 
The tripeptide N,N-dibenzy1-0-ten -butyl-L-tyrosylglycylglycine 21 (310 mg, 0.7 mmol) 
was coupled to L-p-arnino(9-fluorenylmethoxycarbonyl)phenylalanyl-L-leucine tert-butyl 
ester 10 as described by Method I, except that DMF instead of THF/DMF was used as the 79 
solvent. The crude material was purified by flash silica gel chromatography using EtOAc 
as the eluent to give 0.57 g (74%) of 22 as a foam: Rf (EtOAc) = 0.43; HPLC (col. A) tR = 
42.3 min; [a]) = -8.63 ° (c = 1.2, CHC13); FAB-MS [M+H]+ 1085.7 (calc. 1085). 
N,N-dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L­
leucine tert-butyl ester (23) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-amino(9-fluorenyhnethoxycarbonyl) 
phenylalanyl-L-leucine tert-butyl ester 22 (269 mg, 0.25 mmol) was dissolved in DCM 
(2.0 mL) and tris(2- aminoethyl)amine (1.8 mL, 12.5 mmol) was then added. A white 
precipitate formed immediately. After 3.0 h, the solvent was removed in vacuo, and the 
residue was dissolved in EtOAc (30 mL). The EtOAc layer was washed with saturated 
NaC1, phosphate buffer at pH 5.5 (p. = 1.0, 3 x 10 mL), and saturated NaC1, and then 
dried over MgSO4. The solvent was removed in vacuo, and the crude residue was applied 
to a flash silica gel column with EtOAc as the eluent to give 160 mg (75%) of 23 as a clear 
glass: Rf (EtOAc) = 0.14; Rf [chloroform/methanol/acetic acid, (CMA) 95:5:1] = 0.18; Rf 
(BAW, 3:1:1) = 0.67; HPLC (col. A) tR = 34.0 min; FAB-MS [M+H]+ 863.5 (calc. 863). 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-isothiocyanato­
phenylalanyl-L-leucine tert-butyl ester (24) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L-leucine ten­
butyl ester 23 (37 mg, 0.04 mmol) was dissolved in DCM (0.5 mL). To the solution, 
DIPEA (6.5 p.L, 0.08 mmol) was added, followed by thiophosgene (6.5 p.L, 0.08 mmol). 
After 4.0 h, the solvent was removed under a stream of N2, and the crude residue was 
applied to silica gel flash chromatography with EtOAc as the eluent to give 38 mg (94%) of 
24 as a clear glass: Rf (EtOAc) = 0.48, Rf (CMA 95:5:1) = 0.28; HPLC (col. A) tR = 41.2 
min; FAB-MS [M+H]+ 905.8 (calc. 905). 80 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl.L.p-ehloroacetamido­
phenylalanyl-L-leucine tert-butyl ester (25) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L-leucine tert­
butyl ester 23 (77 mg, 0.09 mmol) was dissolved in DCM and chilled to 0°C in an ice 
water bath. To the solution, DIPEA (31 gL, 0.18 mmol) was added, followed by 
bromoacetyl chloride (11 p.L, 0.14 mmol) Upon addition of the bromoacetyl chloride, a 
thick white vapor formed, and the solution quickly turned a dark color. After 1.0 h at 0 °C, 
the solution was allowed to warm to room temperature and the reaction continued 
overnight. The solvent was then removed under an N2 stream, and the residue was applied 
to silica gel flash chromatography with EtOAc as the eluent to give 49 mg (54%) of 25 as a 
clear glass: HPLC (col. A) Rt = 37.0 min; FAB-MS [M+H]+ 941.2 (calc. 939); HRFAB­
MS (calc. for C52H69C1N608) 940.4787, found: 940.4778. 
N,N-dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-bromoacetamido­
phenylalanyl-L-leucine tert-butyl ester (26) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L-leucine tert­
butyl ester 23 (21 mg, 0.02 mmol) was dissolved in DCM and chilled to 0°C in an ice 
water bath. To the solution, DIPEA (8.5 gL, 0.05 mmol) was added, followed by 
bromoacetyl bromide (3.2 tiL, 0.04 mmol) Upon addition of the bromoacetyl bromide, a 
thick white vapor formed, and the solution quickly turned a dark color. After 1.0 h at 0°C, 
the solution was allowed to warm to room temperature and the reaction mixture proceeded 
overnight. The solvent was then removed in vacuo, and the residue was purified by silica 
gel flash chromatography with EtOAc as the eluent to give 16 mg (91%) of 27 as a glass: 
Rf (EtOAc) = 0.62; HPLC (col. A) tR = 37.8 min; FAB-MS [M+H]+ 985.4 (calc. 984); 
N,N-Dibenzyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L-leucine (1) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-aminophenylalanyl-L-leucine tert­
butyl ester 23 (20 mg, 0.02 mmol) was deprotected using Method II to yield 16 mg 81 
(72%) of 1 as a white solid: HPLC (col. A) tR = 46.6 min (94% purity); FAB-MS [M+11] 
751.4 (calc. 751). 
N,N-Dibenzyl-L-tyrosylglycylglycyl-L-p-isothiocyanatophenylalanyl-L­
leucine (2) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-isothiocyanatophenylalanyl-L-leucine 
tert butyl ester 24 (38 mg, 0.04) was deprotected using Method II to yield 15.4 mg 
(41%) of 2 as a white solid: HPLC (col. A) tR = 32.0 min (91% purity); FAB-MS [M+H]F 
793.3 (calc. 793). 
N,N-Dibenzyl-L-tyrosylglycylglycyl-L-p-chloroacetamidophenylalanyl-L­
leucine (3a) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-chloroacetarnidophenylalanyl-L­
leucine tert-butyl ester 25 (20 mg, 0.02) was deprotected using Method II to yield 19.1 
mg (95%) of 3a as a white solid: HPLC (col. A) tR = 27.4 min (87% purity); FAB-MS 
[M+H]+ 827.4 (calc. 827). 
N,N-Dibenzyl-L-tyrosylglycylglycyl-L-p-bromacetamidophenylalanyl-L­
leucine (3) 
N,N-Dibenzy1-0-tert-butyl-L-tyrosylglycylglycyl-L-p-bromoacetamidophenylalanyl-L­
leucine tert-butyl ester 26 (20 mg, 0.02) was deprotected using Method II to yield 14.6 
mg (73%) of 3 as a white solid: HPLC (col. A) tR = 27.8 min (98% purity); FAB-MS 
[M+H]+ 873.3 (calc. 872). 
N,N-Dially1-0-tert-butyl-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L­
p-amino(9-fluorenylmethoxycarbonyl)phenylalanyl-L-leucinetert-butyl ester 
(27) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-arninoisobutyric acid 17 (250 
mg, 0.48 mmol) was coupled to L-p-amino(9-fluorenylinethoxycarbonyl) phenylalanine-L­
leucine tert butyl ester triflate 10 (132 mg, 0.23 mmol) using pivaloyl chloride as described 
in the preparation of 12. Following the standard workup, the crude product was applied to 82 
a silica gel flash column with EtOAc/hexane (4:1) as the eluent to yield 140 mg (57%) of 
27 as a foam: Rf (EtOAc) = 0.61; HPLC (col. B) tR = 37.2 min; FAB-MS [M+H]+ 1041.6 
(calc. 1041). 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl­
L-p-aminophenylalanyl-L-leucine tert-butyl ester (28) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p-amino(9­
fluorenylmethoxycarbonyl)phenylalanyl-L-leucine ten -butyl ester 27 (221 mg, 0.21 mmol) 
was deprotected using TAEA as described in the preparation of 23. The crude residue was 
applied to flash silica gel chromatography with EtOAc as the eluent, to yield 158 mg (91%) 
of 28 as a clear glass: Rf (EtOAc) = 0.25; HPLC (col. B) tR = 35.0 min; FAB-MS [M+H]+ 
819.6 (calc. 819). 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl­
L-p-isothiocyanatophenylalanyl-L-leucine tert-butyl ester (29) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p­
aminophenylalanyl-L-leucine tert-butyl ester 28 (15 mg, 0.02 mmol) was treated as 
described in the preparation of 24 to yield 13.3 mg (80%) of 20 as a clear glass: Rf 
(EtOAc) = 0.54; HPLC (col. B) tR = 25.0 min; FAB-MS [M+H]+ 861 (calc. 861). 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl­
L-p-bromoacetamidophenylalanyl-L-leucine tert-butyl ester (30) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-atninoisobutyryl-a-aminoisobutyryl-L-p­
aminophenylalanyl-L-leucine tert-butyl ester 28 (14 mg, 0.02 mmol) was dissolved in 
dichloromethane and chilled to 0°C in an ice water bath. To the solution, DIPEA (6.0 pL, 
0.03 mmol) was added, followed by bromoacetyl bromide (2.2  0.03 mmol). Upon 
addition of the bromoacetyl bromide, a thick white vapor formed, and the solution quickly 
turned a dark color.  After 2.0 h at 0°C, the solution was allowed to warm to room 
temperature for 1 h. The solvent was then removed under an N2 stream, and the residue 83 
was applied to a silica gel flash column with EtOAc as the eluent to yield 9.1 mg (58%) of 
30 as a clear glass: HPLC (col. B) tR = 40.9 min; FAB-MS EM+Hr 941 (calc. 940). 
N,N-Diallyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p-amino­
phenylalanyl-L-leucine (4) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p­
aminophenylalanyl-L-leucine tert-butyl ester 28 (9.9 mg, 0.01 mmol) was deprotected as 
described in Method II to yield 8.9 mg (78%) of 4 as a white solid: HPLC (col. B) tR = 
22.5 min. (96% purity); FAB-MS [M+H]+ 707.4 (calc. 707). 
N,N-Diallyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p-isothio­
cyanatophenylalanyl-L-leucine (5) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p­
isothiocyanatophenylalanyl-L-leucine tert-butyl ester 29 (13 mg, 0.01 mmol) was 
deprotected as described in Method II to yield 9.1 mg (70%) of 5 as a white solid: HPLC 
(col. B) tR = 33.3 min (98% purity); FAB-MS [M+H]+ 749.3 (calc. 749). 
N,N-Diallyl-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p-bromo­
acetamidophenylatanyl-L-leucine (6) 
N,N-Dially1-0-tert-butyl-L-tyrosyl-a-aminoisobutyryl-a-aminoisobutyryl-L-p­
bromoacetamidophenylalanyl-L-leucine tert-butyl ester 30 (9 mg, 0.01 mmol) was 
deprotected as described in Method II to yield 8.5 mg (98%) of 6 as a white solid: HPLC 
(col. B) tR = 40.9 min (98% purity) ; FAB-MS [M+H]+ 829.3 (calc. 828). 
4.7.2.2 Standard binding assays 
Radioligands binding assays of the potential affinity label derivatives were performed 
with Chinese hamster ovary (CHO) cells stably ransfected with either mouse 8 or rat i 
opioid receptors. Cells were harvested 72 h following transfection in 50 mM Tris buffer, 
pH 7.4, at 4 0C and homogenized using a Dounce homogenizer. The homogenate was 
then centrifuged at 45,000 x g for 10 min at 4 °C. The pellet was washed twice by 84 
resuspension and recentrifugation as in the previous step. The pellet was resuspended in 50 
mM Tris buffer, pH 7.4, at 4 0C to yield a protein concentration of 30-60 1.4/mL. 
Incubations were performed for 90 min at 22 0C with [3H]DPDPE and [3H]DAMGO for 8 
and p. receptors, respectively. Binding assays were carried out in mixtures containing 100 
lig membrane protein, 3 mM Mg2+, and peptidase inhibitors (10 g/4 bestatin, 30 AM 
captopril, and 50 gM L-leucyl-L-leucine) in a final volume of 2 mL 50 mM Tris buffer, pH 
7.4, at 22 °C. Nonspecific binding was determined in the presence of 10 11.14 unlabeled 
DPDPE and DAMGO for the 8 and p. binding assays, respectively. The reactions were 
terminated by rapid filtration over Whatman GF/B glass fiber filters using a Brandel M24-R 
cell harvester. The filters were presoaked for at least 2 h in 0.5% polyethylenimine to 
decrease nonspecific binding. The filter disks were then placed in minivials with 4 mL 
Cytoscint (ICN radiochemicals) and allowed to elute for at least 6 h before counting in a 
Beckman LS 6800 scintillation counter. IC50 values were then derived from nonlinear 
regression analysis of competition curves. 
4.7.2.3 Wash-resistant binding assays 
Potential affinity label derivatives for the 8 opioid receptor were examined for wash-
resistant inhibition of binding to opioid receptors. CHO cell membranes expressing 
receptors were incubated in the absence or presence of the enkephalin derivatives for 90 
min at room temperature. The homogenates were then centrifuged at 40,000 x g for 15 min 
at 4 0C and the pellet resuspended in 50 mM Tris buffer, pH 7.4, at 4 °C. The 
centrifugation and resuspension steps were repeated four times as the washing protocol. 
After the fifth resuspension, the homogenate  was recentrifuged and the final pellet 
resuspended in 50 mM Tris buffer, pH 7.4, at 4 °C. These final CHO cell membrane 
homogenates were then subjected to radioligand binding assays as described above. The 
radioligand binding to membranes treated with the enkephalin analogues were then 
compared to binding to untreated control membranes. 85 
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5.1 Abstract
 
In an ongoing effort to synthesize affinity labels based on 8-selective peptide 
antagonists, we have prepared derivatives of the tetrapeptide Tyr-Tic-Phe-Phe (TIPP) 
containing an isothiocyanate moiety as potential irreversible ligands. The isothiocyanate 
substituent was positioned at the para position of either Phe3 or Phe4 of the peptide. The 
synthesis was accomplished through a [2+2] convergent synthesis combining the common 
N-terminus Tyr-Tic to the C-terminal dipeptide fragments Phe-Phe, with a p-amine group 
protected as the 9-fluorenylmethoxycarbamate (Fmoc) at either position 3 or 4. This 
synthetic procedure was developed in our laboratory, and it allows for the late introduction 
of affinity labeling groups late in the synthesis for a variety of peptide substrates. 
Once the derivatives were synthesized, the [(p-NCS)Phe3]TIPP and [(p-NCS)Phe4] 
TIPP derivatives (and their corresponding amine derivatives) were tested for inhibition of 
radioligand binding in 8 and g opioid receptors expressed in Chinese hamster ovary (CHO) 
cells. All of the derivatives exhibited low nanomolar affinity and excellent selectivity for 
the 8 opioid receptor. Also, differences seen in the binding affinity profiles of these 
derivatives and the previously synthesized N,N-dialkylated enkephalin series suggest that 
neither the Phe3 and Phe4 residues in TIPP correspond to the Phe4 residue of enkephalin­
like peptides at the 8 and tt opioid receptors. The nature of these substituents at the pant 
positions of these Phe residues can be further exploited to increase affinity and/or 
selectivity of these peptides for 8 opioid receptors. 
When tested for wash-resistant binding inhibition of radioligand binding, both the 
[Phe(p-NCS)3]1IPP and [Phe(p-NCS)4]TIPP were able to inhibit [3H]DPDPE binding at 
the 8 receptor at a low nanomolar concentration. Therefore, [Phe(p-NCS)3]TIPP and 
[Phe(p- NCS)4]TIPP represent two potential affinity labels that may prove useful in the 
pharmacological study of 8 opioid receptors. 87 
5.2 Abbreviations 
Abbreviations used for amino acids arc according to the rules specified by the TUPAC­
IUB Joint Commission of Biochemical Nomenclature in Eur. J. Biochem. 1984, 138, 9­
37. All amino acids are in the L-configuration unless otherwise specified. Additional 
abbreviations used are: Boc, tert-butyloxycarbonyl; Cbz, benzyloxycarbonyl; CHO, 
Chinese hamster ovary; DAMGO, Tyr-D-Ala-Gly-MePhe-Leu-Gly-ol; DCCI, 
dicyclohexylcarbodiimide; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; 
DMF, N,N-dimethylformamide; DMSO, dimethylsulfoxide; DPDPE, Tyr-cyclo[D-Pen­
Gly-Phe-D- Pen] -OH; FAB-MS, fast atom bombardment mass spectroscopy; Fmoc, 9­
fluorenylmethoxycarbonyl; Fmoc-C1, 9-fluorenylmethyl chloroformate; HOBt, 1­
hydroxybenzotriazole; HPLC, high performance liquid chromatography; Mel, melphalan; 
MVD, mouse vas deferens; NMM, N-methylmorpholine; NMR, nuclear magnetic 
resonance spectroscopy; NTI, naltrindole; NTII, naltrindole isothiocyanate; PyBOP, 
benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate; TAEA, tris(2­
aminoethyl)amine; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Tic, 1,2,3,4­
tetrahydroisoquinoline-3-carboxylic acid; TIPP, Tyr-Tic-Phe-Phe; TMS -OTf, trimethylsilyl 
trifluoromethane-sulfonate; Tris, tris(hydroxymethyl)aminomethane. 88 
5.3 Introduction 
Affinity labels are ligands that exhibit such a high affinity for a receptor that the 
interaction is considered non-equilibrium. Most commonly, affinity labels interact with 
receptors via a covalent linkage through electrophilic attack. Due to their irreversible 
nature, affinity labels exhibit a number of advantages over traditional reversible ligands in 
various receptor studies. By forming a covalent linkage with the receptor, an affinity label 
can irreversibly block a receptor for in vivo studies, or if radiolabeled, enable the receptor 
to be purified and mapped. Affinity labels have greatly aided the study and characterization 
of the mu (p.), kappa (c), and delta (8) opioid receptors (Takemori and Portoghese, 1985). 
In the study of 8 opioid receptors, irreversible ligands have been used to demonstrate 8­
mediated analgesia, and the (+)-3R,45 enantiomer of 3-methyl fentanyl isothiocyanate 
(SUPERFIT) was used to purify 8 receptors from NG108-15 cells to apparent 
homogeneity (Simonds et al., 1975). Most recently, SUPERFIT has been used in chimeric 
receptor binding assays to identify domains of the 8 opioid receptor which are important for 
high affinity binding of this ligand (Zhu et al., 1996). The binding pocket of receptors are 
usually made up of non-contiguous amino acid residues, and a variety of affinity labels that 
interact with different receptor-based nucleophiles would help depict a clearer picture of the 
receptor binding site. 
For the development of an affinity label, the parent compound should exhibit high 
affinity and selectivity for the receptor to be studied. In an effort to synthesize affinity 
labels based on peptide antagonists for the 8 opioid receptor, the potent and selective 
tetrapeptide antagonist Tyr-Tic-Phe-Phe (TIPP) (Schiller et al., 1992) was chosen to be the 
parent peptide. TIPP was synthesized by Schiller and co-workers, and its development 
helped illustrate the differences and similarities in g and 8 receptor binding requirements. 
The goal of this project was to utilize a general synthetic methodology for the preparation of 
peptide-based affinity labels previously described by our laboratory (Chapter 4) and 
prepare TIPP derivatives containing an isothiocyanate moiety at the para-position of either 89 
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Phe3 or Phe4 (see Fig. 5.1).  These compounds were then tested for wash-resistant 
inhibition of radioligand binding to 8 opioid receptors expressed on Chinese hamster ovary 
(CHO) cells. 
In opioid peptides derived from amphibian skin (i.e. deltorphins, dermorphins), the 
familiar Tyr-Gly-Gly-Phe sequence seen in endogenous mammalian opioid peptides is 
replaced by the tripeptide sequence Tyr-D-Xaa-Phe (Erspamer, 1992). Through the 
synthesis and testing of para-substituted Phe derivatives of opioid peptides (Schiller et al., 
1983), it has been postulated that the Phe3 and Phe4 residues of various opioid peptides 
interact with different aromatic binding regions located on the opioid receptors. In an effort 
to utilize both of these putative aromatic binding regions, Schiller and co-workers first 
synthesized the tetrapeptide amide Tyr-D-Ala-Phe-Phe-NH2 (Schiller et al., 1989). This 
peptide contains a Phe residue at both positions 3 and 4, and can be thought of as a 
dermorphin/enkephalin hybrid. This tetrapeptide amide was shown to be a v.-selective 
agonist. In subsequent studies (Schiller et al., 1992), D-Phe was substituted for the D-Ala 
at position 2, resulting in a fully aromatic peptide, which also exhibited v-selective 
agonism. N-Methylation of Phe2 was found to have a divergent effect on the opioid 
activity profiles of the diastereomeric tetrapeptides. The D-N-Me-Phe2 containing analog 
showed a marked decrease in affinity for v receptors, and slightly reduced affinity for the 8 
receptor. By comparison, the L-N-Me-Phe2 analog showed an increase in v.-receptor 
binding, and slightly enhanced 8-receptor affinity. Schiller and co-workers then focused 
on the orientation of the aromatic residue at position 2, which was evidently important for 
receptor selectivity. They substituted both isomers of Tic (tetrahydroisoquinoline-3­
carboxylic acid) for the Phe at position 2. Tic is a conformationally constrained analog of 
Phe in which the aromatic ring is locked into place by a methylene bridge from the ortho 
position of the ring to the a-amine. The conformational constraint of Tic is such that it 
locks the aromatic ring of Phe into either a gauche (+) or gauche (-) conformation. It was 91 
found that the D-Tic2 analog of TIPP was a t- selective agonist, whereas the L-Tic2 analog 
exhibited 8-selective antagonism. 
To develop TIPP into an affinity label, direct incorporation of a nitro-containing 
phenylalanine followed by later reduction and derivatization would be precluded because 
the benzylic C-N bond of Tic within a peptide has been shown to be susceptible to certain 
forms of hydrogenation (Majer et al., 1994).  Therefore, the previously described 
Boc/Fmoc orthogonal protection strategy would be utilized to protect an amine at the para 
position of a phenylalanine, which would be deprotected at a later stage in the synthesis, 
followed by derivatization and final deprotection of the peptide. TIPP is an unusual opioid 
peptide in that it is completely comprised of aromatic amino acids, with two adjacent Phe 
residues at the C-terminus. It was decided to synthesize two potential affinity labels: one 
with an isothiocyanate at the para-position of Phe3, the other with an isothiocyanate on 
Phe4. The bromoacetamides were not considered for development due to the adverse 
effects on binding affinity seen in the previous enkephalin series (see Chapter 5). As an 
antagonist for the 8 opioid receptor, TIPP is more selective and potent than N,N-dibenzyl 
leucine enkephalin , and it was hoped that through derivatization, the increased selectivity 
and affinity of TIPP would result in more potent affinity labels for 8 opioid receptors. 
5.4 Chemistry 
A [2+2] convergent synthesis was envisioned in which C-terminal dipeptides containing 
an Fmoc-protected anilide amine at either Phe3 or Phe4 would be coupled to the common 
Boc-protected N-terminal sequence of Tyr-Tic. The N-terminal dipeptide was initially 
synthesized as the methyl ester, but saponification of the methyl ester required long reaction 
times and the reaction yields were somewhat low (50-60%).  The possibility for 
racemization of the C-terminal aromatic residue under such prolonged basic conditions 
prompted us to utilize the phenyl ester as the carboxyl protecting group. As early as 1959, 
the phenyl ester was suggested as a carboxyl protecting group, but it was initially found to 92 
be unsatisfactory due to excessive racemization of the peptide substrate upon saponification 
attempts.  Kenner and Seely (Galpin et al., 1979, Kenner and Seely, 1972) then 
serendipitously discovered that basic peroxide was an effective and mild method to remove 
the phenyl ester protecting group. The modified synthesis is depicted in Fig.5.2. The 
synthesis of the N-protected Tyr-Tic fragment began with the esterification of Boc-Tic with 
DCC and phenol to provide the fully protected amino acid S. The Boc group was then 
selectively removed using 30% TFA in DCM to provide the carboxyl-protected Tic 
derivative 6 in 69% yield. 
Due to the secondary nature of the a-amine of Tic, difficulties in coupling the Tyr 
residue to Tic due to increased steric hindrance were expected. In order to overcome these 
difficulties, the coupling reagent PyBOP (Coste et al., 1990) was used. PyBOP has been 
shown to be very effective in the coupling of N-methyl and other sterically hindered amino 
acids. The protected phenyl ester 6 was coupled to Boc-Tyr(OtBu)-OH using PyBOP, and 
the phenyl ester of the resultant dipeptide 7 was saponified with excess hydrogen peroxide 
and one equivalent of NaOH in dioxane/H20 to give the desired N-terminal dipeptide 8 in 
72% yield. 
Synthesis of both C-terminal dipeptides were very similar, as can be seen in Figs. 5.3 
and 5.4. The synthesis of H-Phe(p-NHFmoc)-Phe-OtBu 12 will be discussed. In the 
synthesis of the Phe3-substituted derivatives, Boc-Phe(p-NO2)-OH was coupled to H-Phe-
OtBu using isobutyl chloroformate, which provided dipeptide 9 in 91% yield. The 
coupling was followed by reduction of the nitro group by catalytic transfer hydrogenation 
(Anwar and Spatola, 1980), and the resulting amine 10 then protected using 9­
fluorenylmethyl chloroformate, to give the fully protected dipeptide 11. In order to 
selectively remove the Boc group in the presence of a t-butyl ester, one equivalent of 
trimethylsilyl trifluoromethanesulfonate (TMS -OTf) (Marsmann and Horn, 1972, 
Vorbruggen and Kroliklewicz, 1975) ,which was used successfully in the previous 93 
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Fig. 5.3  Synthesis of the C-terminal dipeptide fragment 12 for 3-substituted TIPP
derivatives 95 
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Fig. 5.4  Synthesis of the C-terminal dipeptide fragment 17 for 4-substituted TIPP 
derivatives 96 
syntheses of the enkephalin analogs (see Chapter 4), was utilized once again to provide the 
desired C-terminal dipeptide fragment 12 in 75% yield. 
The common N-terminal dipeptide fragment was then coupled to the Phe3- and Phe4­
substituted C-terminal dipeptides through the use of PyBOP. The final syntheses of the 
target compounds can be seen in Figs. 5.5 and 5.6. The Fmoc group was then removed by 
treatment of the peptides with piperidine. After purification of the resultant amines by silica 
gel column chromatography, thiophosgene treatment provided the corresponding 
isothiocyanate derivatives. The peptides were then fully deprotected using TFA containing 
anisole as a scavenger. 
5.5 Pharmacological evaluation 
5.5.1 Binding assays under standard conditions 
The amine- and isothiocyanate-substituted derivatives were then tested for affinity in 
radioligand binding assays using cloned 6- and pt-receptors expressed in CHO cells vs. 
[311]DPDPE and [3H]DAMGO, respectively (Table 5.1). In general, substitution on the 
aromatic rings of the Phe residues resulted in a slight drop in affinity for the 8 receptor, but 
slightly increased affinity at the 11 receptor. Despite the overall decrease in selectivity for 8 
over 11 receptors, all of the derivatives exhibited low nanomolar affinity and excellent 
selectivity for 8 receptors, which was expected from the pharmacological profile of the 
parent peptide TIPP. 
Despite overall similarities in binding affinities for 8 and 1.1. receptors, binding 
differences as a result of amine and isothiocyanate substitution at the para position of Phe3 
and Phe4 could be observed. The [Phe(p-NCS)3]TIPP derivative exhibited a slight drop in 
affinity at the 6 receptor but also resulted in an increase of affinity for the pt opioid receptor. 
This is in contrast with the [Phe(p-NH2)3]TIPP derivative, which resulted in a sharp 97 
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Fig. 5.6 Synthesis of the Phe4-substituted TIPP derivatives 3 and 4 Table 5.1 Binding affinities of TIPP derivatives 1-4 under standard conditions 
IC50 
compound  vs. [3H]DPDPE (nM)  vs. [3H]DAMGO (pM)  IC50 ratio (p/S) 
TIPP  5.8 ± 1.2  22.7 ± 15  3900 
[Phe(p-NH2)3]T1PP 1  87.7 ± 15.3  >100  >1140 
[Phe(p-NCS)3]TIPP 2  12.4 ± 2.4  7.2  580 
[Phe(p-N1-12)4]TIPP 3  11.8 ± 2.5  1.59 ± 0.3  135 
[Phe(p-NCS)4]7'IPP 4  5.4 ± 1.3  6.7  1200 100 
decrease in t receptor affinity, suggesting that an amine at this position is not well tolerated 
for binding at the .t receptor. The [Phe(p-NH2)4] and [Phe(p- NCS)4]TIPP derivatives 
exhibited similar 8-receptor affinity to the parent compound, but both substitutions at the 
para position of Phe4 resulted in an increase of g-receptor binding affinity. 
5.5.2 Wash-resistant binding assays 
The peptides were then tested for wash-resistant inhibition of binding through pre-
incubation of the test compounds with the CHO cells, followed by a washing procedure, 
and then subjected to a standard radioligand binding assay. The washing procedure 
consisted of centrifugation, decanting of the supernatant, followed by re-suspension of the 
CHO cells in fresh buffer. This cycle was repeated five times, which was found to be 
sufficient enough to remove most of the amine-containing control peptides without 
sacrificing large amounts of receptor protein. Due to their highly lipophilic nature, low 
concentrations of the TIPP derivatives were tested. Peptides 1, 2, 3, and 4 were tested for 
wash-resistant inhibition of radioligand binding at concentrations of 60, 10, 8, and 9 nM, 
respectively.  For comparison, the 8-selective affinity label NTII was tested at a 
concentration of 1 gM. 
In the wash-resistant binding assays (Fig. 4.7), the Phe3 isothiocyanate-containing 
compound exhibited excellent wash-resistant binding inhibition of radioligand binding. 
Due to the large variance seen in the wash-resistant assays for the Phe4 compounds, 
additional tests must be done in order to ascertain its labeling capabilities.  These 
compounds were tested at a concentration near their IC50's as determined by the reversible 
binding assays, and so the highest effective inhibition of the radioligand should be 
approximately 50%. The [Phe(p- NCS)3]TIPP derivative exhibited inhibition at a much 
lower concentration than the previously synthesized N,N-dibenzyl[Phe(p-NCS)4]leucine 
enkephalin, which suggests that the increased affinity of the TIPP derivatives facilitated the 
primary binding step of the labeling process, resulting in a more potent affinity label. 101 
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Fig. 5.7 Graphical representation of the percent radioligand binding (normalized against
 
control values) displayed by the peptide derivatives 1-4 following incubation and washing.
 
Compounds 1, 2, 3, 4 and NM were tested at concentrations of 60 nM, 10 nM, 8 nM, 9
 
nM, and 11.1.M, respectively.
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5.6 Results and discussion 
In continuing our efforts to synthesize affmity labels for the 8 opioid receptor based on 
peptide antagonists, we have once again used a Boc/Fmoc orthogonal protection strategy 
which highlights its overall versatility for the introduction of affinity labeling moieties into a 
variety of peptide substrates. The key step in the synthesis was the selective removal of a 
Boc protecting group in the presence of a t-butyl ester. This selective deprotection was 
accomplished through the use of one equivalent of TMS -OTf in toluene. Difficulty in 
saponifying a methyl ester was encountered during the synthesis of the common N-terminal 
dipeptide fragment, prompting us to use the phenyl ester for carboxylic acid protection, 
which is an effective and often overlooked method in peptide chemistry. 
The peptides synthesized were the [Phe(p-NH2)3], [Phe(p- NCS)3], [Phe(p-NH2)4] and 
[Phe(p-NCS)4] derivatives of TIPP, which were then tested in binding assays using cloned 
8 receptors. At the 8 receptor, the substitutions at the para position on either Phe seem to 
be well tolerated, as evidenced by the low nanomolar affinity and selectivity of the peptide 
derivatives. When tested for wash-resistant inhibition of radioligand binding, [Phe(p-
NCS)3]TIPP 2 exhibited wash-resistant inhibiton of radioligand binding. If this peptide is 
truly interacting with the receptor in a non-equilibrium fashion, then this ligand may 
provide an important tool with which to study the binding pocket of 8 opioid receptors. 
It is difficult to tell whether or not the corresponding isothiocyanate 4 is inhibiting 
radioligand binding in a wash-resistant fashion. The high lipophilicity of these compounds 
and the instability of the isothiocyanate group during storage in aqueous solutions made 
testing these derivatives difficult, and further tests must be done in order to determine the 
effectiveness of compound 4 as a potential affinity label. 
The binding pocket of G-protein coupled receptors are oftentimes made up of non-
contiguous segments of amino acids, which are located on the transmembrane regions 
and/or different regions of the extracellular loops. Through their irreversible nature, 
affinity labels can be used to determine the regions which are near the binding site of the 103 
receptor. A recent study had shown that the 8-selective non-peptide affinity label 
SUPERFIT required the region consisting of the beginning of the first intracellular loop to 
the middle of the third transmembrane region of the 8 opioid receptor for reversible and 
irreversible binding (Zhu et al., 1996). In another study, Liu-Chen and co-workers (Chen 
et al., 1996) had determined that the 11-selective non-peptide affinity label P-FNA interacted 
with a Lys residue located near the beginning of the fifth transmembrane region (Lys233). 
These studies have shown the utility of affinity labels in the determination of important 
residues located at or near the binding site locus. 
Many questions have been raised about the interaction of the 8 opioid receptor and its 
ligands, most specifically concerning the binding of the tetrapeptide TIPP. The TIPP 
tetrapeptide is considered an unusual opioid peptide in that it is completely comprised of 
aromatic amino acids.  It is generally believed that the requirements for opioid receptor 
recognition are a protonated amine, a phenol ring, and an aromatic ring. In the case of the 
TIPP molecule, there has been much speculation as to which aromatic residue fulfills the 
requirement of the aromatic pharmacophore. From molecular modeling studies, it has been 
speculated that either Tice or Phe3 fulfill this requirement (Chao et al., 1996, Wilkes and 
Schiller, 1995). 
In the case of other opioid peptides, it was also questioned whether or not the Phe3 of 
select opioid peptides interacted with the receptor in an identical fashion as the Phe4 residue 
of the endogenous mammalian peptides. Through analysis of the binding affinities of 
Phe(p-NO2) derivatives, Schiller and co-workers (Schiller et al., 1983) had concluded that 
the Phe3 residue of morphiceptin and dermorphin may bind to a site different from that 
interacting with the Phe4 side chain of enkephalins at the g and 8 receptors. It was thought 
that the binding affinities of TIPP and its Phe3- and Phe4-substituted derivatives compared 
with the binding data of the N,N-dialkylated enkephalins substituted at Phe4 may offer 
some similar insight as to the receptor binding requirements for the TIPP -like peptide 
antagonists. 104 
In Table 5.2, the IC50 ratios of the substituted derivatives of the enkephalin- and TIPP-
based peptides are presented. These ratio values are comparisons between the IC50 of the 
substituted derivative with respect to the IC50 of the unsubstituted parent compound. The 
earlier study done with N,N-dialkylated enkephalin analogs showed that identical 
substitution at the para position of Phe4 resulted in similar changes in 5 and g opioid 
receptor affinity. With respect to the underivatized parent compounds (i.e. N,N-dibenzyl 
leucine enkephalin and ICI-174,864), substitution of an amine at the para position in both 
peptides decreases affinity at both 8 and g receptors, whereas substitution of an 
isothiocyanate increases affinity at the 8 receptor with similar affmity at the p. receptor. 
Therefore, analogous substitution resulted in similar changes in affmity for the 6 and g 
receptors, which is to be expected if both peptides are using the same binding subsite for 
the Phe4 aromatic rings. 
Analysis of the IC50 ratios of the TIPP derivatives suggests that Phe3 and Phe4 of TIPP 
may bind to different subsites on the g receptor than does the Phe4 residue of the 
enkephalin-based series, but the same conclusion could not be made with respect to the 8 
opioid receptor. At the g receptor, incorporation of an amine at Phe3 of TIPP resulted in a 
large decrease in affinity, while incorporation of an isothiocyanate resulted in a slight 
increase in p. affinity.  These binding results contrast with the decrease in p. affinity 
exhibited by both the amine- and isothiocyanate-containing enkephalin derivatives at the g 
receptor. Likewise, the Phe4-substituted derivatives of TIPP also exhibited different 
binding characteristics than the enkephalin-based series at the p. receptor. An amine moiety 
at Phe4 resulted in a large increase of affinity at the g receptor, which is the only example 
where incorporation of an amine resulted in an increase in g binding. The corresponding 
isothiocyanate resulted in a slight increase in g receptor binding.  The unique 
pharmacological profile exhibited by the Phe4-substituted TIPP derivatives strongly 
suggests that the Phe4 aromatic ring does not utilize the same p. receptor binding subsite as 
the Phe4 aromatic moiety of enkephalin-based analogs. 105 
Table 5.2 IC50 ratios of enkephalin- and TIPP -based derivatives. IC50 ratio = IC50 of 
the substituted analog divided by the IC50 of the parent compound. 
compound  8 
N ,N- dibenzyl[(p- NH2)Phe4]leucine enkephalin  6.2  14.4 
11  11 "  [(p-NCS)Phe4]  0.4  1.2 
N,N-diallyl[Aib2,Aib3,(p-NH2)Phe4]leucine enkephalin  2.0  4.6 
"  [(p-NCS)Phe4]  0.5  1.8 
[(p- NH2)Phe3]TIPP  15.1  101 
[(p-NCS)Phe3]1IPP  2.1  0.3 
[(p- NH2)Phe4]TIPP  2.0  0.07 
[(p- NCS)Phe4]TIPP  0.9  0.3 106 
The differences seen in the A. receptor IC50 ratio's were not seen in the binding data 
obtained from 8 receptor binding. In contrast with the enkephalin-based series, a slight 
decrease in affinity was observed when an isothiocyanate group was placed on the Phe3 
residue of TIPP, but the difference was not enough to suggest the use of a different 
aromatic binding subsite. 
Despite the lack of distinct differences in the IC50 binding ratios for binding to 8 opioid 
receptors, experimental data obtained from other research laboratories have suggested that 
the Phe3 and Phe4 residues of TIPP do not correspond to the aromatic residue needed for 8 
opioid receptor binding. Truncation studies have shown that Tyr-Tic-Phe (Schiller et al., 
1992) and Tyr-Tic (Temussi et al., 1994) are able to bind to 8 opioid receptors. This 
would indicate that Tice provides the second aromatic moiety for 8 opioid receptor binding, 
and Phe3 and Phe4 may be interacting with auxiliary binding subsites. 
In our assays, [Phe(p-NCS)3]TIPP showed wash-resistant inhibition of radioligand 
binding. At a concentration of 10 nM, this peptide was able to inhibit radioligand binding 
by 57% following a wash procedure. The corresponding isothiocyanate derivative [Phe(p-
NCS)4]TIPP also showed some measure of wash-resistant inhibition of radioligand 
binding, but additional tests are needed to obtain more consistent results. The possibility 
that the Phe3 and Phe4 residues of TIPP might interact with different binding subsites could 
mean that the affinity labels based on TIPP may be interacting with different receptor-based 
nucleophiles.  Further pharmacological studies with these affinity labels may offer 
additional information about residues at or near the binding site of the 8 opioid receptor. 
5.7 Experimental section 
5.7.1 Materials 
All amino acids except for Boc-Phe(p-NO2) and Tic were purchased from Sigma 
Chemical Co. (St. Louis, MO). Synthetic reagents and the amino acids Boc-Phe(p-NO2) 107 
and Tic were purchased from Aldrich Chemical Co (Milwaukee, WI). General lab solvents 
were obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ), and HPLC-grade solvents 
were obtained from Burdick and Jackson (Muskegon, MI). 
Syntheses were monitored using thin-layer chromatography using Kieselgel 60 F254 
plates of 0.20 mm thickness purchased from EM Separations (Gibbstown, NJ). 
Intermediates were purified by flash chromatography using 230-400 mesh, 60A silica gel 
also purchased from E. Merck. 
NMR analyses were done on an Bruker AC300 instrument at the Department of 
Chemistry, Oregon State University, Corvallis, OR. The molecular weights of the amino 
acid derivatives and peptides were determined by fast atom bombardment (FAB) mass 
spectrometry in the postitive mode on a Kratos MS5ORFTC in the Department of 
Agricultural Chemistry at Oregon State University, Corvallis, OR. 
The purity of intermediates and the final peptides were determined by analysis on a 
Beckman System Gold high performance liquid chromatography (HPLC) system 
consisting of a model 126 solvent module, model 168 detector, and model 507 
autosampler. The HPLC column used was a Vydac analytical column (C18, 300 A, 5 g, 
4.6 x 250 mm) equipped with a guard cartridge. The compounds were eluted using a linear 
gradient of 25 to 100% B over 50 min at a flow rate of 1.5 m14/min and detected at 214 nm; 
solvent A was aqueous 0.1% TFA and solvent B was acetonitrile containing 0.1% TFA. 
5.7.2 Methods 
5.7.2.1 Synthetic methods 
Isobutyl chloroformate-mediated peptide coupling (Method I): Under an N2 
atmosphere, a 0.25 M solution of the carboxyl component (1.0 eq) in dry THE was cooled 
to -15 0C (dry ice/Me0H) and neutralized with one equivalent of N-methylmorpholine. A 108 
stochiometric amount of isobutyl chloroformate is then added, followed 90 sec later by a 
cold 0.5 M solution of the amine component and N-methylmorpholine (each 1.0 eq) in 
DMF. The reaction mixture is kept at -15 °C for 30 min, and then allowed to warm to 
room temperature. After completion of the reaction, the THE was evaporated, and the 
residue suspended in EtOAc. The organic layer was washed with H2O, 5% KHSO4, H2O, 
5% NaHCO3, H2O, and finally with saturated NaCl. The organic layer was then dried 
over MgSO4 and the EtOAc evaporated to give the crude peptide. 
Final deprotection with TFA (Method II): The peptide was treated with a 10% 
anisole/TFA for one hour at room temperature. The TFA was then evaporated and the 
product precipitated with cold ether. The precipitate was washed five times with cold ether, 
and then dried in vacuo. 
tert-Butyloxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl phenyl
 
ester (5)
 
tert-Butyloxycaronyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (2.6 g, 9.4 mmol)
 
and phenol (0.88 g, 9.4 mmol) were dissolved in EtOAc (20 mL) and cooled to -15 °C in a
 
dry ice/ Me0H bath. To the chilled solution, dicyclohexylcarbodiimide (DCCI, 2.13 g,
 
10.3 mmol) suspended in EtOAc (5 mL) was added, and the reaction mixture was allowed 
to warm to room temperature and stirred overnight. Following the addition of a few drops 
of glacial acetic acid, the dicyclohexylurea reaction by-product was filtered off, and the 
filtrate was washed with 5% NaHCO3, H2O, 0.1 N HC1, H2O, and saturated NaCl. The 
organic layer was then concentrated in vacuo and passed through a plug of silica gel with 
30% hexane/EtOAc as the eluent. The filtrate was then collected and evaporated to give 
2.86 g (86%) of 5 as crystals which formed spontaneously during the evaporation process: 
Rf (EtOAc) = 0.65; HPLC tR = 25.7 min; mp 75-78 °C; 1H NMR (CDC13) 8 = 1.51 (s, 
9H), 1.55 (s, 9H), 3.31 (d, 2H, J = 5.3 Hz), 3.33 (dd, 2H, J = 5, 10 Hz), 4.63 109 
(overlapping dd, 4H), 5.02 (t, 1H, J = 5.2), 5.35 (q, 1H, J = 5 Hz), 6.82 (m, 5H), 7.25 
(m, 4H) FAB-MS [M+H]+ 354 (calc. 354). 
Phenyl L-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (6) 
tert-Butyloxycarbonyl-L-1,2,3,4-telrahydroisoquinoline-3-carboxyl phenyl ester 5 (1.00 g, 
2.8 mmol) was dissolved in dichloromethane (DCM, 5 mL) and trifluoroacetic acid (TFA, 
3 mL) added dropwise. Vigorous bubbling was seen, which ceased after approximately 10 
min. After a total reaction time of 0.5 h, the DCM and TFA were removed in vacuo with 
repeated dilutions of ethyl ether (5 x 5 mL aliquots). At the fmal dilution, white crystals 
spontaneously began to form. These crystals were filtered and washed with additional 
ethyl ether to yield 0.72 g (69%) of 6 as the TFA salt: Rf (EtOAc) = 0.44; HPLC tR = 20.8 
min; mp (dec.) 106 °C; [a]D = -56.4° (c = 1.32, DMSO); 1H NMR (CDC13) 8 = 2.68 
(broad s, 1H), 3.27 (dd, 2H, J = 10 Hz, 5 Hz), 4.08 (dd, 1 H, J = 4.9, 10 Hz), 4.24 (d, 
2H, J = 4.6 Hz), 7.17 (m, 5H), 7.30 (m, 2H), 7.46 (m, 2H); FAB-MS [M+H]+ 254 (calc. 
254). 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxyl phenyl ester (7) 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosine (0.33 g, 1.0 mmol), L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxylic acid 6 (0.30 g, 1 mmol) and benzotriazol-1-yl-oxy-tris­
pyrrolidinophosphonium hexafluorophosphate (PyBOP, 0.42 g, 1.0 mmol) were dissolved 
in DCM (5 mL) at room temperature. After a few minutes, N,N-diisopropylethylamine 
(DIPEA, 420 1.1L, 3 mmol) was added dropwise. After reacting overnight, the reaction 
mixture was diluted with EtOAc (15 mL) and washed with H2O, 5% KHSO4, H2O, 5% 
NaHCO3, H2O, and then saturated NaCl. The organic layer was dried over MgSO4, 
concentrated in vacuo and passed over a silica gel plug with EtOAc as the eluent. The 
filtrate was then evaporated to give 0.42 g (90%) of 7 as a whitish foam: Rf (EtOAc) = 
0.69; HPLC tR = 47.5 min; mp 110-113 0C; [a]D = -5.2 0 (c = 1.24, toluene); FAB-MS 110 
[M+H]+ 573 (calc. 573). Anal.: calcd for C34H40N206: C, 71.31%; H, 7.04%; N, 
4.89%. Found: C, 71.09; H, 7.00; N, 4.94. 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxylic acid (8) 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl 
phenyl ester 7 (0.40 g, 0.69 mmol) was dissolved in dioxane (5 mL). 30% H202 (785 
gL) was added, followed by 1 N NaOH (700 gL). The reaction was allowed to proceed 
overnight. The reaction mixture was then chilled in an ice bath, and the solution neutralized 
using 1 N HC1. The solution was concentrated in vacuo, and dissolved in EtOAc. The 
organic layer was washed with saturated Na2SO3, saturated NaC1, and dried over MgSO4. 
The EtOAc was removed in vacuo, which yielded 0.25 g (72%) of 8 as a clear glass: Rf 
(EtOAc) = 0.21-0.40; HPLC tR = 38.0 min; [WI) = -53.8 0 (c = 1.19, MeCN); FAB-MS 
[M-H]- 495 (calc. 495). 
tert-Butyloxycarbonyl-L-4-nitrophenylalanyl-L-phenylalaninetert-butyl ester 
(9)
 
tert-Butyloxycarbonyl-L-4-nitrophenylalanine (1.40 g, 4.50 mmol) was coupled to L-

phenylalanine tert-butyl ester hydrochloride (1.08 g, 4.20 mmol) as described by Method 
I to yield a white solid (1.95 g, 91%). This was recrystallized from hot Me0H to give 
1.64 g (76%) of 9 as a white solid: Rf (EtOAc) = 0.59; (EtOAc/hexane, 4:1) = 0.51; 
[chloroform/methanol/acetic acid (CMA), 85:10:5] = 0.80; HPLC tR = 26.2 min; mp 125 
-127 0C; NOD = -1.60 (c = 1.23, Me0H); 1H NMR (CDC13) 8 = 1.36 (s, 9H), 1.39 (s, 
9H), 3.02 (d, 2H, J = 6.0 Hz), 3.08 (overlapping signal, 1H), 3.16 (d of d, 1H, J = 6.8 
Hz, J = 17 Hz), 4.35 (m, 1H), 4.62 (q, 1H, J = 6.1 Hz), 4.95 (broad s, 1H), 6.18 (broad 
d, 1H), 7.07 (m, 2H), 7.21 (m, 3H), 7.32 (d, 2H, J = 8.6 Hz), 8.09 (d, 2H, J = 8.7 Hz); 
FAB-MS [M+H]+ = 514.3 (calc. 514). 111 
tert-Butyloxycarbonyl-L-4-aminophenylalanyl-L-phenylalanine tert-butyl
 
ester (10)
 
tert-Butyloxycarbonyl-L-4-nitrophenylalanyl-L-phenylalanine tert butyl ester 9 (1.02 g,
 
2.00 mmol) and ammonium formate (1.13 g, 18.0 mmol) was dissolved in Me0H (15 
mL). Once the ammonium formate had dissolved, 10% Pd/C (0.10 g) was added as a 
suspension in Me0H/H20 (1:1, 1 mL). The reaction mixture was allowed to stir for 0.5 h, 
and filtered through Celite and the Me0H removed in vacuo. The residue was dissolved in 
EtOAc (10 mL) and the organic layer washed with H2O, and saturated NaCl. The EtOAc 
layer was dried over MgSO4 and evaporated. The resulting white solid (10) weighed 0.93 
g (97%): Rf (EtOAc) = 0.42; HPLC tR = 14.5 min; [a]l) = -4.1° (c = 1.28, Me0H); FAB­
MS [M+H]+ 484.1 (calc. 484). 
tert-Butyloxycarbonyl-L-4-amino(9-fluorenylmethoxycarbonyl)phenylalanyl 
-L-phenylalanine tert-butyl ester (11) 
tert-Butyloxycarbonyl-L-4-aminophenylalanyl-L-phenylalanine tert-butyl ester 10 (0.48 g, 
1.0 mmol) was dissolved in dioxane (7 mL). 9-Fluorenylmethyl chloroformate (0.25 g, 
1.0 mmol) was then added as a solution in dioxane (1 mL) and 10% Na2CO3 was added 
dropwise in order to keep the pH at 8. A white precipitate formed upon the addition of the 
Na2CO3 solution. Once the pH of the suspension stabilized, the reaction mixture was 
allowed to proceed overnight. The white precipitate was then filtered, washed with cold 
10% citric acid, and dried. The resulting white solid weighed 0.56 g (89%): Rf (EtOAc) = 
0.70; (EtOAc/hexane, 2:3) = 0.29; mp 173-174 °C; [a]D = 9.90 (c = 0.45, DMSO); 1H 
NMR (CDC13) 8 = 1.33 (s, 9H), 1.39 (s, 9H), 3.00 (m, 4H), 4.25 (t, 1H, J = 6.6 Hz), 
4.29 (overlapping signal, 1H), 4.51 (d, 2H, J = 6.7 Hz), 4.62 (q, 1H), 5.11 (broad s, 
1H), 6.32 (broad d, 1H), 6.67 (s, 1H), 7.04 (m, 4H), 7.21 (m, 2H), 7.29 (t, 4H, J = 8.0 
Hz), 7.39 (t, 2H, J = 7.3 Hz,), 7.59 (d, 2H, J = 7.4 Hz), 7.74 (d, 1H, J = 8.1 Hz), 7.75 
(d, 2H, J = 7.4 Hz) ; FAB-MS [M+H]+ = 706 (calc. 706). 112 
tert-Butyl L-4-amino(9-fluorenylmethoxycarbonyl)phenylalanyl-L-phenyl­
alanate (12) 
tert-Butyloxycarbonyl-L-4-amino(9-fluorenylmethoxycarbonyl)phenylalanyl-L­
phenylalanine tert-butyl ester 11 (66 mg, 0.09 mmol) was dissolved in DCM (0.5 mL) 
To this solution, TMS -OTf (0.967 M solution in toluene, 100 gL, 0.09 mmol) was added 
dropwise via syringe. Unlike previous deprotections with this reagent, the product did not 
precipitate out of solution as the inflate salt, and so the workup was modified as follows: 
after 3 h, the reaction mixture was diluted with EtOAc (10 mL) and the organic layer was 
washed with 5% NaHCO3, H2O, and saturated NaCl. The organic layer was then dried 
over MgSO4 and concentrated in vacuo. The residue was then applied to silica gel flash 
chromatography with EtOAc as the eluent to give 45 mg (75%) of 12 as a whitish foam: 
1H NMR (CDC13) 8 = 1.38 (s, 9H), 2.54 (d of d, 1H, J = 13.8 Hz, J = 4.5 Hz), 3.04 (d, 
2H, J = 6.3 Hz), 3.09 (partially obscured d of d, 111, J = 3.7 Hz), 3.53 (d of d, 1H, J = 
9.3 Hz, J = 3.9 Hz), 4.25 (t, 1H, J = 6.7 Hz), 4.51 (d, 2H, J = 6.6 Hz), 4.74 (q, 1H, J = 
6.3 Hz), 6.84 (broad s, 1H), 7.08 (m, 4H), 7.21 (m, 2H), 7.29 (t, 4H, J = 8.0 Hz), 7.39 
(t, 2H, J = 7.3 Hz), 7.59 (d, 2H, J = 7.4 Hz), 7.74 (d, 1H, J = 8.1 Hz), 7.75 (d, 2H, J = 
7.4 Hz); FAB-MS [M+H]+ (-tBu) = 550.6 (calc. 550). 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-nitrophenylalaninetert-butyl ester 
(14) 
tert-Butyloxycarbonyl-L-phenylalanine (1.19 g, 4.50 mmol) was coupled to L-4-nitro­
phenylalanine tert-butyl ester (1.16 g, 4.50 mmol) as described for Method I to yield 2.15 
g (93%) as a white solid. The crude product was then recrystallized from hot Me0H to 
give 1.69 (73%) of 14 as a white solid: Rf (EtOAc) = 0.64; HPLC: tR = 25.7 min; mp 
147-149 °C; [ct]D = -15.3° (c = 1.16, Me0H); 1H NMR (CDC13) 8 = 1.34 (s, 9H), 1.39 
(s, 9H), 3.01 (d of d, 2H, J = 3.3 Hz, J = 6.8 Hz), 3.12 (t, 2H, J = 6.2 Hz), 4.29 (q, 1H, 
J = 6.3 Hz), 4.62 (q, 1H, J = 6.5 Hz), 4.88 (broad s, 1H), 6.37 (broad d, 1H) 7.23 (m, 
7H), 8.07 (d, 2H, J = 8.7 Hz); FAB-MS [M+11]+ = 514.3 (calc. 514). 113 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-aminophenylalaninetert-butyl
 
ester (15)
 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-nitrophenylalaninetert butyl ester 14 (1.02 g,
 
2.00 mmol) was reduced through catalytic transfer hydrogenation as described for the 
preparation of 10 to yield 0.94 g (97%) of 15 as a white solid: Rf (EtOAc) = 0.48; HPLC 
tR = 13.5 min; mp 166-167 °C; [G]D = -4.8° (c = 1.31, Me0H); FAB-MS [M+H]+ 484.1 
(calc. 484). 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-amino(9-fluorenylmethoxy­
carbonyl) phenylalanine tert-butyl ester (16) 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-aminophenylalanine tert-butyl ester 15 (0.48 g, 
1.0 mmol) was protected as the Fmoc carbamate as described for the preparation of 11 to 
yield 0.74 g (95%) of 16 as a white solid: Rf (EtOAc) = 0.28; HPLC tR = 26.2 mill, mp 
113-115 °C; [WI) = -5.3° (c = 1.19, Me0H); FAB-MS [M+H]+ = 706.3 (calc. 706). 
tert-Butyl L-phenylalanyl-L-4-amino(9-fluorenylmethoxycarbony1)-phenyl­
alanate (17) 
tert-Butyloxycarbonyl-L-phenylalanyl-L-4-amino(9-fluorenyknethoxycarbonyl) 
phenylalanine tert-butyl ester 16 (96 mg, 0.14 mmol) was selectively deprotected using 
TMS -OTf as described for the preparation of 12 to yield 70 mg (80%) of 17 as a foam: Rf 
(EtOAc/hexane, 4:1) = 0.10 - 0.21; FAB-MS [M+H]+ = 606 (calc. 606). 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetra hydro­
isoquinoline-3-carboxyl-L-4-amino(9-Buorenylmethoxycarbonyl) 
phenylalanyl-L-phenylalanine tert-butyl ester (18) 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosy1-1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid 8 (61 mg, 0.12 mmol), tert-butyl L-4-amino(9-fluorenylmethoxycarbony1)­
phenylalanyl-L-phenylalanate 12 (93 mg, 0.12 mmol), and PyBOP (64 mg, 0.12 mmol) 
was dissolved in DMF (1.0 mL) at room temperature. After a few minutes, DIPEA (64 
0.36 mmol) was added dropwise to the reaction mixture. Once the addition was complete, 114 
the reaction was allowed to proceed overnight. The DMF was then removed in vacuo, and 
the residue redissolved in EtOAc (10 mL) The organic layer was then washed with 5% 
KHSO4, H2O, 5% NaHCO3, H2O, and saturated NaC1, and dried over MgSO4. The 
organic layer was concentrated, and the resulting oil was applied to a silica gel flash column 
with DCM/hexane (4:1) as the eluent to give 117 mg (88 %) of 18 as a whitish foam: Rf 
(EtOAc) = 0.67; HPLC tR = 39.7 min; FAB-MS [M+Na]+ = 1106 (calc. 1106). Anal.: 
calcd. for C65H73N5010.1/2 H2O: C, 71.44%; H, 6.79%, N, 6.46%. found: C, 71.44; H, 
6.85; N, 6.38. 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxyl-L-4-aminophenylalanyl-L-phenylalanine tert-butyl 
ester (19) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-4-amino(9-fluorenylmethoxycarbony1)-phenylalanyl-L-phenylalanine tert -butyl ester 18 
(70 mg, 0.063 mmol) was dissolved in DMF (1 0 mL) at room temperature. To the 
solution, piperidine (6.0 p.L) was then added. The reaction was allowed to proceed for 1.5 
h, then the reaction mixture was concentrated under vacuo, and the residue applied to silica 
gel flash chromatography with EtOAc/hexane (3:1) as the eluent. The amount obtained 
from the column was 54 mg (99%) of 19 as a foam: Rf (EtOAc/hexane, 3:1) = 0.47; 
HPLC tR = 25.3 min; FAB-MS [M+H]+ 862 (calc. 862). 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxyl-L-4-isothiocyanatophenylalanyl-L-phenylalanine 
tert-butyl ester (20) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-4- aminophenylal anyl-L-phenylalanine tert -butyl ester 19 (14 mg, 0.016 mmol) was 
dissolved in DCM (1.0 ml) at room temperature. To the solution, thiophosgene (1.9 .tL, 
0.024 mmol) was added, followed by slow addition of DIPEA (7.0 mL, 0.04 mmol). The 
reaction was allowed to proceed for 1.5 h, then the reaction mixture was concentrated and 115 
applied to silica gel flash chromatography with EtOAc/hexane (4:1) as the eluent. The 
amount obtained from the column was 13.9 mg (95%) of 20 as a clear glass: HPLC tR = 
39.0 min; FAB-MS [M+H]+ 904.2 (calc. 904). 
L-Tyrosyl-L-1,2,3,4-tetrahydro-isoquinoline-3-carboxyl-L-4-amino­
phenylalanyl-L-phenylalanine (1) 
Tert-butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-4-aminophenylalanyl-L-phenylalanine tert-butyl ester 19 (14 mg, 0.016 mmol) was 
deprotected as described in Method II to yield 11 mg (80%) as a white solid: HPLC (0 to 
75% B over 50 min) tR = 25.5 min (96% purity); FAB-MS [M+H]+ 650 (calc. 650). 
L-Tyrosyl-L-1,2,3,4-tetrahydro-isoquinoline-3-carboxyl-L-4-isothio­
cyanatophenylalanyl-L-phenylalanine (2) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydro-isoquinoline-3­
carboxyl-L-4-isothiocyanatophenylalanyl-L-phenylalanine tert-butyl ester 20 (11 mg, 0.010 
mmol) was deprotected as described by Method II to yield 7 mg (65%) of peptide 2 as a 
white solid: HPLC (0 to 75% B over 50 min) tR = 32.5 min (96% purity); FAB-MS 
[M+H]+ 692 (calc. 692). 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxyl-L-phenylalanyl-L-4-amino(9-fluorenylmethoxy­
carbony1)-phenylalanine tert-butyl ester (21) 
tert-Butyloxycarbonyl-L-0-tert-butyl-tyrosy1-1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid 8 (130 mg, 0.26 mmol) was coupled to tert-butyl L-phenylalanyl-L-4-amino(9­
fluorenylmethoxycarbony1)-phenylalanate 17 (140 mg, 0.19 mmol) using PyBOP (136 
mg, 0.26 mmol) as described by the preparation of 18 to give 174 mg (87 %) of 21 as a 
whitish foam: HPLC tR = 39.9 min; FAB-MS [M+H]+ 1085 (calc. 1084). Anal.: calcd. for 
C65H73N5010H20: C, 70.82%; H, 6.86%; N, 6.35%. found: C, 70.86; H, 6.76; N, 
6.39. 116 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydro­
isoquinoline-3-carboxyl-L-phenylalanyl-L-4-aminophenylalanine tert-butyl 
ester (22) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-phenylalanyl-L-4-amino(9-fluorenylmethoxycarbony1)-phenylalanine ten -butyl ester 21 
(100 mg, 0.09 mmol) was treated with piperidine (200 gl) as described for the preparation 
of 19 to yield 67 mg (84%) of 22 as a foam: HPLC tR = 24.3 min; FAB-MS [M+H]+ 862 
(calc. 862). 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4­
tetrahydroisoquinoline-3-carboxyl-L-phenylalanyl-L-4-isothiocyanato­
phenylalanine tert -butyl ester (23) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-phenylalanyl-L-4-aminophenylalanine tert-butyl ester 22 (14 mg, 0.016 mmol) was 
treated with thiophosgene (1.9 Ill, 0.024 mmol) as described in the preparation of 20 to 
yield 13.9 mg (95%) of 23 as a clear glass: HPLC tR = 38.8 min; FAB-MS [M+H]+ 905 
(calc. 905). 
L-Tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl-L-phenylalanyl-L­
4-aminophenylalanine (3) 
Tert-butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl-
L-phenylalanyl-L -4- aminophenylalanine tert butyl ester 22 (17 mg, 0.02 mmol) was 
deprotected as described in Method II to give 13 mg (78%) of 3 as a white solid: HPLC 
(0 to 75% B over 50 min.) tR = 29.3 min (94% purity); FAB-MS [M+H]+ 650 (calc. 650). 
L-Tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl-L-phenylalanyl-L­
4-isothiocyanatophenylalanine (4) 
tert-Butyloxycarbony1-0-tert-butyl-L-tyrosyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxyl­
L-phenylalanyl-L-4-isothiocyanatophenylalanine tert -butyl ester 23 (10 mg, 0.011 mmol) 
was deprotected as described by Method II to yield 6 mg of 4 (70%) as a white solid: 117 
HPLC (0 to 75% B over 50 min.) tR = 32.3 min (97% purity); FAB-MS [M+H]+ 692 
(calc. 692). 
5.7.2.2 Standard binding assays 
Radioligands binding assays of the potential affinity label derivatives were performed 
with Chinese hamster ovary (CHO) cells stably transfected with either mouse 8 or rat g 
opioid receptors. Cells were harvested 72 h following transfection in 50 mM Tris buffer, 
pH 7.4, at 4 0C and homogenized using a Dounce homogenizer. The homogenate was 
then centrifuged at 45,000 x g for 10 min at 4 °C. The pellet was washed twice by 
resuspension and recentrifugation as in the previous step. The pellet was resuspended in 50 
mM Tris buffer, pH 7.4, at 4 0C to yield a protein concentration of 30-60 gemL. 
Incubations were performed for 90 min at 22 0C with [3H]DPDPE and [3H]DAMGO for 8 
and t receptors, respectively. Binding assays were carried out in mixtures containing 100 
gg membrane protein, 3 mM Mg2+, and peptidase inhibitors (10 pM bestatin, 30 pM 
captopril, and 50 gM L-leucyl-L-leucine) in a final volume of 2 mL 50 mM Tris buffer, pH 
7.4, at 22 °C. Nonspecific binding was determined in the presence of 10 pM unlabeled 
DPDPE and DAMGO for the 8 and g binding assays, respectively. The reactions were 
terminated by rapid filtration over Whatman GF/B glass fiber filters using a Brandel M24-R 
cell harvester. The filters were presoaked for at least 2 h in 0.5% polyethylenimine to 
decrease nonspecific binding. The filter disks were then placed in minivials with 4 mL 
Cytoscint (ICN radiochemicals) and allowed to elute for at least 6 h before counting in a 
Beckman LS 6800 scintillation counter. IC50 values were then derived from nonlinear 
regression analysis of competition curves. 
5.7.2.3 Wash-resistant binding assays 
Potential affmity label derivatives for the 8 opioid receptor were examined for wash-
resistant binding inhibition of opioid receptors. CHO cell membranes expressing 8 118 
receptors were incubated in the absence or presence of the TIPP derivatives for 90 min at 
mom temperature. The homogenates were then centrifuged at 40,000 x g for 15 min at 4 
0C and the pellet resuspended in 50 mM Tris buffer, pH 7.4, at 4 0C. The centrifugation 
and resuspension steps were repeated four times as the washing protocol. After the fifth 
resuspension, the homogenate is recentrifuged and the final pellet resuspended in 50 mM 
Tris buffer, pH 7.4, at 4 0C. These final CHO cell membrane homogenates were then 
subjected to radioligand binding assays as described above. The radioligand binding to 
membranes treated with the TIPP analogues were then compared to binding to untreated 
control membranes. 119 
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6.1 Introduction 
Affinity labels (irreversible ligands) are important pharmacological tools used in the 
study of receptors. In the area of opioid pharmacology, affinity labels have been used in 
the isolation and mapping of the various opioid receptors (Takemori and Portoghese, 
1985). In addition, affinity labels based on antagonists can also be used in determining the 
physiological effects of opioid receptor activation, which is an area of research still under 
active investigation. The potential irreversible ligand should ideally exhibit both high 
affinity and selectivity for the receptor to be investigated. In order to develop affinity labels 
for the delta (8) opioid receptor, the tetrapeptide Tyr-Tic-Phe-Phe (TIPP) (Schiller et al., 
1992) was an ideal candidate for affinity label derivatization, due to its high selectivity and 
affinity for the 8 receptor, as well as its lack of intrinsic activity. In our previous efforts to 
synthesize affinity labels based on TIPP (chapter 5), we had found that introduction of an 
isothiocyanate group at the para position of either Phe3 or Phe4 was well tolerated. Both 
derivatives exhibited wash-resistant binding inhibition of [3H]DPDPE binding to cloned 8 
receptors at low nanomolar concentrations. In an effort to further explore affinity labels 
based on TIPP, we investigated the possibility of introducing an isothiocyanate group onto 
the aromatic ring of the constrained Phe analog Tic at position 2 of the peptide. 
It is generally believed that the prerequisites for 8 opioid receptor binding are a 
protonated amine, a phenolic moiety, and a second aromatic moiety. Due to its fully 
aromatic character, there has been much speculation as to which aromatic amino acid of 
TIPP fulfills the requirement of the second aromatic ring (see Chapter 3). Antagonist 
activity at the 8-receptor has been reported for the Tyr-Tic-Ala tripeptide and the Tyr-Tic 
dipeptide fragments of TIPP (Temussi et al., 1994), which illustrates the importance of the 
Tice residue over Phe3. Furthermore, substitution of pipecolic acid for Tic at the 2-position 
resulted in a complete loss of of 8-selective antagonism. These experiments strongly 
suggest that the Tic residue at position 2 is responsible for the antagonist activity of TIPP. 121 
The significance of the Tic2 residue has also been emphasized by molecular modeling 
studies comparing TIPP to the rigid, non-peptide 8-selective antagonist naltrindole (N11). 
This antagonist was develeped by Portoghese and co-workers using the "message-address" 
concept of ligand design (Portoghese et al., 1988). It is postulated that the addition of an 
indole moiety to the naltrexone skeleton provided the second aromatic group needed to 
complete the pharmacophore for 8-selective binding. NTI is a potent and selective 
antagonist for the 8 opioid receptor, and various computational studies have shown that the 
Tic2 residue of TIPP corresponds to the indole aromatic region of NTT (Amodeo et al., 
1996, Chew et al., 1993, Wilkes and Schiller, 1994, Wilkes and Schiller, 1995). 
In a subsequent experiment done by Portoghese and co-workers (Portoghese et al., 
1990), N11 has been developed into a very potent affinity label for the 8-opioid receptor by 
incorporation of an isothiocyanate group at the 5' position of the indole aromatic ring. If 
the Tic residue mimics the indole aromatic moiety of NTI, then it is possible that 
introduction of an isothiocyanate group onto the Tic residue of TIPP may also result in an 
effective affinity label like naltrindole 5'-isothiocyanate (NTH). 
In the earlier syntheses, the isothiocyanate was introduced via a synthetic scheme 
developed by our laboratory utilizing Phe(p-NO2). The nitro group was reduced to an 
amine and protected as the Fmoc carbamate, which was deprotected and derivatized to the 
isothiocyanate at a later step in the synthesis. In this case, because the isothiocyanate is to 
be on the Tic residue, a Tic(NO2) derivative was needed. 
6.2 Chemistry 
The Tic(7-NO2) derivative was reported to have been prepared via Pictet-Spengler 
cyclization of Phe(p-NO2) (Miyake et al., 1984). The Pictet-Spengler reaction (Figure 6.1) 
has proven to be a very effective method in preparing tetrahydroisoquinolines from Phe 
(Hayashi et al., 1983). It involves condensation of formaldehyde and the a-amine to 122 
formaldehyde 
OH  OH  N  COOH 
Cl  H2+ 0 
Fig. 6.1 Pictet-Spengler cyclization of Phe to Tic 123 
the Schiff base, followed by acid catalyzed electrophilic attack of the aromatic ring by the 
imine. In our attempts, standard Pictet-Spengler reaction conditions were insufficient to 
promote cyclization of Phe(p-NO2) to Tic(7-NO2). The strong electron withdrawing effect 
of the nitro group was enough to preclude electrophilic attack of the aromatic ring by the 
imine. 
As an alternative route to Tic(7-NO2), direct nitration of optically active Tic was then 
considered.  Although generation of mixed nitration products was a possibility, we 
reasoned that the desired regioisomer could be obtained as the major product through 
examination of the substitution pattern of Tic (Fig. 6.2). Alkyl groups are ortho/para 
directing groups in electrophilic substitution of aromatic rings. The 5- and 8-positions 
directly adjacent to the methylenes of Tic were not expected to undergo extensive nitration 
due to steric hindrance. Of the two portions left for nitration, the electronegativity of the 
methyl amine substituent should disfavor carbocation formation between positions 1 and 8, 
therefore nitration would be directed towards the 7-position of the aromatic ring. 
The reaction of Tic with HNO3/H2SO4 resulted in one major product evident by HPLC. 
Mass spectroscopy identified the molecular ion of the Tic(NO2) derivative, and the 
molecular formula was confirmed through elemental analysis. 1H NMR indicated that 
nitration occurred at either positions 6 or 7, as evidenced by the apparent ABX coupling 
pattern in the aromatic region. But the specific regiochemistry of the nitration reaction was 
still undetermined. Differential nOe NMR spectroscopy was used to selectively irradiate 
the aromatic proton singlet (Figure 6.3) at 8 = 4.81. When the singlet was irradiated, the 
benzylic protons at C-1 (8 = 2.10, q, J = 16 Hz) were perturbed. This suggested that these 
protons are near to the isolated aromatic proton, thereby implicating nitration at the 7­
position. 
It was then decided that the peptide would be constructed in a linear fashion, for the 
sake of synthetic simplicity (Fig. 6.4). The Tic derivative was protected as the Fmoc 
carbamate, then coupled to Phe-Phe-OtBu dipeptide via PyBOP (Coste et al., 1990) 124 
7 
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Fig. 6.2 Expected regiochemistry of nitration onto Tic. 8 7  6  5 4 3 
Fig. 6.3 Differential nOe spectroscopy of Tic(NO2). The 1H NMR spectra of Tic(NO2) in 37% DCI in D20 is shown below, the 
effects of irradiation at the aromatic singlet proton are shown in the above spectra. The benzylic protons (8  3.5) are perturbed, 
indicating close proximity to the proton being irradiated. 126 
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i) HNO3/H2SO4, 0 °C, (53%);  Fmoc-C1, 10% Na2CO3, (53%); iii) PyBOP, DIPEA 
(82% total mass). 
Fig. 6.4 Synthetic scheme towards 2-substituted affinity labels based on TIPP. 127 
condensation. Upon the work up of the reaction, it was found that there were two major 
products as evidenced by TLC. The two major products were separated by silica gel 
chromatography. The earlier eluting product (Rf = 0.68) represented 31% of the expected 
yield, while the slower eluting product (Rf = 0.50) was 51%. Mass spectral analyses 
showed that both of the compounds exhibited the expected molecular ion peak and very 
similar fragmentation patterns as would be expected for Fmoc-Tic(7-NO2)-Phe-Phe-OtBu 
(Fig. 6.5). NMR analyses of the major components proved to be difficult due to extensive 
line broadening and overlap, but both spectra were very similar. 
6.3 Discussion and future studies 
In order to introduce reactive functionalities onto the Tice residue of the 8-selective 
tetrapeptide antagonist TIPP, a nitrated Tic derivative was prepared. The nitration was 
accomplished through treatment of Tic with HNO3 and H2SO4. The homogeneity of the 
reaction was confirmed by HPLC, the molecular formula of the nitrated Tic derivative was 
confirmed through mass spectral and elemental analyses, and the regiochemistry of the 
reaction was examined through 1H NMR. 
However, the coupling of Fmoc-Tic(7-NO2)-OH to H-Phe-Phe-OtBu resulted in two 
major products as evidenced by TLC. Upon mass spectral analyses, both products 
exhibited the expected molecular peak, and displayed identical fragmentation patterns. 
The most probable explanation for the two major products at the tripeptide stage is due 
to racemization of Tic(7-NO2), resulting in diastereomer formation. In order to check the 
chiral integrity of Tic(7-NO2), the amino acid was examined through derivatization with 
Marfey's reagent (Marfey, 1984). HPLC analysis of the derivatives indicated that the 
product of the nitration reaction was predominantly comprised of one isomer of Tic(7-NO2) 
(Fig. 6.6). 128 
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Fig. 6.5 Mass spectral data for products resulting from the Fmoc-Tic(7-NO2) to Phe­
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Fig. 6.6 Marfey derivatization and HPLC analysis of I) L-Tic(NO2); and H) blank 
Marfey's reagent. 130 
Future work will involve further analysis of the problems in the syntheses.  If 
racemization is occuring, it could be happening at either of two steps: the Fmoc protection 
of Tic(7-NO2), or the coupling of Fmoc-Tic(7-NO2) to Phe-Phe-OtBu. Deprotection of 
Fmoc-Tic(7-NO2) followed by Marfey derivatization would indicate if extensive 
racemization is occuring during amine protection. Problems during Fmoc protection could 
then perhaps be circumvented by using a milder base for neutralization, or through the use 
of a different protection strategy. If the coupling reaction proves to be the problem step, 
then use of a different coupling reagent may help to alleviate the problem. 
Once the questions surrounding this synthesis are answered, then the target 
isothiocyanate containing TIPP analog can be prepared. Evaluation of this peptide may 
help in identifying the role of the Tic aromatic ring in 8 selective binding, and may provide 
another affinity label for the study of 8 opioid receptors. 
6.4 Experimental section 
6.4.1 Materials 
Synthetic reagents and amino acids were purchased from Aldrich Chemical Co 
(Milwaukee, WI). General laboratory solvents were obtained from Mallinckrodt Baker 
Inc. (Phillipsburg, NJ), and HPLC-grade solvents were obtained from Burdick and 
Jackson (Muskegon, MI). 
Syntheses were monitored using thin-layer chromatography using Kieselgel 60 F254 
plates of 0.20 mm thickness purchased from EM Separations (Gibbstown, NJ). 
Intermediates were purified by flash chromatography using 230-400 mesh, 60A silica gel 
also purchased from E. Merck. 
NMR analyses were done on an Bruker AC300 instrument at the Department of 
Chemistry, Oregon State University, Corvallis, OR. The molecular weights of the amino 
acid derivatives and peptides were determined by fast atom bombardment (FAB) mass 131 
spectrometry in the postitive mode on a Kratos MS5ORFTC in the Department of 
Agricultural Chemistry at Oregon State University, Corvallis, OR. 
The purity of intermediates and the derivatization of Tic(7 -NO2) by Marfey's reagent 
were determined by analysis on a Beckman System Gold high performance liquid 
chromatography (HPLC) system consisting of a model 126 solvent module, model 168 
diode array detector, and model 507 autosampler. The HPLC column used was a Vydac 
analytical column (C18, 300 A, 5 g, 4.6 x 250 mm) equipped with a guard cartridge. The 
compounds were eluted using a linear gradient of 0 to 75% B over 50 min at a flow rate of 
1.5 mL/min and detected at 214 nm; solvent A was aqueous 0.1% TFA and solvent B was 
acetonitrile containing 0.1% TFA. 
6.4.2 Synthetic methods 
L-1,2,3,4-Tetrahydroisoquinoline-7-nitro-3-carboxylic acid 
L-Tic (0.45 g, 2.5 mmol) was dissolved in concentrated H2SO4 (2 mL) and cooled in an 
ice/H20 bath.  10 N HNO3 (0.43 mL, 4.35 mmol) was then added dropwise, and the 
solution was then allowed to warm to room temperature and stirred for 24 h. The solution 
was then warmed to 50 °C for 2 h, then cooled in an ice/H20 bath and neutralized with 
NaOH. The white precipitate was then collected and recrystallized from H2O to give 0.29 
g (53%) as a white amorphous solid: HPLC tR = ;  [a]D25 (c = 1.0, 3N HC1) = - 126.7 °; 
1H NMR (37% DC1/D20) 8 = 0.94 (dd, 1H, J = 11 Hz, 17 Hz), 1.13 (dd, 1H, J = 5 Hz, 
17 Hz), 2.07 (m, 1H), 2.10 (q, 2H, J = 16), 4.81 (s, 1H), 5.08 (d, 2H, J = 8.3 Hz), 5.63 
(d, 2H, J = 8.3); FAB-MS [M+H]+ 223 (calc. 223). 
Derivatization of 1,2,3,4-tetrahydroisoquinoline-7-nitro-3-carboxylic acid 
with Marfey's reagent 
1,2,3,4-Tetrahydroisoquinoline-7-nitro-3-carboxylic acid (1.1 mg, 5 gmoles) and Na­
(2,4-dinitro-5-fluoropheny1)-L-alaninamide (1.9 mg, 7 gmoles) were dissolved in acetone 132 
(200 1.a..) and 1.0 M NaHCO3 (40 ML). The solution was then warmed to 40 0C for 1 h, 
then neutralized with 2 M HC1 (20 1.iL). The resulting solution was then subjected to 
HPLC analysis and monitored at 340 nm. 
N-9-Fluorenylmethoxycarbony1-1,2,3,4-tetrahydroisoquinoline-7-nitro-3­
carboxylic acid 
L-1,2,3,4-Tetrahydroisoquinoline-7-nitro-3-carboxylic acid (0.20 g, 0.90 mmol) was 
suspended in 10% Na2CO3 (2.4 mL) and dioxane (1.4 mL). The suspension was warmed 
to 50 0C to dissolve the starting material. The resulting solution was cooled in an ice/H20 
bath, and Fmoc-Cl (0.23 g, 0.90 mmol) was then added in small portions over 15 min, 
then left overnight. The reaction mixture was then acidified to Congo using 4N HC1, and 
the white precipitate was collected, washed with H2O, and dried to yield 0.21 g (53%) as a 
white solid: Rf (BAW) = 0.84; HPLC tR = 21.7 min; [a]D25 = +63.2 0 (c = 1.2, CHC13); 
FAB-MS [M+H]+ 445 (calc. 445). 
N-9-Fluorenylmethoxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-7-nitro­
3-carboxyl-L-phenylalanyl-L-phenylalanine tert-butyl ester 
N-9-Fluorenylmethoxycarbonyl-L-1,2,3,4-tetrahydroisoquinoline-7-nitro-3-carboxylic acid 
(0.10 g, 0.23 mmol) and L-phenylalanyl-L-phenylalanine tert-butyl ester (0.82 g, 0.23 
mmol) was dissolved in DCM (1 mL). PyBOP (0.12 g, 0.23 mmol) was then added to the 
solution, followed by the dropwise addition of DIPEA (78 ML, 0.46 mmol). The reaction 
was then allowed to proceed overnight. The reaction mixture was applied directly to flash 
chromatography with EtOAc/hexane (1:1) as the eluent. The column yielded 55 mg (31%) 
of an early eluting product (A) as a glass; and later fractions yielded 94 mg (51%) of a later 
eluting product (B), which also appeared as a glass: Rf (EtOAc/hexane 1:1) compound A = 
0.68; compound B = 0.50; FAB-MS [M+H]+ compounds A and B: 795 (calc. 795). 133 
Chapter 7
 
Conclusions
 
Potential affinity label derivatives of 8 selective opioid peptide antagonists were 
prepared for future use as pharmacological probes for 8 opioid receptors. These peptide 
analogs were assembled using an orthogonal tert-butyloxycarbonyl  (Boc)/9­
fluorenylmethoxycarbonyl (Fmoc) protection strategy, a versatile method which should 
prove useful for the preparation of a wide variety of peptide-based affinity labels. The key 
step in this synthetic scheme was the selective removal of the Boc group in the presence of 
a tert-butyl ester. This selective deprotection was accomplished through the use of one 
equivalent of trimethylsilyl trifluoromethanesulfonate (TMS -OTf) in toluene.  The 
orthogonal nature of the synthesis allows for the selective removal of the Fmoc group, 
freeing an anilide amine for conversion to the reactive isothiocyanate or bromoacetamide 
groups. 
In our first study, the peptides chosen for derivatization were the 8 peptide antagonists 
N,N-dibenzyl leucine enkephalin (Lovett and Portoghese, 1987) and N,N­
diallyl[Aib2,Aib3]leucine enkephalin (ICI-174,864) (Cotton et al., 1984). Instead of 
glycines at positions 2 and 3, ICI-174,864 has the highly hindered 2-aminoisobutyric acid 
(Aib) at these positions. A [3+2] convergent synthesis was used, in which the two N-
terminal tripeptides were coupled to a common C-terminal dipeptide fragment. 
Isothiocyanate and bromoacetamide groups were incorporated into these peptides, but it 
was found that extended reaction times using bromoacetyl chloride for acylation gave rise 
to a chloroacetamide due to halide exchange. Also synthesized were the amine-containing 
compounds as reversible controls for use in the wash-resistant binding assays. These 
pentapeptides were then tested for inhibition of radioligand binding using Chinese hamster 
ovary (CHO) cells stably transfected with mouse 8 opioid receptors. 134 
From the binding assays done under standard conditions, these enkephalin derivatives 
all exhibited nanomolar to micromolar affinity for 8 opioid receptors, and in general, 
substitution at the para position of Phe4 led to decreased affinity but increased selectivity 
for 8 receptors. Surprisingly, the parent peptides exhibited a switch in rank-order potency 
when compared to previous studies done on the mouse vas deferens (MVD) smooth muscle 
assay [Lovett, 1987 #10} . This discrepancy points to possible differences in 8 receptors in 
the MVD and CHO cells, which may indicate subtype differences. 
Of the five potential affinity labels tested, only N,N-dibenzyl [Phe(p-NCS)4]leucine 
enkephalin (JVA-602) exhibited wash-resistant inhibition of radioligand binding in the 
CHO cell assays. The corresponding N,N- diallyl [Aib2,Aib3,Phe(p- NCS)4]leucine 
enkephalin analog (JVA-606) did not exhibit wash-resistant inhibition, despite its apparent 
similarity to JVA-602. After pretreatment and washing, JVA-602 still exhibited only 60% 
of control radioligand binding at a test concentration of 0.1 tiM, and this inhibition 
increased to 81% when a test concentration of 111M was used 
In order to develop other potential affinity labels for 8 opioid receptors, and test the 
versatility of our synthetic scheme, the tetrapeptide antagonist Tyr-Tic-Phe-Phe (TIPP) was 
selected for derivatization. At its 2-position, TIPP has the constrained phenylalanine 
analog Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), and it is more potent and 
selective for 8 opioid receptors than the parent enkephalin derivatives. It was anticipated 
that these attributes would result in a more effective affinity label after functionalization. 
The two phenylalanines of TIPP allowed introduction of an isothiocyanate group at the 
para positions of either Phe3 or Phe4, and so a [2+2] convergent synthesis was planned in 
which Tyr-Tic was coupled to either Phe(p-NHFmoc)-Phe-OtBu or Phe-Phe(p-NHFmoc)-
OtBu. The selective deprotection using TMS -OTf was once again used, which allowed the 
assembly of the isothiocyanate- and amine-containing TIPP derivatives. 
The CHO cell binding assays indicated that the amine- and isothiocyanate-containing 
derivatives of TIPP still retained low nanomolar affinity and good selectivity for 8 opioid 135 
receptors. Due to their highly lipophilic nature, the TIPP analogs were tested at a very low 
concentrations in the wash-resistant binding assays, but both isothiocyanate-containing 
compounds were still able to inhibit radioligand binding after the wash procedures. The 
peptide [Phe(p-NCS)3]TIPP (NA-611) was tested at a concentration of only 10 nM, and it 
was able to inhibit binding to 45% of control, and [Phe(p-NCS )4]TIPP (JVA-613) 
inhibited binding to only 30% of control at a test concentration of only 9 nM. 
In an effort to further explore synthesizing affinity labels based on TIPP, we 
investigated the possibility of introducing an isothiocyanate group onto the aromatic ring of 
the constrained Phe analog Tic at position 2 of the peptide. An isothiocyanate group at the 
2-position of TIPP may help to explain the significance of the Tic aromatic residue in 8­
selective binding. To introduce an isothiocyanate at this position, a nitrated Tic derivative 
was needed, which was prepared via direct nitration of Tic using HNO3/H2S 04. 
However, upon coupling of this Tic derivative onto Phe-Phe-OtBu, two major products 
were visible by thin layer chromatography. Both products exhibited the expected molecular 
ion peak and fragmentation pattern consistent with the desired tripeptide. The reason for 
two products is uncertain at this time; their appearance may be due to loss of chiral integrity 
of the Tic(7-NO2) derivative, resulting in diastereomer formation. Once the reason for the 
second product is identified and corrected, the synthesis of the potential affinity label 
[Tic(7-NCS)2]TIPP can resume, and evaluation of this peptide might be used in the further 
characterization of 8 opioid receptors. 
From this study, three potential affinity labels have been identified. They are peptides 
containing a Phe(p-NCS) derivative, which are able to still inhibit radioligand binding to 
CHO cells even after extensive washing. These peptides (JVA-602, 611, 613) will be 
subjected to further pharmacological tests to validate whether or not their interactions with S 
opioid receptors involve covalent binding. Our laboratory is also investigating means to 
synthesize these peptides in radiolabeled form, in order to make them more useful in 8 
receptor isolation and domain-mapping experiments. 136 
To our knowledge, JVA-602, 611, and 613 represent the only examples of affinity 
labels which use based on 6- selective peptide antagonists.  These peptides, used in 
conjunction with other agonist- and non-peptide-based affinity labels, may help to further 
understand the binding requirements and physiological actions of 8 opioid receptors. 137 
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